


Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
69		-2.25	< 0.3
70		-2.25	<0.3

[1](4-BrPh): 4-bromo-phenyl.

The entire contents of U.S. Provisional Application Nos. 60/909,315, filed March 30, 2007, and 60/982,309, filed October 24, 2007, are hereby incorporated by reference in the present application so far as needed to supplement the present disclosure and/or rectify any errors. Moreover, the patent and non-patent references disclosed herein are incorporated by reference. In the event that the incorporated patent and non-patent reference contains a term that conflicts with a term disclosed in either one of the two Provisional Applications or the present application text, the meaning of the term contained in the present application text and the two Provisional Applications controls provided that the overall meaning of the incorporated subject matter is not lost.

We claim:

1. A compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

Gilead Exhibit 2026
PGR2023-00046 - Page 001739

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl,

Gilead Exhibit 2026
PGR2023-00046 - Page 001740

cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl,substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6; including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$

Gilead Exhibit 2026
PGR2023-00046 - Page 001741

alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally

Gilead Exhibit 2026
PGR2023-00046 - Page 001742

substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) $–C{=}CH_2$, or (iii) $–NO_2$.

2. A compound its stereoisomer, salt, hydrate, solvate, or crystalline form thereof selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001743

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001745

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001748

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001749

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-y l]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate.

3. A composition for the treatment and/or prophylaxis of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, represented by formula I:



Gilead Exhibit 2026
PGR2023-00046 - Page 001754

I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen

Gilead Exhibit 2026
PGR2023-00046 - Page 001755

or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

Gilead Exhibit 2026
PGR2023-00046 - Page 001756

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, CH=$CHCO_2H$, or CH=$CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

Gilead Exhibit 2026
PGR2023-00046 - Page 001758

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

4. A composition for the treatment and/or prophylaxis of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-

Gilead Exhibit 2026
PGR2023-00046 - Page 001759

pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001760

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001761

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001762

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001763

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001764

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001765

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001766

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001768

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-y l]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-p hosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate.

5. A use of the compound represented by formula I in the manufacture of a medicament for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

wherein the compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, are represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_e(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3,

Gilead Exhibit 2026
PGR2023-00046 - Page 001771

$CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

Gilead Exhibit 2026
PGR2023-00046 - Page 001772

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:

Gilead Exhibit 2026
PGR2023-00046 - Page 001773



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and R^{11} are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

Gilead Exhibit 2026
PGR2023-00046 - Page 001774

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C\equiv C-H$, (ii) $-C=CH_2$, or (iii) $-NO_2$.

6. A use of

a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

Gilead Exhibit 2026
PGR2023-00046 - Page 001775

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001776

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001779

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001780

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001781

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001783

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001784

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-yl]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

Gilead Exhibit 2026
PGR2023-00046 - Page 001785

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and


80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

in the manufacture of a medicament for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

7. A method of treatment in a subject in need thereof, which comprises:

administering a therapeutically effective amount of the compound represented by formula I to the subject;

wherein the compound or its stereoisomer, salt, hydrate, solvate, or crystalline form thereof represented by formula I:



I

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a}

Gilead Exhibit 2026
PGR2023-00046 - Page 001787

and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen,

Gilead Exhibit 2026
PGR2023-00046 - Page 001788

including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;


(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:

Gilead Exhibit 2026
PGR2023-00046 - Page 001789



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'_2, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'_2, each R'

Gilead Exhibit 2026
PGR2023-00046 - Page 001790

comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH{=}CHCO_2H$, or $CH{=}CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) $-C{\equiv}C-H$, (ii) $-C{=}CH_2$, or (iii) $-NO_2$.

8. A method of treatment in a subject in need thereof, which comprises:

administering a therapeutically effective amount of a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001791

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001792

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001794

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001800

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-y l]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

Gilead Exhibit 2026
PGR2023-00046 - Page 001801


77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and

80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate.

9. A process for preparing a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, represented by formula I:



I

Gilead Exhibit 2026
PGR2023-00046 - Page 001802

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_eCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring; (iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $–N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3,

Gilead Exhibit 2026
PGR2023-00046 - Page 001803

$CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, -CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, -$CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, -$CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is –OR' or -$N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., -$(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;


(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

Gilead Exhibit 2026
PGR2023-00046 - Page 001804

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:

Gilead Exhibit 2026
PGR2023-00046 - Page 001805



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,


wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

Gilead Exhibit 2026
PGR2023-00046 - Page 001806


R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) $–C=CH_2$, or (iii) $–NO_2$;

said process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5

10. A process for preparing a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-

Gilead Exhibit 2026
PGR2023-00046 - Page 001807

hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-

methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001809

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001811

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001813

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001816

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-yl]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

Gilead Exhibit 2026
PGR2023-00046 - Page 001817

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;


78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and


80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

said process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4




5


11. A product its stereoisomer, salt, hydrate, solvate or crystalline form thereof, prepared a process comprising:

Gilead Exhibit 2026
PGR2023-00046 - Page 001818

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5

wherein

(a) R^1 is hydrogen, n-alkyl; branched alkyl; cycloalkyl; or aryl, which includes, but is not limited to, phenyl or naphthyl, where phenyl or naphthyl are optionally substituted with at least one of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, F, Cl, Br, I, nitro, cyano, C_{1-6} haloalkyl, $-N(R^{1'})_2$, C_{1-6} acylamino, $-NHSO_2C_{1-6}$ alkyl, $-SO_2N(R^{1'})_2$, $COR^{1''}$, and $-SO_2C_{1-6}$ alkyl; ($R^{1'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{1''}$ is –OR' or $-N(R^{1'})_2$);

(b) R^2 is hydrogen, C_{1-10} alkyl, R^{3a} or R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, $C(O)CR^{3a}R^{3b}NHR^1$, where n is 2 to 4 and R^1, R^{3a}, and R^{3b};

(c) R^{3a} and R^{3b} are (i) independently selected from hydrogen, C_{1-10} alkyl, cycloalkyl, $-(CH_2)_c(NR^{3'})_2$, C_{1-6} hydroxyalkyl, $-CH_2SH$, $-(CH_2)_2S(O)_dMe$, $-(CH_2)_3NHC(=NH)NH_2$, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, $-(CH_2)_cCOR^{3''}$, aryl and aryl C_{1-3} alkyl, said aryl groups optionally substituted with a group selected from hydroxyl, C_{1-10} alkyl, C_{1-6} alkoxy, halogen, nitro and cyano; (ii) R^{3a} and R^{3b} both are C_{1-6} alkyl; (iii) R^{3a} and R^{3b} together are$(CH_2)_f$ so as to form a spiro ring;

Gilead Exhibit 2026
PGR2023-00046 - Page 001819

(iv) R^{3a} is hydrogen and R^{3b} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms (v) R^{3b} is hydrogen and R^{3a} and R^2 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms, where c is 1 to 6, d is 0 to 2, e is 0 to 3, f is 2 to 5, n is 2 to 4, and where $R^{3'}$ is independently hydrogen or C_{1-6} alkyl and $R^{3''}$ is -OR' or $-N(R^{3'})_2$); (vi) R^{3a} is H and R^{3b} is H, CH_3, CH_2CH_3, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl; or (viii) R^{3a} is CH_3, $-CH_2CH_3$, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2Ph, CH_2-indol-3-yl, $-CH_2CH_2SCH_3$, CH_2CO_2H, $CH_2C(O)NH_2$, CH_2CH_2COOH, $CH_2CH_2C(O)NH_2$, $CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, CH_2-imidazol-4-yl, CH_2OH, $CH(OH)CH_3$, CH_2((4'-OH)-Ph), CH_2SH, or lower cycloalkyl and R^{3b} is H, where $R^{3'}$ is independently hydrogen or alkyl, which includes, but is not limited to, C_{1-20} alkyl, C_{1-10} alkyl, or C_{1-6} alkyl, $R^{3''}$ is – OR' or $-N(R^{3'})_2$);

(d) R^4 is hydrogen, C_{1-10} alkyl, C_{1-10} alkyl optionally substituted with a lower alkyl, alkoxy, di(lower alkyl)-amino, or halogen, C_{1-10} haloalkyl, C_{3-10} cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aminoacyl, aryl, such as phenyl, heteroaryl, such as, pyridinyl, substituted aryl, or substituted heteroaryl;

(e) R^5 is H, a lower alkyl, CN, vinyl, O-(lower alkyl), hydroxyl lower alkyl, i.e., $-(CH_2)_pOH$, where p is 1 -6, including hydroxyl methyl (CH_2OH), CH_2F, N_3, CH_2CN, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or halogen, including F, Cl, Br, or I, with the provisos that when X is OH, base is cytosine and R^6 is

Gilead Exhibit 2026
PGR2023-00046 - Page 001820


H, R^5 cannot be N_3 and when X is OH, R^6 is CH_3 or CH_2F and B is a purine base, R^5 cannot be H;

(f) R^6 is H, CH_3, CH_2F, CHF_2, CF_3, F, or CN;

(g) X is H, OH, F, OMe, halogen, NH_2, or N_3;

(h) Y is OH, H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{1-4}$ alkyl), $OC(O)O(C_{2-4}$ alkynyl), $OC(O)O(C_{2-4}$ alkenyl), OC_{1-10} haloalkyl, O(aminoacyl), $O(C_{1-10}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{2-4}$ alkynyl), $C(O)O(C_{2-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{2-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{2-4}$ alkynyl), $S(C_{2-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{2-4}$ alkynyl), $SO(C_{2-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{2-4}$ alkynyl), $SO_2(C_{2-4}$ alkenyl), $OS(O)_2(C_{1-4}$ acyl), $OS(O)_2(C_{1-4}$ alkyl), $OS(O)_2(C_{2-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{2-4}$ alkenyl), $NH(C_{2-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$;

the base is a naturally occurring or modified purine or pyrimidine base represented by the following structures:



a **b** **c** **d**

wherein

Z is N or CR^{12};

R^7, R^8,R^9, R^{10}, and $R^{11}$are independently H, F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6 such as C≡CH, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$,

wherein R' is an optionally substituted alkyl , which includes, but is not limited to, an optionally substituted C_{1-20} alkyl, an optionally substituted C_{1-10} alkyl, an optionally substituted lower alkyl; an optionally substituted cycloalkyl; an optionally substituted alkynyl of C_2-C_6, an optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, which includes but is not limited to C(O) alkyl, C(O)(C_{1-20} alkyl), C(O)(C_{1-10} alkyl), or C(O)(lower alkyl) or alternatively, in the instance of NR'$_2$, each R' comprise at least one C atom that are joined to form a heterocycle comprising at least two carbon atoms; and

Gilead Exhibit 2026
PGR2023-00046 - Page 001822


R^{12} is an H, halogen (including F, Cl, Br, I), OH, OR', SH, SR', NH_2, NHR', NR'_2, NO_2 lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6 , lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', $CONR'_2$, $CH=CHCO_2H$, or $CH=CHCO_2R'$; with the proviso that when base is represented by the structure c with R^{11} being hydrogen, R^{12} is not a: (i) –C≡C–H, (ii) $–C=CH_2$, or (iii) $–NO_2$

and


wherein X' is a leaving group, such as, Cl.

12. A product its stereoisomer, salt, hydrate, solvate or crystalline form thereof, prepared a process comprising:

reacting a substituted phosphochloridate compound **4** with a nucleoside analog **5**



4



5 ;

wherein the product comprises a compound, its stereoisomer, salt, hydrate, solvate, or crystalline form thereof, selected from among

5 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-alanyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-

Gilead Exhibit 2026
PGR2023-00046 - Page 001823

hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester);

6 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

7 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

8 2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate (((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester);

9 N^4-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine;

10 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-alanyl phosphate (((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenyoxy-phosphorylamino}-propionic acid methyl ester);

11 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate (2'-Deoxy-2'-fluoro-2'-*C*-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate ((S)-2-{(4-bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-

Gilead Exhibit 2026
PGR2023-00046 - Page 001824

yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-3-methyl-butyric acid methyl ester);

12 2'-deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-valyl phosphate ((S)-2-{[(2R,3R,4R,5R)-5-(2-oxo-3-amino-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-3-methyl-butyric acid methyl ester;

13 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid ethyl ester;

14 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid benzyl ester;

15 {[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-acetic acid methyl ester;

16 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

17 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-1-yloxy)-phosphorylamino]-propionic acid methyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001825

18 (S)-1-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphoryl}-pyrrolidine-2-carboxylic acid methyl ester;

19 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

20 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

21 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid methyl ester;

22 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

23 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid methyl ester;

24 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid sec-butyl ester;

25 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

26 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid butyl ester;

27 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid ethyl ester;

28 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

29 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

30 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid isopropyl ester;

31 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid benzyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001827

32 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

33 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid isopropyl ester;

34 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid butyl ester;

35 (S)-2-{(3,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

36 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

37 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-methoxy-phenoxy)-phosphorylamino]-propionic acid benzyl ester;

38 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid pentyl ester;

39 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

40 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

41 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

42 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid butyl ester;

43 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-p-tolyloxy-phosphorylamino}-propionic acid benzyl ester;

44 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid methyl ester;

45 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 4-fluoro-benzyl ester;

46 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

47 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 3-methyl-butyl ester;

48 (S)-2-{(2,4-Dichloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid ethyl ester;

49 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclohexyl ester;

50 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid butyl ester;

51 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester;

52 (R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid benzyl ester;

53 (S)-2-{(2-Chloro-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid butyl ester;

54 (S)-2-{(4-Bromo-phenoxy)-[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-propionic acid isopropyl ester;

55 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

56 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-bromo-phenoxy)-phosphorylamino]-propionic acid cyclohexyl ester;

57 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid isopropyl ester;

58 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclohexyl ester;

59 (S)-2-[[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(4-fluoro-phenoxy)-phosphorylamino]-butyric acid cyclohexyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001831

60 (S)-2-{(4-Chloro-phenoxy)-[(2R,3R,4 R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phosphorylamino}-butyric acid isopropyl ester;

61 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2-difluoro-ethyl ester;

62 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2,2,2-trifluoro-1-trifluoromethyl-ethyl ester;

63 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid 2-fluoro-1-fluoromethyl-ethyl ester;

64 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo- 3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid cyclopropyl methyl ester;

65 (S)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-butyric acid cyclopentyl ester;

66 (S)-2-{[(2R,3R,4R,5R)-5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

67 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-hydroxy-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

68 (S)-2-{(R)-[(2R,3R,4R,5R)-5-(2,6-Diamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

69 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclopentylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

70 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-azetidin-1-yl-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

71 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-diethylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

72 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-propylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

73 (S)-2-{[(2R,3R,4R,5R)-5-(2-Amino-6-cyclobutylamino-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid methyl ester;

74 (S)-2-({(2R,3R,4R,5R)-5-[2-Amino-6-(4-methyl-piperazin-1-yl)-purin-9-yl]-4-fluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic acid methyl ester;

Gilead Exhibit 2026
PGR2023-00046 - Page 001833

75 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(propylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

76 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

77 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

78 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(aziridin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate;

79 (2S)-methyl 2-((((2R,3R,4R,5R)-4-fluoro-3-hydroxy-4-methyl-5-(6-(piperidin-1-yl)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate; and


80 (2S)-methyl 2-((((2R,3R,4R,5R)-5-(6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

wherein Base' is as recited in each of compounds 5-74; and

wherein X' is a leaving group, such as, Cl.

ABSTRACT

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:



I

Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula **I**.

Electronic Patent Application Fee Transmittal

Application Number:	14254737
Filing Date:	16-Apr-2014
Title of Invention:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
First Named Inventor/Applicant Name:	Jinfa Du
Filer:	Lawrence F. Rozsnyai/Sylvia Brennan
Attorney Docket Number:	PH3080.PC6-TRK1

Filed as Large Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Utility Appl Size fee per 50 sheets >100	1081	14	400	5600
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
		Total in USD ($)		**5600**

Electronic Acknowledgement Receipt

EFS ID:	19297809
Application Number:	14254737
International Application Number:	
Confirmation Number:	1596
Title of Invention:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
First Named Inventor/Applicant Name:	Jinfa Du
Customer Number:	25000
Filer:	Lawrence F. Rozsnyai/Sylvia Brennan
Filer Authorized By:	Lawrence F. Rozsnyai
Attorney Docket Number:	PH3080.PC6-TRK1
Receipt Date:	13-JUN-2014
Filing Date:	16-APR-2014
Time Stamp:	12:44:53
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$5600
RAM confirmation Number	10190
Deposit Account	071250
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Applicant Response to Pre-Exam Formalities Notice	PH3080PC6TRK1_Rsp_Notc_Crrct_Appl_Docs.pdf	71445 c832bc606f3bede809619b68e5d4c7d1c588b5f9	no	2
Warnings:					
Information:					
2	Preliminary Amendment	PH3080PCTRK1_Revised_Preliminary_Amndt.pdf	76085 5b71a0002489540eb7d98fa416c22be4ee850b53	no	3
Warnings:					
Information:					
3	Oath or Declaration filed	PH3080PC6TRK1_Declarations.pdf	446052 5fe649939900fc9963255663f919e363f82cb8ed	no	4
Warnings:					
Information:					
4	Specification	PH3080PC6TRK1_Rvsd_Spec_Part1.pdf	12646350 be9cc62bad0c74d34d61aca2a9b480c68ffa7dcd	no	363
Warnings:					
Information:					
5	Specification	PH3080PC6TRK1_Rvsd_Spec_Part2.pdf	18370412 33dd8eb0843c99df49ba6310b8ef6cfeb1e21456	no	600
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
6		PH3080PC6TRK1_Rvsd_Claims_Abstrct_Crrct_Appl.pdf	4023905 a68699e14477b52905b8ce705211afb2630d8d3f	yes	97

Multipart Description/PDF files in .zip description

Document Description	Start	End
Claims	1	96
Abstract	97	97

Warnings:	
Information:	

7	Fee Worksheet (SB06)	fee-info.pdf	30474 ecb030a7223495e24d98be186ff87909abfee268	no	2

Warnings:	
Information:	
Total Files Size (in bytes):	35664723

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 06/17/2014

CCETIN SALE #00000007 Mailroom Dt: 06/13/2014 071250 14254737
01 FC : 1081 1,600.00 DA

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 06/17/2014

CCETIN ADJ #00000001 Mailroom Dt: 06/13/2014
Seq No: 10190 Sales Acctg Dt: 06/13/2014 071250 14254737
01 FC : 1081 5600.00 CR

PATENT APPLICATION FEE DETERMINATION RECORD
Substitute for Form PTO-875

Application or Docket Number: 14/254,737

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	280
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	600
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	720
TOTAL CLAIMS (37 CFR 1.16(i))	2 minus 20 =	*			OR	x 80 =	0.00
INDEPENDENT CLAIMS (37 CFR 1.16(h))	1 minus 3 =	*				x 420 =	0.00
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						5600
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							0.00
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	7200

APPLICATION AS AMENDED - PART II

04-16-14

AMENDMENT A		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
	Total (37 CFR 1.16(i))	* 2	Minus	** 20	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	* 1	Minus	*** 3	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

06-13-14

AMENDMENT B		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE($)	ADDITIONAL FEE($)	OR	RATE($)	ADDITIONAL FEE($)
	Total (37 CFR 1.16(i))	* 2	Minus	** 20	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	* 1	Minus	*** 3	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 14/254,737

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	280
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	600
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	720
TOTAL CLAIMS (37 CFR 1.16(i))	2 minus 20 =	*			OR	x 80 =	0.00
INDEPENDENT CLAIMS (37 CFR 1.16(h))	1 minus 3 =	*				x 420 =	0.00
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						5600
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							0.00
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	7200

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE($)	ADDITIONAL FEE($)		RATE($)	ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
14/254,737	04/16/2014	1629	10140	PH3080.PC6-TRK1	2	1

CONFIRMATION NO. 1596

UPDATED FILING RECEIPT

25000
GILEAD SCIENCES, INC
333 LAKESIDE DR
FOSTER CITY, CA 94404

OC000000069071318

Date Mailed: 06/18/2014

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Jinfa Du, Redwood City, CA;
Dhanapalan Nagarathnam, Bethany, CT;
Michael Joseph Sofia, Doylestown, PA;
Peiyuan Wang, Foster City, CA;

Applicant(s)

Gilead Pharmasset LLC, Foster City, CA

Assignment For Published Patent Application

Gilead Pharmasset LLC, Foster City, CA

Power of Attorney: The patent practitioners associated with Customer Number 25000

Domestic Priority data as claimed by applicant

This application is a CON of 14/057,675 10/18/2013 PAT 8735372
which is a CON of 13/609,614 09/11/2012 PAT 8580765
which is a CON of 13/099,671 05/03/2011 PAT 8334270
which is a CON of 12/053,015 03/21/2008 PAT 7964580
which claims benefit of 60/982,309 10/24/2007
and claims benefit of 60/909,315 03/30/2007

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

If Required, Foreign Filing License Granted: 05/06/2014

Gilead Exhibit 2026
PGR2023-00046 - Page 001845

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 14/254,737**

Projected Publication Date: 09/25/2014

Non-Publication Request: No

Early Publication Request: No
Title

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Preliminary Class

514

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

Gilead Exhibit 2026
PGR2023-00046 - Page 001846

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

GILEAD SCIENCES, INC
333 LAKESIDE DR
FOSTER CITY CA 94404

MAILED
JUN 20 2014
OFFICE OF PETITIONS

Doc Code: TRACK1.GRANT

Decision Granting Request for Prioritized Examination (Track I or After RCE)	Application No.: 14/254,737

In view of the specific circumstances surrounding this application and, in particular, the filing of the Track 1 Request requirements, the Office hereby waives, *sua sponte*, the Processing Fee date requirement of the Prioritized Examination, Track 1, program to the extent necessary to render the processing fee as timely paid and sufficient to fulfill such requirement. The requisite $140.00 processing fee (Fee Code 1830), under 37 CFR 1.17(i), has been charge to applicants' deposit account, pursuant to authorization.

1. THE REQUEST FILED April 16, 2014 IS **GRANTED.**

The above-identified application has met the requirements for prioritized examination

A. ☒ for an original nonprovisional application (Track I).
B. ☐ for an application undergoing continued examination (RCE).

2. **The above-identified application will undergo prioritized examination.** The application will be accorded special status throughout its entire course of prosecution until one of the following occurs:

A. filing a **petition for extension of time** to extend the time period for filing a reply;
B. filing an **amendment to amend the application to contain more than four independent claims, more than thirty total claims**, or a multiple dependent claim;
C. filing a **request for continued examination**;
D. filing a notice of appeal;
E. filing a request for suspension of action;
F. mailing of a notice of allowance;
G. mailing of a final Office action;
H. completion of examination as defined in 37 CFR 41.102; or
I. abandonment of the application.

Telephone inquiries with regard to this decision should be directed to Brian W. Brown at 571-272-5338.

/Brian W. Brown/
[*Signature*]

Petitions Examiner, Office of Petitions
(Title)

Organization _____ Bldg./Room _____

UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
Alexandria, VA. 22313-1450
If Undeliverable Return In Ten Days

Official Business
Penalty For Private Use, $300

AN EQUAL OPPORTUNITY EMPLOYER

UNITED STATES PATENT AND TRADEMARK OFFICE

IFW

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

GILEAD SCIENCES, INC
333 LAKESIDE DR
FOSTER CITY CA 94404

MAILED
JUN 20 2014
OFFICE OF PETITIONS

OPAP AKIMA-13
JUN 20 2014
MAIL & TRADE

Doc Code: TRACK1.GRANT

Decision Granting Request for Prioritized Examination (Track I or After RCE)	Application No.: 14/254,737

In view of the specific circumstances surrounding this application and, in particular, the filing of the Track 1 Request requirements, the Office hereby waives, *sua sponte*, the Processing Fee date requirement of the Prioritized Examination, Track 1, program to the extent necessary to render the processing fee as timely paid and sufficient to fulfill such requirement. The requisite $140.00 processing fee (Fee Code 1830), under 37 CFR 1.17(i), has been charge to applicants' deposit account, pursuant to authorization.

1. THE REQUEST FILED April 16, 2014 IS **GRANTED.**

The above-identified application has met the requirements for prioritized examination

A. ☒ for an original nonprovisional application (Track I).
B. ☐ for an application undergoing continued examination (RCE).

2. **The above-identified application will undergo prioritized examination.** The application will be accorded special status throughout its entire course of prosecution until one of the following occurs:

A. filing a **petition for extension of time** to extend the time period for filing a reply;
B. filing an **amendment to amend the application to contain more than four independent claims, more than thirty total claims**, or a multiple dependent claim;
C. filing a **request for continued examination**;
D. filing a notice of appeal;
E. filing a request for suspension of action;
F. mailing of a notice of allowance;
G. mailing of a final Office action;
H. completion of examination as defined in 37 CFR 41.102; or
I. abandonment of the application.

Telephone inquiries with regard to this decision should be directed to Brian W. Brown at 571-272-5338.

/Brian W. Brown/
[*Signature*]

Petitions Examiner, Office of Petitions
(Title)

Gilead Exhibit 2026
PGR2023-00046 - Page 001850

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

25000 e 2014-06-30

GILEAD SCIENCES, INC
333 LAKESIDE DR
FOSTER CITY, CA 94404

Paper No.

Application No.:	**14/254,737**	**Date Mailed:**	**2014-06-30**
First Named Inventor:	Du, Jinfa,	Examiner:	LEWIS, PATRICK T
Attorney Docket No.:	PH3080.PC6-TRK1	Art Unit:	1672
Confirmation No.:	1596	Filing Date:	2014-04-16

Please find attached an Office communication concerning this application or proceeding.

Commissioner for Patents

PTO-90c (Rev.08-06)

Notice of Non-Compliant Amendment (37 CFR 1.121)	Application No. 14/254,737	Applicant(s) DU ET AL.
		Art Unit 1700

-- ***The MAILING DATE of this communication appears on the cover sheet with the correspondence address*** --

The amendment document filed on *13 June, 2014* is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121 or 1.4. In order for the amendment document to be compliant, correction of the following item(s) is required.

THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:

- ☐ 1. Amendments to the specification:
  - ☐ A. Amended paragraph(s) do not include markings.
  - ☐ B. New paragraph(s) should not be underlined.
  - ☐ C. Other _____.
- ☐ 2. Abstract:
  - ☐ A. Not presented on a separate sheet. 37 CFR 1.72.
  - ☐ B. Other _____.
- ☐ 3. Amendments to the drawings:
  - ☐ A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d).
  - ☐ B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required.
  - ☐ C. Other _____.
- ☒ 4. Amendments to the claims:
  - ☐ A. A complete listing of all of the claims is not present.
  - ☐ B. The listing of claims does not include the text of all pending claims (including withdrawn claims)
  - ☐ C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended).
  - ☐ D. The claims of this amendment paper have not been presented in ascending numerical order.
  - ☒ E. Other: *See Continuation Sheet*.
- ☐ 5. Other (e.g., the amendment is unsigned or not signed in accordance with 37 CFR 1.4): For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714.

TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:

1. Applicant is given **no new time period if the non-compliant amendment is an** after-final amendment or an amendment filed after allowance, or a drawing submission (only) If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the **entire corrected amendment** must be resubmitted.

2. Applicant is given **two months** from the mail date of this notice to supply the correction, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a Quayle action. If any of above boxes 1 to 4 are checked, the correction required is only the corrected section of the non-compliant amendment in compliance with 37 CFR 1.121.

Extensions of time are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a *Quayle* action.

Failure to timely respond to this notice will result in:

Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a *Quayle* action; or

Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.

Legal Instruments Examiner (LIE), if applicable /PAUL I. NEAL/ Telephone No: (571)272-1034

Gilead Exhibit 2026
PGR2023-00046 - Page 001852

Continuation of 4. Other: claims 1 and 2 was cancel and check amendt. dated 04/16/14 and 06/13/14.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	04/16/2014	Jinfa Du	PH3080.PC6-TRK1	1596

25000 7590 08/21/2014

GILEAD SCIENCES, INC
333 LAKESIDE DR
FOSTER CITY, CA 94404

EXAMINER	
LEWIS, PATRICK T	
ART UNIT	PAPER NUMBER
1672	

NOTIFICATION DATE	DELIVERY MODE
08/21/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

IPDocketing@gilead.com
IPUS2@gilead.com

Office Action Summary	Application No. 14/254,737	Applicant(s) DU ET AL.	
	Examiner PATRICK LEWIS	Art Unit 1672	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☒ Claim(s) 4 and 5 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) 4 is/are rejected.

8)☒ Claim(s) 5 is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

4) ☐ Other: _____.

Gilead Exhibit 2026
PGR2023-00046 - Page 001855

DETAILED ACTION

1. The present application is being examined under the pre-AIA first to invent provisions.

Claim Objections

2. The numbering of claims is not in accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not).

Misnumbered claims 1 and 2 have been renumbered as claims 4 and 5, respectively.

Double Patenting

3. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process... may obtain a patent therefor..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

4. Claim 4 is rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 2 of prior U.S. Patent No. 8,735,372. This is a statutory double patenting rejection.

Conclusion

5. Claims 4-5 are pending. Claim 4 is rejected. Claim 5 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Contacts

Any inquiry concerning this communication or earlier communications from the examiner should be directed to PATRICK LEWIS whose telephone number is (571)272-0655. The examiner can normally be reached on Monday - Thursday 10 am to 3 pm (Maxi Flex).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brandon Fetterolf can be reached on 571-272-2919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/PATRICK LEWIS/
Primary Examiner, Art Unit 1672

/PL/

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 1596

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
14/254,737	04/16/2014 RULE	514	1672	PH3080.PC6-TRK1

APPLICANTS

Gilead Pharmasset LLC, Foster City, CA, Assignee (with 37 CFR 1.172 Interest);

INVENTORS

Jinfa Du, Redwood City, CA;
Dhanapalan Nagarathnam, Bethany, CT;
Michael Joseph Sofia, Doylestown, PA;
Peiyuan Wang, Foster City, CA;

**** CONTINUING DATA ***************************

This application is a CON of 14/057,675 10/18/2013 PAT 8735372
which is a CON of 13/609,614 09/11/2012 PAT 8580765
which is a CON of 13/099,671 05/03/2011 PAT 8334270
which is a CON of 12/053,015 03/21/2008 PAT 7964580
which claims benefit of 60/982,309 10/24/2007
and claims benefit of 60/909,315 03/30/2007

**** FOREIGN APPLICATIONS ***************************

**** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ****

05/06/2014

Foreign Priority claimed ☐ Yes ☑ No 35 USC 119(a-d) conditions met ☐ Yes ☑ No Verified and Acknowledged /PATRICK T LEWIS/ Examiner's Signature	☐ Met after Allowance Initials	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
		CA	0	2	1

ADDRESS

GILEAD SCIENCES, INC
333 LAKESIDE DR
FOSTER CITY, CA 94404
UNITED STATES

TITLE

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

FILING FEE RECEIVED	FEES: Authority has been given in Paper	☐ All Fees
10140	No._____ to charge/credit DEPOSIT ACCOUNT	☐ 1.16 Fees (Filing)
	No._____ for following:	☐ 1.17 Fees (Processing Ext. of time)
		☐ 1.18 Fees (Issue)
		☐ Other _____
		☐ Credit

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14254737	DU ET AL.
	Examiner	Art Unit
	PATRICK LEWIS	1672

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	08/18/2014								
	1	-								
	2	-								
	3	-								
	4	✓								
	5	O								

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14254737	DU ET AL.
	Examiner	Art Unit
	PATRICK LEWIS	1672

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES		
Search Notes	Date	Examiner
Inventor, Updated search of USSN 14/057,675	8/18/2014	/PL/

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

PTO/AIA/80 (07-12)
Approved for use through 11/30/2014. OMB 0651-0035
U.S. Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(c).

I hereby appoint:

☒ Practitioners associated with Customer Number: 117796

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

As attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignments documents attached to this form in accordance with 37 CFR 3.73(c).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(c) to:

☒ The address associated with Customer Number: 117796

OR

☐	Firm or Individual Name			
	Address			
	City		State	Zip
	Country			
	Telephone		Email	

Assignee Name and Address: Gilead Pharmasset LLC
c/o Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404

A copy of this form, together with a statement under 37 CFR 3.73(c) (Form PTO/AIA/96 or equivalent) is required to be Filed in each application in which this form is used. The statement under 37 CFR 3.73(c) may be completed by one of The practitioners appointed in this form, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	March 4, 2014
Name	J. Elin Hartrum	Telephone	650-522-1871
Title	Associate General Counsel, Intellectual Property		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	19945161
Application Number:	14254737
International Application Number:	
Confirmation Number:	1596
Title of Invention:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
First Named Inventor/Applicant Name:	Jinfa Du
Customer Number:	25000
Filer:	Lorna Lea Tanner/christa carter
Filer Authorized By:	Lorna Lea Tanner
Attorney Docket Number:	PH3080.PC6-TRK1
Receipt Date:	22-AUG-2014
Filing Date:	16-APR-2014
Time Stamp:	17:19:53
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Assignee showing of ownership per 37 CFR 3.73.	14254737.pdf	422384 ba79ed63da08e662b866c16ee9c07e18951df838	no	2

Warnings:	
Information:	

2	Power of Attorney	POA.pdf	191047 aab7d0d90adf9937af431a08ad69bd7029f8 3009	no	2

Warnings:

The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing

Information:

Total Files Size (in bytes):	613431

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/AIA/96 (08-12)
Approved for use through 01/31/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(c)

Applicant/Patent Owner: GILEAD PHARMASSET LLC

Application No./Patent No.: 14/254,737 Filed/Issue Date: April 23, 2014

Titled: NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

GILEAD PHARMASSET LLC, a CORPORATION

(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that, for the patent application/patent identified above, it is (choose **one** of options 1, 2, 3 or 4 below):

1. [X] The assignee of the entire right, title, and interest.

2. [ ] An assignee of less than the entire right, title, and interest (check applicable box):

   [ ] The extent (by percentage) of its ownership interest is _____%. Additional Statement(s) by the owners holding the balance of the interest must be submitted to account for 100% of the ownership interest.

   [ ] There are unspecified percentages of ownership. The other parties, including inventors, who together own the entire right, title and interest are:

   Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

3. [ ] The assignee of an undivided interest in the entirety (a complete assignment from one of the joint inventors was made). The other parties, including inventors, who together own the entire right, title, and interest are:

   Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the entire right, title, and interest.

4. [ ] The recipient, via a court proceeding or the like (*e.g.*, bankruptcy, probate), of an undivided interest in the entirety (a complete transfer of ownership interest was made). The certified document(s) showing the transfer is attached.

The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose **one** of options A or B below):

A. [ ] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

B. [X] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: DU ET AL. To: PHARMASSET , INC.

   The document was recorded in the United States Patent and Trademark Office at Reel 033404, Frame 0944, or for which a copy thereof is attached.

2. From: PHARMASSET, INC. To: GILEAD PHARMASSET LLC

   The document was recorded in the United States Patent and Trademark Office at Reel 033429, Frame 0375, or for which a copy thereof is attached.

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.FormsWorkflow.com

PTO/AIA/96 (08-12)
Approved for use through 01/31/2013. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(c)

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

4. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

5. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

6. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

☒ As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

NThakur (Reg. No. 59,123)	Aug. 22, 2014
Signature	Date
for Lorna L. Tanner	50782
Printed or Typed Name	Title or Registration Number

American LegalNet, Inc.
www.FormsWorkflow.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Du, et al.
Title:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
Appl. No.:	14/254,737
Filing Date:	04/16/2014
Examiner:	Lewis, Patrick T
Art Unit:	1672
Confirmation Number:	1673

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

This communication is responsive to the Notice of Non-Compliant Amendment dated June 30, 2014 concerning the above-referenced patent application. The Office set a two-month period to reply and as such this Response to Notice of Non-Compliant Amendment is timely filed before its due date of August 30, 2014.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks/Arguments begin on page 3 of this document.

Please amend the application as follows:


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1.-12. (Canceled)

13. (New) A method of treating a human infected by hepatitis C virus, comprising administering to the subject an effective amount of an NS3 inhibitor and an effective amount of a compound represented by the following formula:



14. (New) The method of claim 13, wherein the NS3 inhibitor is a compound represented by the following formula:



Gilead Exhibit 2026
PGR2023-00046 - Page 001869

REMARKS

Applicants respectfully request reconsideration of the present application in view of the foregoing amendments and in view of the reasons that follow.

Claim Amendments

Applicants note that the application was filed on April 16, 2014 with 12 original claims and a preliminary amendment was submitted along with the application, where claims 1-3 were canceled and new claims 4 and 5 were added. Further, in response to Notice to file Corrected papers dated May 9, 2014, the revised application with correct line spacing was filed on June 13, 2014 with 12 original claims and a preliminary amendment was submitted along with the application, where claims 1-3 were canceled and new claims 1 and 2 were added.

Applicants apologize for this inadvertent error regarding the claim numbers and submit herewith the listing of claims with the correct numbering in compliance with 37 CFR 1.121. Applicants have also corrected the dependency of the new claim 14 by making it dependent from claim 13.

The claims are amended in an effort to place the application in condition for allowance. The amendment of the claims is not intended to be a dedication to the public of the subject matter of the claims as previously presented. Applicants reserve the right to pursue the subject matter of the claims as previously presented in a continuing application. No new matter has been added by this amendment.

Upon entry of the amendment, claims 13 and 14 will be pending and under examination.

CONCLUSION

Applicants submit that this application is in condition for allowance, and they request an early indication to this effect. Examiner Lewis also is invited to contact the undersigned directly, should she feel that any issue warrants further consideration.

Gilead Exhibit 2026
PGR2023-00046 - Page 001870

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-6219. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-6219.

Respectfully submitted,

Date August 29, 2014

By /Neeta C. Thakur/

Sheppard, Mullin, Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, California 94301
Customer No. 117796

Neeta C. Thakur, Ph.D.
Agent for Applicants
Registration No. 59,123

Electronic Acknowledgement Receipt

EFS ID:	20009535
Application Number:	14254737
International Application Number:	
Confirmation Number:	1596
Title of Invention:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
First Named Inventor/Applicant Name:	Jinfa Du
Customer Number:	117796
Filer:	Neeta C. Thakur/Rachel Mena
Filer Authorized By:	Neeta C. Thakur
Attorney Docket Number:	PH3080.PC6-TRK1
Receipt Date:	29-AUG-2014
Filing Date:	16-APR-2014
Time Stamp:	17:16:22
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		37JD_199059_US6_Response_to_Notice_of_Non_Compliant_Amendment_.pdf	114374 f5a2e4e49cdfa2c221faef7948582d5fe50a94a5	yes	4

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Supplemental Response or Supplemental Amendment	1	1
	Claims	2	3
	Applicant Arguments/Remarks Made in an Amendment	4	4
Warnings:			
Information:			
	Total Files Size (in bytes):	114374	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
14/254,737	04/16/2014	Jinfa Du	PH3080.PC6-TRK1

CONFIRMATION NO. 1596

117796
Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

POA ACCEPTANCE LETTER

OC000000070434787

Date Mailed: 09/02/2014

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 08/22/2014.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/qtran/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

Gilead Exhibit 2026
PGR2023-00046 - Page 001874

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
14/254,737	04/16/2014	Jinfa Du	PH3080.PC6-TRK1

CONFIRMATION NO. 1596

25000
GILEAD SCIENCES, INC
333 LAKESIDE DR
FOSTER CITY, CA 94404

POWER OF ATTORNEY NOTICE

OC000000070434778

Date Mailed: 09/02/2014

NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 08/22/2014.

- The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

/qtran/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

117796 7590 09/25/2014

Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

EXAMINER
LEWIS, PATRICK T

ART UNIT	PAPER NUMBER
1672	

DATE MAILED: 09/25/2014

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	04/16/2014	Jinfa Du	37JD-199059-US6	1596

TITLE OF INVENTION: NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$960	$0	$0	$960	12/26/2014

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Gilead Exhibit 2026
PGR2023-00046 - Page 001876

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

117796 7590 09/25/2014
Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	04/16/2014	Jinfa Du	37JD-199059-US6	1596

TITLE OF INVENTION: NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$960	$0	$0	$960	12/26/2014

EXAMINER	ART UNIT	CLASS-SUBCLASS
LEWIS, PATRICK T	1672	514-051000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
- ❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
- ❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.
1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. The following fee(s) are submitted:
- ❑ Issue Fee
- ❑ Publication Fee (No small entity discount permitted)
- ❑ Advance Order - # of Copies _____

4b. Payment of Fee(s): (**Please first reapply any previously paid issue fee shown above**)
- ❑ A check is enclosed.
- ❑ Payment by credit card. Form PTO-2038 is attached.
- ❑ The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)
- ❑ Applicant certifying micro entity status. See 37 CFR 1.29
  NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
- ❑ Applicant asserting small entity status. See 37 CFR 1.27
  NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
- ❑ Applicant changing to regular undiscounted fee status.
  NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

PTOL-85 Part B (10-13) Approved for use through 10/31/2013. OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Gilead Exhibit 2026
PGR2023-00046 - Page 001877

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	04/16/2014	Jinfa Du	37JD-199059-US6	1596

117796 7590 09/25/2014

Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

EXAMINER	
LEWIS, PATRICK T	

ART UNIT	PAPER NUMBER
1672	

DATE MAILED: 09/25/2014

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Gilead Exhibit 2026
PGR2023-00046 - Page 001878

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 14/254,737	Applicant(s) DU ET AL.	
	Examiner PATRICK LEWIS	Art Unit 1672	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *Amendment dated 9/2/2014*.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on_____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are *13 and 14*. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov .
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:
   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____ .
5. ☐ Examiner's Amendment/Comment
6. ☐ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/PATRICK LEWIS/
Primary Examiner, Art Unit 1672

Gilead Exhibit 2026
PGR2023-00046 - Page 001880

Notice of References Cited	Application/Control No. 14/254,737	Applicant(s)/Patent Under Reexamination DU ET AL.	
	Examiner PATRICK LEWIS	Art Unit 1672	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Siddiqui et al. J. Med. Chem. (1999), Vol. 42, pages 393-399.
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Gilead Exhibit 2026
PGR2023-00046 - Page 001881

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14254737	DU ET AL.
	Examiner	Art Unit
	PATRICK LEWIS	1672

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES		
Search Notes	Date	Examiner
Inventor, Updated search of USSN 14/057,675	8/18/2014	/PL/
Inventor, Updated search of USSN 14/057,675	9/21/2014	/PL/

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
514	42, 43, 49, 50, 51	9/21/2014	/PL/

WEST Search History

Hide Items | Restore | Clear | Close

DATE: Sunday, June 16, 2013

Hide?	Set Name	Query	Hit Count
Interference			
DB=PGPB,USPT; PLUR=YES; OP=ADJ			
☐	L3	L2 and (hcv or polio or west nile or dengue or hepatitis a or rhinovirus)	41
☐	L2	L1 and phosphoramidate prodrug	53
☐	L1	(514/42,43,49,50,51)![CCLS]	4222

END OF SEARCH HISTORY

Gilead Exhibit 2026
PGR2023-00046 - Page 001883

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14254737	DU ET AL.
	Examiner	Art Unit
	PATRICK LEWIS	1672

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	08/18/2014	09/21/2014							
	1	-	-							
	2	-	-							
	3	-	-							
	4	✓	-							
	5	O	-							
	6		-							
	7		-							
	8		-							
	9		-							
	10		-							
	11		-							
	12		-							
	13		=							
	14		=							

Gilead Exhibit 2026
PGR2023-00046 - Page 001884

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14254737	DU ET AL.
	Examiner	**Art Unit**
	PATRICK LEWIS	1672

CPC						
Symbol					**Type**	**Version**
C07H		19	/	06	F	2013-01-01
C07D		417	/	14	I	2013-01-01
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			

CPC Combination Sets							
Symbol				**Type**	**Set**	**Ranking**	**Version**
			/				
			/				

NONE (Assistant Examiner)	(Date)	**Total Claims Allowed:** 2	
/PATRICK LEWIS/ Primary Examiner.Art Unit 1672 (Primary Examiner)	9/21/2014 (Date)	O.G. Print Claim(s) 1	O.G. Print Figure NONE

Gilead Exhibit 2026
PGR2023-00046 - Page 001885

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14254737	DU ET AL.
	Examiner	**Art Unit**
	PATRICK LEWIS	1672

US ORIGINAL CLASSIFICATION	
CLASS	**SUBCLASS**
514	51

CROSS REFERENCE(S)

CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)				
514	42	43	49	50	

INTERNATIONAL CLASSIFICATION										
CLAIMED					**NON-CLAIMED**					
A	0	1	N	43 / 04 (2006.01.01)						
A	6	1	K	31 / 70 (2006.01.01)						

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	2	
/PATRICK LEWIS/ Primary Examiner.Art Unit 1672	9/21/2014	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	NONE

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	14254737	DU ET AL.
	Examiner	**Art Unit**
	PATRICK LEWIS	1672

☒ **Claims renumbered in the same order as presented by applicant** ☐ **CPA** ☐ **T.D.** ☐ **R.1.47**

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1														
	2														
	3														
	4														
	5														
	6														
	7														
	8														
	9														
	10														
	11														
	12														
	13														
	14														

NONE (Assistant Examiner)	(Date)	**Total Claims Allowed:** 2	
/PATRICK LEWIS/ Primary Examiner.Art Unit 1672 (Primary Examiner)	9/21/2014 (Date)	O.G. Print Claim(s) 1	O.G. Print Figure NONE

Gilead Exhibit 2026
PGR2023-00046 - Page 001887

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
14/254,737	04/16/2014	Jinfa Du	37JD-199059-US6

CONFIRMATION NO. 1596

117796
Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

PUBLICATION NOTICE



Title:NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Publication No.US-2014-0288020-A1
Publication Date:09/25/2014

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Office of Public Records. The Office of Public Records can be reached by telephone at (703) 308-9726 or (800) 972-6382, by facsimile at (703) 305-8759, by mail addressed to the United States Patent and Trademark Office, Office of Public Records, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently http://pair.uspto.gov/. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

Gilead Exhibit 2026
PGR2023-00046 - Page 001888

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Jinfa Du, et al.
Title:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
Appl. No.	14/254,737
Filing Date	04/16/2014
Examiner:	LEWIS, PATRICK T.
Art Unit:	1672
Confirmation No.:	1596

AMENDMENT UNDER 37 CFR 1.312

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

Applicant acknowledges receipt of a Notice of Allowance in the above-captioned application. Prior to payment of the issue fee, please amend the application as follows:

Amendments to the Specification begin on page 2 of this document.





Remarks/Arguments begin on page 7 of this document.






Please amend the application as follows:

Amendment to the Specification





Please delete the table starting on page 676, line 6 ending on page 678, last line and also delete the footnote under the table on page 679, line 1.

Please add the following table with the footnote starting on page 676, line 6.




Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
5		-1.21	3.0
6		-0.45	ND
7		0.31	ND
8		-1.48	2.11

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
10		-1.25	19.15
11		-0.55	ND
12		0.31	ND
15		ND	0.86
25		-2.22	0.39




SMRH:433507508.1

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
27		-2.25	0.66
28		-2.16	0.75
36		-1.64	21.9
39		-1.78	0.47

SMRH:433507508.1

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
49		-2.69	0.126
53		-1.33	<0.3
54		-1.55	0.57

SMRH:433507508.1

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
55		-2.38	<0.3
69		-2.25	< 0.3
70		-2.25	<0.3

[1](4-BrPh): 4-bromo-phenyl.

REMARKS

Applicants note that in the specification filed on 4/16/2014, the chemistry structures in the table on pages 676-678 are not legible. Applicants have redrawn the chemical structures of the compounds in the table on pages 676-678 such that they are now legible. Further, Applicants opted for "deleting and adding" instead of "replacing" the table by showing mark-ups in order to make the structures as clear as possible.

Applicants submit that no new matter has been added and respectfully request the entry thereof.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-6219. If any additional extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-6219.

Respectfully submitted,

Date October 22, 2014

By /Neeta C. Thakur/

Sheppard, Mullin, Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301
Telephone: (650) 815-2600

Neeta C. Thakur, Ph.D.
Attorney for Applicant
Registration No. 59,123

SMRH:433507508.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Jinfa Du, et al.
Title:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
Appl. No.	14/254,737
Filing Date	04/16/2014
Examiner:	LEWIS, PATRICK T
Art Unit:	1672
Confirmation No.:	1596

COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

Applicant submits herewith Form PTO/SB/08 in accordance with 37 C.F.R. §§1.56 and 1.98. The references listed in the attached PTO/SB/08 were submitted on October 18, 2013 in U.S. Parent Application No. 14/057,675. Applicant assumes that the references submitted in the parent were considered by the Examiner in this case per MPEP §609.02 A2. A listing of the references is being resubmitted in the new PTO/SB/08 attached in this continuing application because the Applicant desires the information to be printed on the patent. Although the copies of references are not being provided here as they were provided in the parent case(s), Applicant would be pleased to provide copies of any such documents at the Examiner's request.

The submission of any document herewith is not an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 C.F.R. §1.56(b). Applicant does not waive

any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document submitted herewith.

Respectfully submitted,

Date October 22, 2014

By /Neeta C. Thakur/

Sheppard, Mullin, Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301
Telephone: (650) 815-2600
Customer No. 117796

Neeta C. Thakur, Ph.D.
Attorney for Applicant
Registration No. 59,123

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 1 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		RE29835	1978-11-14	WITKOWSKI ET AL.	
		3798209	1974-03-19	WITKOWSKI ET AL.	
		3852267	1974-12-03	MEYER, JR. ET AL.	
		4814477	1989-03-21	WIJNBERG ET AL.	
		4957924	1990-09-18	BEAUCHAMP	
		5026687	1991-06-25	YARCHOAN ET AL.	
		5118820	1992-06-02	HERTEL	
		5149794	1992-09-22	YATVIN ET AL.	
		5157027	1992-10-20	BILLER ET AL.	
		5192549	1993-03-09	BARENOLZ ET AL.	
		5194654	1993-03-16	HOSTETLER ET AL.	
		5223263	1993-06-29	HOSTETLER ET AL.	
		5256641	1993-10-26	YATVIN ET AL.	
		5256798	1993-10-26	CHOU ET AL.	
		5372808	1994-12-13	BLATT ET AL.	
		5376380	1994-12-27	KIKUCHI ET AL.	
		5405598	1995-04-11	SCHINAZI ET AL.	
		5411947	1995-05-02	HOSTETLER ET AL.	
		5420266	1995-05-30	BRITTON ET AL.	
		5426183	1995-06-20	KJELL	
		5453499	1995-09-26	CHOU ET AL.	
		5462724	1995-10-31	SCHINAZI ET AL.	
		5463092	1995-10-31	HOSTETLER ET AL.	
		5496546	1996-03-05	WANG ET AL.	
		5538865	1996-07-23	REYES ET AL.	
		5543389	1996-08-06	YATVIN ET AL.	
		5543390	1996-08-06	YATVIN ET AL.	
		5543391	1996-08-06	YATVIN ET AL.	
		5554728	1996-09-10	BASAVA ET AL.	
		5610054	1997-03-11	DRAPER	
		5633358	1997-05-27	GRUETZKE ET AL.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 2 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		5633388	1997-05-27	DIANA ET AL.	
		5676942	1997-10-14	TESTA ET AL.	
		5703058	1997-12-30	SCHINAZI ET AL.	
		5711944	1998-01-27	GILBERT ET AL.	
		5725859	1998-03-10	OMER	
		5738845	1998-04-14	LMAKAWA	
		5738846	1998-04-14	GREENWALD ET AL.	
		5747646	1998-05-05	HAKIMI ET AL.	
		5767097	1998-06-16	TAM	
		5792834	1998-08-11	HAKIMI ET AL.	
		5830455	1998-11-03	VALTUENA ET AL.	
		5830905	1998-11-03	DIANA ET AL.	
		5834594	1998-11-10	HAKIMI ET AL.	
		5837257	1998-11-17	TSAI ET AL.	
		5846964	1998-12-08	OZEKI	
		5849696	1998-12-15	CHRETIEN ET AL.	
		5869253	1999-02-09	DRAPER	
		5891874	1999-04-06	COLACINO ET AL.	
		5905070	1999-05-18	SCHINAZI ET AL.	
		5908621	1999-06-01	GLUE ET AL.	
		5922757	1999-07-13	CHOJKIER	
		5928636	1999-07-27	ALBER ET AL.	
		5942223	1999-08-24	BAZER ET AL.	
		5980884	1999-11-09	BLATT ET AL.	
		5990276	1999-11-23	ZHANG ET AL.	
		6004933	1999-12-21	SPRUCE ET AL.	
		6034134	2000-03-07	GOLD ET AL.	
		6043077	2000-03-28	BARBER ET AL.	
		6056961	2000-05-02	LAVIE ET AL.	
		6060080	2000-05-09	KIKUCHI ET AL.	
		6090932	2000-07-18	MCGEE ET AL.	
		6130326	2000-10-10	RAMASAMY ET AL.	
		6132763	2000-10-17	FISHER	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 3 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		6156501	2000-12-05	MCGALL ET AL.	
		6180134	2001-01-30	ZALIPSKY ET AL.	
		6232300	2001-05-15	SCHINAZI ET AL.	
		6239159	2001-05-29	BROWN ET AL.	
		6348587	2002-02-19	SCHINAZI ET AL.	
		6372883	2002-04-16	ATTWOOD ET AL.	
		6391859	2002-05-21	SCHINAZI ET AL.	
		6410531	2002-06-25	LLINAS-BRUNET ET AL.	
		6420380	2002-07-16	LLINAS-BRUNET ET AL.	
		6455513	2002-09-24	MCGUIGAN ET AL.	
		6455690	2002-09-24	TAM ET AL.	
		6475985	2002-11-05	WAGNER ET AL.	
		6479463	2002-11-12	WANG ET AL.	
		6495677	2002-12-17	RAMASAMY ET AL.	
		6509320	2003-01-21	WANG ET AL.	
		6534523	2003-03-18	LLINAS-8RUNET ET AL.	
		6552183	2003-04-22	RAMASAMY ET AL.	
		6555677	2003-04-29	PETRILLO ET AL.	
		6573248	2003-06-03	RAMASAMY ET AL.	
		6642206	2003-11-04	RAMASAMY ET AL.	
		6660721	2003-12-09	DEVOS ET AL.	
		6677314	2004-01-13	KLECKER ET AL.	
		6677315	2004-01-13	KLECKER ET AL.	
		6680303	2004-01-20	SCHINAZI ET AL.	
		6682715	2004-01-27	KLECKER ET AL.	
		6683045	2004-01-27	KLECKER ET AL.	
		6703374	2004-03-09	KLECKER ET AL.	
		6753309	2004-06-22	KLECKER ET AL.	
		6777395	2004-08-17	BHAT ET AL.	
		6784166	2004-08-31	DEVOS ET AL.	
		6787305	2004-09-07	LI ET AL.	
		6787526	2004-09-07	BRYANT ET AL.	
		6815542	2004-11-09	HONG ET AL.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 4 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		6846810	2005-01-25	MARTIN ET AL.	
		6897201	2005-05-24	BOYER ET AL.	
		6908924	2005-06-21	WATANABE ET AL.	
		6911424	2005-06-28	SCHINAZI ET AL.	
		6914054	2005-07-05	SOMMADOSSI ET AL.	
		6962991	2005-11-08	DEMPCY ET AL.	
		7018985	2006-03-28	BOYER ET AL.	
		7018989	2006-03-28	MCGUIGAN ET AL.	
		7081449	2006-07-25	PIETRZKOWSKI ET AL.	
		7105499	2006-09-12	CARROLL ET AL.	
		7148206	2006-12-12	SOMMADOSSI ET AL.	
		7163929	2007-01-16	SOMMADOSSI ET AL.	
		7202224	2007-04-10	ELDRUP, ET AL.	
		7217523	2007-05-15	WAGNER	
		7268119	2007-09-11	COOK ET AL.	
		7307065	2007-12-11	SCHINAZI ET AL.	
		7365057	2008-04-29	LACOLLA ET AL.	
		7390791	2008-06-24	BECKER, ET AL.	
		7754699	2010-07-13	CHUN ET AL.	
		7429572	2008-09-30	CLARK	
		7601820	2009-10-13	WANG ET AL.	
		7879815	2011-02-01	MACCOSS ET AL.	
		7964580	2011-06-21	SOFIA ET AL.	
		8148349	2012-04-03	MEPPEN ET AL.	
		8173621	2012-05-08	DU, ET AL.	
		8334270	2012-12-18	SOFIA, ET AL.	
		8551973	2013-10-08	BAO ET AL.	
		20070087960	2007-04-19	STORER ET AL.	
		2009280084	2009-11-12	SCHINAZI ET AL.	
		20010034440	2001-10-25	SHEPARD ET AL.	
		20020058635	2002-05-16	AVERETT	
		20020198173	2002-12-26	SCHINAZI ET AL.	
		20030060400	2003-03-27	LACOLLA ET AL.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 5 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		20030120071	2003-06-26	MCGUIGAN ET AL.	
		20030144502	2003-07-31	PIETRZKOWSKI ET AL.	
		20030153744	2003-08-14	MEKOUAR ET AL.	
		20030050229	2003-03-13	SOMMADOSSI ET AL.	
		20030187018	2003-10-02	LLINAS-BRUNET ET AL.	
		20040006007	2004-01-08	GOSSELIN ET AL.	
		20040014108	2004-01-22	ELDRUP ET AL.	
		20040023240	2004-02-05	MARLIERE ET AL.	
		20040023901	2004-02-05	COOK ET AL.	
		20040059104	2004-03-25	COOK ET AL.	
		20040063622	2004-04-01	SOMMADOSSI ET AL.	
		20040067901	2004-04-08	BHAT ET AL.	
		20040072788	2004-04-15	BHAT ET AL.	
		20040097461	2004-05-20	SOMMADOSSI ET AL.	
		20040097462	2004-05-20	SOMMADOSSI ET AL.	
		20040101535	2004-05-27	SOMMODOSSI ET AL.	
		20040102414	2004-05-27	SOMMADOSSI ET AL.	
		20040110717	2004-06-10	CARROLL ET AL.	
		20040167140	2004-08-26	SCHINAZI ET AL.	
		20040191824	2004-09-30	DEMPCY ET AL.	
		20040214844	2004-10-28	OTTO ET AL.	
		20040229839	2004-11-18	BABU ET AL.	
		20040229840	2004-11-18	BHAT ET AL.	
		20040248892	2004-12-09	WANG	
		20040254141	2004-12-16	SCHINAZI ET AL.	
		20040259934	2004-12-23	OLSEN ET AL.	
		20040265969	2004-12-30	LI ET AL.	
		20040266996	2004-12-30	RABI	
		20050009737	2005-01-13	CLARK	
		20050020825	2005-01-27	STORER ET AL.	
		20050026853	2005-02-03	MEKOUAR ET AL.	
		20050031588	2005-02-10	SOMMADOSSI ET AL.	
		20050059632	2005-03-17	STORER ET AL.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 6 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		20050075309	2005-04-07	STORER ET AL.	
		20050080034	2005-04-14	STANDRING ET AL.	
		20050090660	2005-04-28	WATANABE ET AL.	
		20050124532	2005-06-09	SOMMADOSSI ET AL.	
		20050130931	2005-06-16	BOYER ET AL.	
		20050137161	2005-06-23	SOMMADOSSI ET AL.	
		20050148534	2005-07-07	CASTELLINO ET AL.	
		20050154056	2005-07-14	YANG ET AL.	
		20050164960	2005-07-28	OLSEN ET AL.	
		20050215513	2005-09-29	BOOJAMRA ET AL.	
		20050227947	2005-10-13	CHEN ET AL.	
		20050261237	2005-11-24	BOOJAMRA ET AL.	
		20050267018	2005-12-01	BLATT ET AL.	
		20060003951	2006-01-05	MAKOUAR ET AL.	
		20060014943	2006-01-19	DEMPCY ET AL.	
		20060035866	2006-02-16	CANNIZZARO ET AL.	
		20060040890	2006-02-23	MARTIN ET AL.	
		20060040927	2006-02-23	BLAKE ET AL.	
		20060040944	2006-02-23	GOSSELIN ET AL.	
		20060079478	2006-04-13	BOOJAMRA ET AL.	
		20060110727	2006-05-25	MCGALL ET AL.	
		20060199738	2006-09-07	OTSUBO ET AL.	
		20060122146	2006-06-08	CHUN ET AL.	
		20060122154	2006-06-08	OLSEN ET AL.	
		20060142238	2006-06-29	MCGUIGAN	
		20060166964	2006-07-27	HUDYMA ET AL.	
		20060194749	2006-08-31	KEICHER ET AL.	
		20060199783	2006-09-07	WANG ET AL.	
		2006/116557	2006-11-02	GENELABS TECHNOLOGIES, INC	
		20060241064	2006-10-26	ROBERTS ET AL.	
		20060276511	2006-12-07	SERRANO-WU ET AL.	
		20060293306	2006-12-28	BEAULIEU ET AL.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 7 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		20070015905	2007-01-18	LACOLLA ET AL.	
		20070037735	2007-02-15	GOSSELIN ET AL.	
		20070037773	2007-02-15	SOMMADOSSI ET AL.	
		20070042939	2007-02-22	LACOLLA ET AL.	
		20070042988	2007-02-22	KLUMPP ET AL.	
		20070042990	2007-02-22	GOSSELIN ET AL.	
		20070049754	2007-03-01	BOOJAMRA ET AL.	
		20070060498	2007-03-15	GOSSELIN ET AL.	
		20070060541	2007-03-15	GOSSELIN ET AL.	
		20070197463	2007-08-23	CHUN ET AL.	
		20070225249	2007-09-27	SHI	
		20080070861	2008-03-20	CLARK	
		20080253995	2008-10-16	CLARK	
		20070265222	2007-11-15	MACCOSS ET AL.	
		20070275912	2007-11-29	BHAT ET AL.	
		20070275947	2007-11-29	BERGSTROM	
		20090137521	2009-05-28	HAMILTON ET AL.	
		20090176732	2009-07-09	BEIGELMAN ET AL.	
		20090004135	2009-01-01	CLARK	
		20090036666	2009-02-05	CLARK	
		20090233879	2009-09-17	REDDY ET AL.	
		20090306007	2009-12-10	WAGNER	
		20100029008	2010-02-04	STUTZ ET AL.	
		20100035835	2010-02-11	NARJES ET AL.	
		20100081628	2010-04-01	DU, ET AL.	
		20100137576	2010-06-03	STEC ET AL.	
		20100152128	2010-06-17	ATTENNI ET AL.	
		20100173863	2010-07-08	SCHINAZI ET AL.	
		20100227801	2010-09-09	HOPKINS ET AL.	
		20100048917	2010-02-25	WANG ET AL.	
		20100279973	2010-11-04	CHUN; BYOUNG-KWON; ET AL.	
		20100286083	2010-11-11	BAO; DONGHUI; ET AL.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 8 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		20100298257	2010-11-25	ROSS; BRUCE; ET AL.	
		20100316594	2010-12-16	SOMMADOSSI ET AL.	
		20110015146	2011-01-20	SOFIA; MUCHAEL JOSEPH; ET AL.	
		20110124592	2011-05-26	MCGUIGAN ET AL.	
		20110245484	2011-10-10	ROSS; BRUCE S.; ET AL.	
		20110251152	2011-10-13	ROSS; BRUCE S.; ET AL.	
		20120107278	2012-05-03	BERREY; MIRIAM MICHELLE; ET AL.	
		20110257122	2011-10-20	SOFIA ET AL.	
		20130109647	2013-05-02	BERREY	
		20130136776	2013-05-30	CLEARY	
		20130029929	2013-01-31	SOFIA ET AL.	
		20130165401	2013-06-27	ROSS ET AL.	
		20130165644	2013-06-27	ROSS ET AL.	
		20130288997	2013-10-31	ROSS ET AL.	
		20130310551	2013-11-21	ROSS ET AL.	
		20130109647	2013-05-02	BERREY	
		20130136776	2013-05-30	CLEARY	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Application Document Serial Number-Kind Code[2] (*if known*)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		CN 101108870	2008-01-23	YIXIN LENG		
		DE 199 14 474	1999-10-07	HOFFMANN LA-ROCHE AG		
		EP 0 180 276	1986-05-07	OCE ANDENO BV		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 9 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		EP 0 350 287	1990-01-10	VICAL, INC.		
		EP 1 828 217	2007-09-05	FEBIT BIOTECH GMBH		
		EP 1 881 001	2008-01-23	TIBOTEC PHARM, LTD.		
		EP 2 097 430	2009-09-09	CT BADAN MOLEKULAR I MAKRO		
		EP 2 124 555	2009-12-02	MERCK & CO, INC.		
		EP 2 207 786	2012-03-07	EISAI, INC.		
		JP 5 238939	1993-09-17	NODA SANGYO KAGAKU KENKYUSHO KIKKOMAN CORP		
		WO 1989/002733	1989-04-06	UNIV CALIFORNIA		
		WO 1990/000555	1990-01-25	VICAL, INC.		
		WO 1991/016920	1991-11-14	VICAL, INC.		
		WO 1991/018914	1991-12-12	VICAL, INC.		
		WO 1991/019721	1991-12-26	GLAZIER ARNOLD		
		WO 1993/000910	1993-01-21	VICAL, INC.		
		WO 1994/026273	1994-11-24	HOSTETLER KARL Y		
		WO 1995/013090	1995-05-18	ENZON, INC.		
		WO 1995/024185	1995-09-14	ISIS PHARMACEUTICALS, INC.		
		WO 1996/015132	1996-05-23	UNIV CALIFORNIA		
		WO 1996/032403	1996-10-17	SCHERING AG		
		WO 1997/012033	1997-04-03	UNIV EMORY		
		WO 1997/036554	1997-10-09	VIROPHARMA, INC.		
		WO 1998/016184	1998-04-23	ICN PHARMACEUTICALS		
		WO 1998/017679	1998-04-30	VERTEX PHARMA		
		WO 1998/022496	1998-05-28	HOFFMANN LA-ROCHE AG		
		WO 1999/007734	1999-02-18	BOEHRINGER INGELHEIM, LTD.		
		WO 1999/015194	1999-04-01	SCHERING CORP.		
		WO 1999/032139	1999-07-01	ENZON, INC.		
		WO 1999/032140	1999-07-01	ENZON, INC.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 10 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 1999/043691	1999-09-02	UNIV EMORY UNIV GEORGIA RES FOUND		
		WO 1999/059621	1999-11-25	SCHERING CORP.		
		WO 1999/064016	1999-12-16	HOFFMANN LA-ROCHE AG		
		WO 2000/006529	2000-02-10	ANGELETII P IST RICHERCHE BIO		
		WO 2000/009531	2000-02-24	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2000/037110	2000-06-29	SCHERING CORP		
		WO 2001/009121	2001-02-08	BASF AG		
		WO 2001/032153	2001-05-10	BIOCHEM PHARMA, INC.		
		WO 2001/060315	2001-08-23	IAF BIOCHEM INT		
		WO 2001/081359	2001-11-01	SCHERING CORP.		
		WO 2001/090121	2001-11-29	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2001/091737	2001-12-06	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2001/092282	2001-12-06	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2001/096353	2001-12-20	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2001/079246	2001-10-25	PHARMASSET, LTD.		
		WO 2002/008187	2002-01-31	SCHERING CORP. CORVAS INT. INC.		
		WO 2002/018404	2002-03-07	HOFFMANN LA-ROCHE AG		
		WO 2002/032414	2002-04-25	SCHERING CORP.		
		WO 2002/032920	2002-04-25	PHARMASSET LTD.		
		WO 2002/048116	2002-06-20	BRISTOL-MYERS SQUIBB PHARMA CO		
		WO 2002/048157	2002-06-20	BRISTOL-MYERS SQUIBB PHARMA CO		
		WO 2002/048165	2002-06-20	PHARMASSET LTD.		
		WO 2002/048172	2002-06-20	SCHERING CORP.		
		WO 2002/057287	2002-07-25	MERCK & CO., INC.		
		WO 2002/057425	2002-07-25	MERCK & CO., INC.		
		WO 2002/060926	2002-08-08	SQUIBB BRISTOL MYERS CO.		
		WO 2002/008198	2002-01-31	SCHERING CORP.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 11 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2002/008251	2002-01-31	CORVAS INT., INC. [US]		
		WO 2002/008256	2002-01-31	SCHERING CORP [US] CORVAS INT., INC.		
		WO 2002/100415	2002-12-19	F. HOFFMANN-LA ROCHE AG		
		WO 2003/000713	2003-01-03	GLAXO GROUP LTD.		
		WO 2003/006490	2003-01-23	VERTEX PHARMA., INC.		
		WO 2003/010141	2003-02-06	BOEHRINGER INGELHEIM CA LTD.		
		WO 2003/024461	2003-03-27	SCHERING CORP.		
		WO 2003/026589	2003-04-03	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2003/037895	2003-05-08	GLAXO GROUP LTD.		
		WO 2003/051899	2003-06-26	RIBAPHARM INC.		
		WO 2003/053989	2003-07-03	MRC TECHNOLOGY LTD.		
		WO 2003/061576	2003-07-31	RIBAPHARM INC.		
		WO 2003/062256	2003-07-31	RIBAPHARM INC.		
		WO 2003/064456	2003-08-07	BOEHRINGER INGELHEIM INT		
		WO 2003/068244	2003-08-21	MERCK & CO., INC.		
		WO 2003/101993	2003-12-11	NEOGENESIS PHARMACEUTICALS INC.		
		WO 2003/104250	2003-12-18	KYLIX B V		
		WO 2003/105770	2003-12-24	MERCK & CO., INC.		
		WO 2003/106477	2003-12-24	ISIS PHARMACEUTICALS INC.		
		WO 2004/000858	2003-12-31	MERCK & CO,. INC.		
		WO 2004/002422	2004-01-08	IDENIX CAYMAN LTD UNIV DEGLI STUDI DI CAGLIARI		
		WO 2004/002940	2004-01-08	PHARMACIA & UPJOHN CO.		
		WO 2004/002944	2004-01-08	PHARMACIA & UPJOHN CO.		
		WO 2004/002977	2004-01-08	PHARMACIA & UPJOHN CO.		
		WO 2004/002999	2004-01-08	IDENIX CAYMAN LTD.		
		WO 2004/003000	2004-01-08	IDENIX CAYMAN LTD CENTRE NAT RECH SCIENT		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 12 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2004/003138	2004-01-08	MERCK & CO., INC.		
		WO 2004/007512	2004-01-22	MERCK & CO., INC.		
		WO 2004/009020	2004-01-29	MERCK & CO., INC.		
		WO 2004/009610	2004-01-29	PTC THERAPEUTICS INC.		
		WO 2004/011478	2004-02-05	MICROLOGIX BIOTECH INC.		
		WO 2004/035571	2004-04-29	RIGEL PHARMACEUTICALS INC.		
		WO 2004/041201	2004-05-21	VIROPHARMA INC [US] WYETH CORP.		
		WO 2004/046331	2004-06-03	IDENIX CAYMAN LTD.		
		WO 2004/065367	2004-08-05	BOEHRINGER INGELHEIM INT		
		WO 2004/080466	2004-09-23	RIBAPHARM INC.		
		WO 2004/094452	2004-11-04	SQUIBB BRISTOL MYERS CO.		
		WO 2004/096210	2004-11-11	GLAXO GROUP LTD.		
		WO 2004/096234	2004-11-11	GILEAD SCIENCES INC.		
		WO 2004/096235	2004-11-11	GILEAD SCIENCES INC.		
		WO 2004/096286	2004-11-11	GILEAD SCIENCES INC.		
		WO 2004/106356	2004-12-09	UNIV. SYDDANSK		
		WO 2004/014313	2004-02-19	SQUIBB BRISTOL MYERS CO.		
		WO 2004/014852	2004-02-19	SQUIBB BRISTOL MYERS CO.		
		WO 2005/002626	2005-01-13	GILEAD SCIENCES INC.		
		WO 2005/003147	2005-01-13	PHARMASSET LTD.		
		WO 2005/007810	2005-01-27	GRINSTAFF MARK W		
		WO 2005/009418	2005-02-03	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2005/012327	2005-02-10	UNIV. COLLEGE CARDIFF CONSULTANTS LTD.		
		WO 2005/020884	2005-03-10	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2005/021568	2005-03-10	BIOTA INC.		
		WO 2005/028502	2005-03-31	VERTEX PHARMA INC.		
		WO 2005/037214	2005-04-28	INTERMUNE INC.		
		WO 2005/067900	2005-07-28	ACHILLION PHARMACEUTICALS INC.		
		WO 2005/072361	2005-08-11	MERCK & CO., INC.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 13 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2005/082144	2005-09-09	US GOV HEALTH & HUMAN SERV		
		WO 2005/087788	2005-09-22	UNIV. CALIFORNIA		
		WO 2005/095403	2005-10-13	INTERMUNE INC.		
		WO 2005/103045	2005-11-03	GLAXO GROUP LTD.		
		WO 2005/123087	2005-12-29	MERCK & CO., INC.		
		WO 2006/000922	2006-01-05	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2006/012078	2006-02-02	MERCK & CO., INC.		
		WO 2006/012440	2006-02-02	PHARMASSET INC.		
		WO 2006/020082	2006-02-23	SQUIBB BRISTOL MYERS CO.		
		WO 2006/029081	2006-03-16	NEOPHARM INC.		
		WO 2006/031725	2006-03-23	PHARMASSET INC.		
		WO 2006/035061	2006-04-06	TIBOTEC PHARM LTD.		
		WO 2006/037028	2006-04-06	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2006/050161	2006-05-11	BIOCRYST PHARMACEUTICALS, INC.		
		WO 2006/063149	2006-06-15	UNIV. MINNESOTA		
		WO 2006/063717	2006-06-22	UNIV. KARLSRUHE		
		WO 2006/065335	2006-06-22	MERCK & CO., INC.		
		WO 2006/065590	2006-06-22	XTL BIOPHARMACEUTICAL S INC.		
		WO 2006/093801	2006-09-08	ABBOTT LAB		
		WO 2006/100310	2006-09-28	TIBOTEC PHARM LTD.		
		WO 2006/120251	2006-11-16	IBOTEC PHARM LTD [IE]		
		WO 2006/120252	2006-11-16	TIBOTEC PHARM LTD.		
		WO 2006/121820	2006-11-16	VALEANT RES & DEV		
		WO 2007/002602	2007-01-04	DEPUY SPINE INC.		
		WO 2007/014920	2007-02-08	TIBOTEC PHARM., LTD.		
		WO 2007/014921	2007-02-08	TIBOTEC PHARM., LTD.		
		WO 2007/014922	2007-02-08	TIBOTEC PHARM., LTD.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 14 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2007/014925	2007-02-08	TIBOTEC PHARM., LTD.		
		WO 2007/014926	2007-02-08	TIBOTEC PHARM., LTD.		
		WO 2007/015824	2007-02-08	INTERMUNE INC.		
		WO 2007/020193	2007-02-22	F. HOFFMANN-LA ROCHE AG		
		WO 2007/027248	2007-03-08	VALEANT RES & DEV		
		WO 2007/039142	2007-04-12	GLAXO GROUP LTD.		
		WO 2007/039145	2007-04-12	GLAXO GROUP LTD.		
		WO 2007/065829	2007-06-14	F. HOFFMANN-LA ROCHE AG		
		WO 2007/070556	2007-06-21	GENELABS TECH INC.		
		WO 2007/076034	2007-07-05	ABBOTT LA		
		WO 2007/088148	2007-08-09	SMITHKLINE BEECHAM CORP.		
		WO 2007/093901	2007-08-23	PFIZER LTD.		
		WO 2007/095269	2007-08-23	MERCK & CO., INC.		
		WO 2007/092000	2007-08-16	SQUIBB BRISTOL MYERS CO.		
		WO 2008/010921	2008-01-24	GILEAD SCIENCES INC.		
		WO 2008/045419	2008-04-17	PHARMASSET INC.		
		WO 2008/048128	2008-04-24	CT BADAN MOLEKULAR I MAKRO		
		WO 2008/062206	2008-05-29	UNIV. COLLEGE CARDIFF CONSULTANT LTD.		
		WO 2008/079206	2008-07-03	MERCK & CO., INC.		
		WO 2008/082601	2008-07-10	IDENIX PHARMACEUTICALS INC.		
		WO 2008/085508	2008-07-17	MERCK & CO., INC.		
		WO 2008/142055	2008-11-27	ANGELETII P IST RICHERCHE BIO		
		WO 2009/052287	2009-04-23	EISAL CORP OF NORTH AMERICA		
		WO 2009/115893	2009-09-24	HETERO RESEARCH FOUNDATION		
		WO 2009/120878	2009-10-01	ALNYLAM PHARMACEUTICALS INC.		
		WO 2009/129120	2009-10-22	RFS PHARMA LLC		
		WO 2009/152095	2009-12-17	PHARMASSET INC.		
		WO 2010/042834	2010-04-15	ANADYS PHARMACEUTICALS INC.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 15 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2010/080878	2010-07-15	SCYNEXIS INC.		
		WO 2010/075554	2010-07-01	PHARMASSET INC.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		ABRAHAM et al., "Synthesis and Biological Activity of Aromatic Amino Acid Phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-Arabinofuranosylcytosine: Evidence of Phosphoramidase Activity," J. Med. Chem., Vol. 39, No. 23, pages 4569 - 4575, (1996)	
		ABRAHAM et al., "Synthesis, Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir," Nucleosides, Nucleotides and Nucleic Acids, Vol. 16, No. 10, pages 2079 - 2092 (1997)	
		AQUARO et al., "Activities of Masked 2',3'-Dideoxynucleoside Monophosphate Derivaties Against Human Immunodeficiency Virus in Resting Macrophages," Antimicrobial Agents and Chemotherapy, Vol. 44, No. 1, pages 173-177 (2000)	
		ASIF et al., "Pharmacokinetics of the Antiviral Agent B-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine in Rhesus Monkeys," Antimicrobial Agents and Chemotherapy, Vol. 51, No. 8, pages 2877 - 2882 (2007)	
		BALZARINI et al., "Mechanism of anti-HIV action of masked alaninyl d4t-MP derivatives," Proc. Natl. Acad. Sci., Vol. 93, pages 7295 - 7299 (1996)	
		BANKER et al., "Prodrugs," Modern Pharmaceutics, Third Edition, Revised and Expanded," pages 451 and 596 (1996)	
		BARTENSCHLAGER et al., "Kinetic and Structural Analyses of Hepatitis C Virus Polyprotein Processing," J. Virol., Vol. 68, No. 8, pages 5045 - 5055 (1994)	
		BARTENSCHLAGER et al., "Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions," J. Virol., Vol. 67, No. 7, pages 3835 - 3844 (1993)	
		BASCHANG et al., "Neue Derivate von Thymidin-3',5'-cyclophosphat," Angew. Chem., Vol. 85, No. 1, pages 44 - 45 (1973)	
		BATTAGLIA et al., "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection," The Annals of Pharmacotherapy, Vol. 34, No. 4, pages 487 - 494 (2000)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 16 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		BAZAN et al., "Detection of a Trypsin-like Serine Protease Domain in Flaviviruses and Pestiviruses," Virology, Vol. 171, pages 637 - 639 (1989)	
		BEAULIEUet al., "Inhibitors of the HGV NS5B polymerase: New hope for the treatment of hepatitis C infections," Current Opinion in Investigational Drugs, Vol. 5, No. 8, pages 838 - 850 (2004)	
		BEHRENS et al., "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus," The EMBO Journal, Vol. 15, No. 1, pages 12 - 22 (1996)	
		BERENGUER, M., Hepatitis C virus in the transplant setting, Antiviral Therapy, Vol. 3, Supplement 3, pages 125 - 136 (1998)	
		BHAT et al., "Synthesis and Pharmacokinetic Properties of Nucleoside Analogues as Possible Inhibitors of HCV RNA Replication," (Oral Session V: Hepatitis C Virus, Flaviviruses), 16th International Conference on Antiviral Research, Abstract No. 120, p. A75 (April 27 - May 1, 2003)	
		BROEDERS et al., "A 400- and 600-Mhz 'H NMR Confromational Study on Nucleoside Cyclic 3', 5' PV-TBP Systems. Conformational Transmission Induces Diequatorial Orientation of the 3', 5'-Dioxaphosphorinane Ring in a Nonchair Confirmation," J. Am. Chem. Soc., Vol. 112, No. 21, pages 7475 - 7482 (1990)	
		CALISHER et al., "Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera," J. Gen. Virol., Vol. 70, pages 37 - 43 (1989)	
		CARROLL et al., "Nucleoside Analog Inhibitors of Hepatitis C Virus Replication," Infectious Disorders - Drug Targets, Vol. 6, No. 1, pages 17 - 29 (2006)	
		CHANG et al., "Amino Acid Phosphoramidate Monoesters of 3'-Azido-3'-deoxythymidine: Relationship between Antiviral Potency and Intracellular Metabolism," J. Med. Chem., Vol. 44, No. 2, pages 223 - 231 (2001)	
		CHAPMAN et al., "Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340," Nucleosides, Nucleotides & Nucleic Acids, Vol. 20, No. 4 - 7, pages 621 - 628 (2001)	
		CHAPMAN et al., "Purification of PMPA Amidate Prodrugs by SMB Chromatography and X-Ray Crystallography of the Diastereomerically Pure GS-7340," Nucleosides, Nucleotides & Nucleic Acids, Vol. 20, No. 4 - 7, pages 1085 - 1090 (2001)	
		CHEN et al., "In Vivo Pharmacokinetics and Metabolism of Anti-Human Immunodeficiency Virus Agent D4t-5'-[P-Bromophenyl Methoxyalaninyl Phosphate] {Sampidine) In Mice," Drug Metabolism and Disposition, Vol. 29, No. 7, pages 1035 - 1041 (2001)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 17 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		CHEN et al., "Metabolism of Stavudine-5'-[P-Bromophenyl Methoxyalaninyl Phosphate], Stampidine, in Mice, Dogs, and Cats," Drug Metabolism and Disposition, Vol. 30, No. 12, pages 1523 - 1531 (2002)	
		CHOU et al., "Evidence that Human Histidine Triad Nucleotide Binding Protein 3 (Hint3) is a Distinct Branch of the Histidine Triad (HIT) Superfamily," J. Mol. Biol., Vol. 373, pages 978 - 989 (2007)	
		CHOU et al., "Phosphoramidate Pronucleotides: A Comparison of the Phosphoramidase Substrate Specificity of Human and Escherichia coli Histidine Triad Nucleotide Binding Proteins," Molecular Pharmaceutics, Vol. 4, No. 2, pages 208 - 217 (2006)	
		CHU et al., "Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the Fungus Penicillium Griseofulvum," Bioorg. & Med. Chem. Lett., Vol. 9, pages 1949 - 1952 (1999)	
		CHU et al., "Structure of Sch 68631: A New Hepatitis C Virue Proteinase Inhibitor from Streptomyces sp." Tet. Lett., Vol. 37, No. 40, pages 7229 - 7232 (1996)	
		CIHLAR et al. "Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131," Antimicrobial Agents and Chemotherapy, Vol. 52, No. 2, pages 655 - 665 (2008)	
		Claims of U.S. Patent Application No. 13/956,195 as amended Oct. 21, 2013	
		Claims of U.S. Patent Application No. 14/013,237 as amended Aug. 30, 2013	
		CLARK et al., "Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication," J. Med. Chem., Vol. 48, No. 17, pages 5504 - 5508 {2005)	
		CONGIATU et al. "Molecular Modeling Studies on the Binding of Some Protides to the Putative Human Phosphoramidase Hint1," Nucleosides, Nucleotides and Nucleic Acids, Vol. 26, pages 1121 - 1124 (2007)	
		CONGIATU et al., "Naphthyl Phosphoramidate Derivatives of BVdU as Potential Anticancer Agents: Design, Synthesis and Biological Evaluation," Nucleosides, Nucleotides, and Nucleic Acids, Vol. 24, No. 5 - 7, pages 485 - 489 (2005)	
		CURLEY et al., "Synthesis and anti-HIV evaluation of some phosphoramidate derivatives of AZT: studies on the effect of chain elongation on biological activity," Antiviral Research, Vol. 14, pages 345 - 356 (1990)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 18 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		DAVIS, G. L., "Current Therapy for Chronic Hepatitis C," Gastroenterology, Vol. 118, No. 2, pages S104 - S114 (2000)	
		D'CRUZ et al., "Stampidine: a selective oculo-genital microbicide," Journal of Antimicrobial Chemotherapy, Vol. 56, pages 10 - 19 (2005)	
		DE LOMBAERT et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors," J. Med. Chem., Vol. 37, No. 4, pages 498 - 511 (1994)	
		DRONTLE et al., "Designing a Pronucleotide Stratagem: Lessons from Amino Acid Phosphoramidates of Anticancer and Antiviral Pyrimidines," MiniReviews in Medicinal Chemistry, Vol. 4, No. 4, pages 409 - 419 (2004)	
		DUMEZ et al., "Large-Scale Synthesis and Formulation of GMP-Grade Stampidine, a New Anti-HIV Agent," Arzneim.-Forsch./Drug Res. (2006) 56(2a):136-151.	
		ECKART et al., "The Hepatitis C Virus Encodes a Serine Protease Involved in Processing of the Putative Nonstructural Proteins from the Viral Polyprotein Precursor," Biochemical and Biophysical Research Communications, Vol. 192, No. 2, pages 399 - 406 (1993)	
		EDMUNDSON et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2-dioxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide," J. Chem. Research (S), pages 122 - 123 (1989)	
		EGRON et al., "S-Acyl-2-thioethyl Phosphoramidate Diester Derivatives as Mononucleotide Prodrugs" J. Med. Chem., Vol. 46, No. 21, pages 4564 - 4571 (2003)	
		EISENBERG et al., "Metabolism of GS-7340, A Novel Phenyl Monophosphoramidate Intracellular Prodrug of PMPA, In Blood," Nucleosides, Nucleotides & Nucleic Acids, Vol. 20, No. 4 - 7, pages 1091 - 1098 (2001)	
		ELDRUP et al., "Oral Session V: Hepatitis C Virus, Flaviviruses," Program and Abstracts, The Sixteenth International Conference on Antiviral Research, page A75, Abstract 119 (April 27 to May 1, 2003)	
		ELDRUP et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase," J. Med. Chem., Vol. 47, No. 9, pages 2283 - 2295 (2004)	
		ENGELS et al., "Ctclophosphate, III. Synthese und Eignschaften von Uridin-3',5'-cyclophosphat-estern," Chemische Berichte, Vol. 110, No. 6, pages 2019 - 2027 (1977)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 19 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		Extended search report includes the supplementary European search report issued in European Application No. 05775359.2 dated September 15, 2010 (9 pages)	
		FAILLA et al., "Both NS3 and NS4A are Required for Proteolytic Processing of Hepatitis C Virus Nonstructural Proteins," J. Virol., Vol. 68, No. 6, pages 3753 - 3760 (1994)	
		FARQUHAR et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem., Vol. 26, No. 8, pages 1153 - 1158 (1983)	
		FARQUHAR et al., "Synthesis of Biological Evaluation of 9-[5'-(2-0xo-1,3,2-oxazaphosphorinan-2-yl)-beta-D-arabinosyl] adenine and 9-[5'-(2-0xo-1,3,2-dioxaphosphorinan-2-yl)-beta-D-arabinosyl]adenine: Potential Neutral Precursors of 9- [beta-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem., Vol. 28, No. 9, pages 1358 - 1361 (1985)	
		FREED et al., "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells," Biochemical Pharmacology, Vol. 38, No. 19, pages 3193 - 3198 (1989)	
		GILLESPIE, S., et al., "Stereoselective Inhibition of Cholesterol Esterase by Enantiomeric Phosphonates," Phosphorous, Sulfur and Silicon, 1997, 122: 205-208	
		GOEKJIAN et al., "Synthesis of Fluorinated Marcocyclic Bis(indolyl)maleimides as Potential 19F NMR Probes for Protein Kinase C," J. Org. Chem. Vol., 64., No. 12, pages 4238 - 4246 (1999)	
		GORBALENYA et al., "A conserved NTP-motif in putative helicases," Nature, Vol. 333, page 22 (1988)	
		GORBALENYA et al., "N-terminal domains of putative helicases of flavi-and pestiviruses may be serine proteases," Nucleic Acids Research, Vol. 17, No. 10, pages 3889 - 3897 (1989)	☐
		GRAKOUI et al., "A second hepatitis C virus-encoded proteinase," Proc. Natl. Acad. Sci., Vol. 90, pages 10583 - 10587 (1993)	☐
		GRAKOUI et al., "Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase- Dependent Polyprotein Clevage Sites," J. Viral., Vol. 67, No. 5, pages 2832 - 2843 (1993)	☐
		GRIFFITH et al., "HCV Anti-viral Agents," Annual Reports in Medicinal Chemistry, Vol. 39, pages 223 - 237 (2004)	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 20 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		GROMOVA et al., "Optical Rotatory Dispersion and Circular Dichroism of Mono- and Oligonucleotide-Amino Acids (Amidates)," Biochim. Biophys. Acta., Vol. 240, No. 1, pages 1 - 11 (1971)	
		GUDMUNDSSON et al., "Phosphoramidate Protides of 2',3'-Dideoxy-3'-fluoroadenosine and Related Nucleosides with Potent Activity Against HIV and HBV," Nucleosides, Nucleotides & Nucleic Acids (2003) 22 (10):1953-1961	
		GUDMUNDSSON et al., "Phosphoramidate Protides of Carbocyclic 2',3'-Dideoxy-3'-didehydro-7-Deazaadenosine with Potent Activity Against HIV and HBV", Nucleosides, Nucleotides and Nucleic Acids (2004), 23(12): 1929-1937	
		GUNIC et al., "6-Hydrazinopurine 2'-methyl ribonucleosides and their 5'-monophosphate prodrugs as potent hepatitis C virus inhibitors," Bioorg. & Med. Chem. Lett., Vol. 17, pages 2456 - 2458 (2007)	
		HALSTEAD, S. B., "Pathogenesis of Dengue: Challenges to Molecular Biology," Science, Vol. 239, pages 476 - 481 (1988)	
		HALSTEAD, S. B., "Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XI. Dengue," Review of Infectious Diseases, Vol. 6, No. 2, pages 251 - 263 (1984)	
		HARRIS et al., "Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine," Antiviral Chemistry & Chemotherapy, Vol 12, No. 5, pages 293 - 300 (2001)	
		HERNANDEZ et al., "Synthesis of Highly Functionalized Chiral Nitriles by Radical Fragmentation of beta-Hydroxy Azides. Convenient Transformation of Aldononitriles into 1,4- and 1,5-Iminoalditols," J. Org. Chem., Vol. 69. No. 24, pages 8437 - 8444 (2004)	
		HERTEL et al., "Synthesis of 2-Deoxy-2,2-difluoro-D-ribose and 2-Deoxy-2,2-difluoro-D-ribofuranosyl Nucleosides," J. Org. Chem., Vol. 53, No. 11, pages 2406 - 2409 (1988)	
		HIJIKATA et al., "Two Distinct Proteinase Activities required for the Processing of a Putative Nonstructural Precursor Protein of Hepatitis C Virus," J. Viral., Vol. 67, No. 8, pages 4665 - 4675 (1993)	
		HOSTETTLER et al., "Greatly Enhanced Inhibition of Human Immunodeficiency Virus Type 1 Replication in CEM and HT4-6C Cells by 3' -Deoxythymidine Diphosphate Dimyristoylglycerol, a Lipid Prodrug of 3' -Deoxythymidine," Antimicrobial Agents and Chemotherapy," Vol. 36, No. 9, pages 2025 - 2029 (1992)	
		HOSTETTLER et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and other Antiviral Nucleosides," J. Biol. Chem., Vol. 265, No. 11, pages 6112 - 6117 (1990)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 21 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		HOWES et al., "The Regiospecific One-Pot Phosphorylation of Either the 5'- or 2'-Hydroxyl in 3'-Deoxycytidines Without Protection: Critical Role of the Base," Nucleosides, Nucleotides, and Nucleic Acids, Vol. 22, No. 5 - 8, pages 687 - 689 (2003)	
		HUNSTON et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem., Vol. 27, No. 4, pages 440 - 444 (1984)	
		International Preliminary Examination Report along with Written Opinion of the International Searching Authority issued in International PCT application No. PCT/US2008/058183 issued April 7, 2010 (17 pages)	
		International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued in International Application No. PCT/US2005/025916 (4 pages)	
		International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued in International Application No. PCT/US2005/032406 (4 pages)	
		International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued in International Application No. PCT/EP2006/069060 (13 pages)	
		International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued in International Application No. PCT/US2004/012472 (8 pages)	
		International Search Report and Written Opinion of the International Searching Authority issued in International Application No. PCT/US2009/069475 (21 pages)	
		International Search Report and Written Opinion of the International Searching Authority issued in PCT/US2010/035641 (23 pages)	
		International Search Report issued in International Application No. PCT/US2005/025916 mailed June 15, 2006	
		International Search Report issued in International Application No. PCT/US2004/012472 mailed December 30, 2004 (4 pages)	
		International Search Report issued in International Application No. PCT/US2009/046619 (4 pages)	
		International Search Report issued in International Application No. PCT/EP2006/069060 mailed January 30, 2007 (4 pages)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 22 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		International Search Report issued in International Application No. PCT/US2005/032406 mailed May 8, 2008 (3 pages)	
		International Search Report issued in International PCT application No. PCT/US2008/058183 mailed March 31, 2010 (7 pages)	
		Invitation to Pay Additional Fees & Partial International Search Report issued in International Application No. PCT/ US2010/035641 (10 pages)	
		IYER et al., "Synthesis, in Vitro Anti-Breast Cancer Activity, and Intracellular Decomposition of Amino Acid Methyl Ester and Alkyl Amide Phosphoramidate Monoesters of 3'-Azido-3'-deoxythymidine (AZT)," J. Med. Chem., Vol. 43, No. 11, pages 2266 - 2274 (2000)	
		JIN et al., "Expression, Isolation, and characterization of the Hepatitis C Virus ATPase/RNA Helicase," Archives of Biochemistry and Biophysics, Vol. 323, No. 1, pages 47 - 53 (1995)	
		JONES et al., "Minireview: Nucleotide Prodrugs," Antiviral Research, Vol. 27, No. 1 - 2pages 1 - 17 (1995)	
		JUODKA et al., "Oligonucleotides and Nucleotide-Peptides. XXXIV. Synthesis and Some Properties of Complex Nucleotidyl (Oligonucleotidyl)-(P-N)-Amino Acids (Peptides) and Their Ethyl Esters," J. Carbohydrates Nucleosides Nucleotides, Vol. 6, No. 4, pages 333 - 357 (1979)	
		JUODKA et al., "Oligonucleotides and Nucleotide-Peptides. XXXVII. On the Mechanism of Hydrolysis of Uridylyl-(5'-N)- Amino Acids. Intramolecular Catalysis by the alpha-Carboxyl Group of Amino Acids," J. Carbohydrates Nucleosides Nucleotides, Vol. 8, No. 6, pages 519 - 535 (1981)	
		JUODKA et al., "Oligonucleotides and Nucleotide-Peptides. XXXV. Some Properties of Nucleotidyl-(5'-N)-Amino Acid Esters Differing In Amino Acid and Nucleotide Components," J. Carbohydrates Nucleosides Nucleotides, Vol. 8, No. 1, pages 19 - 39 (1981)	
		KOTRA et al., "Structure-Activity Relationships of 2'-Deoxy-2' ,2'-difluoro-L-erythro-pentofuranosyl Nucleosides," J. Med. Chem., Vol. 40, No. 22, pages 3635 - 3644 (1997)	
		KHAMNEI et al., "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs," J. Med. Chem., Vol. 39, No. 20, pages 4109 - 4115 (1996)	
		KIM et al., "C-Terminal Domain of the Hepatitis C Virus NS3 Protein Contains an RNA Helicase Activity," Biochemical and Biophysical Research Communications, Vol. 215, No. 1, pages 160 - 166 (1995)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 23 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		KIM et al., "Monitoring the Intracellular Metabolism of Nucleoside Phosphoramidate Pronucleotides by 31P NMR," Nucleosides, Nucleotides and Nucleic Acid, Vol. 23, No. 1 & 2, pages 483 - 493 (2004)	
		KOONIN et al., "Evolution and Taxonomy of Positive-Strand RNA Viruses: Implications of Comparatives Analysis of Amino Acid Sequences," Critical Reviews in Biochemistry and Molecular Biology, Vol. 28, No. 5, pages 375 - 430 (1993)	
		KRYUCHKOV et al., "Influence of Solvent on the Strength of Cyclic Oxygen-Containing Phosphorus Acids," Bulletin of the Academy of Sciences of the USSR. Division of Chemical Science, Vol. 36, No. 6, Part 1, pages 1145 - 1148 (1987) Translated from Russian	
		KUCERA et al., "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation," Aids Research and Human Retroviruses, Vol. 6, No. 4, pages 491 - 501 (1990)	
		LACKEY et al., "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase," Biochemical Pharmacology, Vol. 61, No. 2, pages 179 - 189 (2001)	
		LEE et al., "Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue," Antimicrobial Agents and Chemotherapy, Vol. 49, No. 5, pages 1898 - 1906 (2005)	
		LEHSTEN et al., "An Improved Procedure for the Synthesis of Nucleoside Phosphoramidates," Organic Process Research and Development, Vol. 6, pages 819 - 822 (2002)	
		LI et al., "Synthesis of the Phosphoramidite Derivative of 2'-Deoxy-2'-C-beta-methyl cytidine", J. Org. Chem., Vol. 68, No. 17, pages 6799 - 6802 (2003)	
		LOHMANN et al., "Biochemical Properties of Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase and Identification of Amino Acid Sequence Motifs Essential for Enzymatic Activity," J. Viral., Vol. 71, No. 11, pages 8416 - 8428 (1997)	
		LOPEZ-APARICIO et al., "Synthesis of Saccharinic Acid Derivatives," Carbohydrate Research, Vol. 129, pages 99 - 109 (1984)	
		MA et al., "Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor B-D-2'-Deoxy-2-Fluoro-2'-C-Methylcytidine {PSI-6130) and Identification of a Novel Active 5'-Triphosphate Species," J. Biol. Chem., Vol. 282, No. 41, pages 29812 - 29820 (October 12, 2007)	
		MCGUIGAN et al., "Application of Phosphoramidate Pronucleotides Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency," J. Med. Chem., Vol. 48, No. 10, pages 3504 - 3515 (2005)	
		MCGUIGAN et al., "Application of Phosphoramidate ProTide Technology Significantly Improves Antiviral Potency of Carbocyclic Adenosine Derivatives," J. Med. Chem., Vol. 49, No. 24, pages 7215 - 7226 (2006)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 24 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		MCGUIGAN et al., "Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT," Antiviral Research, Vol. 17, pages 311 - 321 (1992)	
		MCGUIGAN et al., "Aryl Phosphoramidate Derivatives of d4T Have Improved Anti-HIV Efficacy in Tissue Culture and May Act by the Generation of a Novel Intracellular Metabolite," J. Med. Chem., Vol. 39, No. 8, pages 1748 – 1753 {1996)	
		MCGUIGAN et al., "Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a rapid predictive test for antiviral potency," Antiviral Chemistry and Chemotherapy, Vol 9, pages 109 - 115 (1998)	
		MCGUIGAN et al., "Synthesis and evaluation of some novel phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT) as anti-HIV compounds," Antiviral Chemistry and Chemotherapy, Vol. 1, No. 2, pages 107 - 113 (1990)	
		MCGUIGAN et al., "Synthesis and evaluation of some novel phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT) as anti-HIV compounds," Antiviral Chemistry and Chemotherapy, Vol. 1, No.2, pages 107-113 (1990)	
		MCGUIGAN et al., "Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T)," Antiviral Chemistry & Chemotherapy, Vol. 9, pages 473 - 479 (1998)	
		MCINTEE et al., "Amino Acid Phosphoramidate Nucleosides: Potential ADEPT/GDEPT Substrates," Bioorganic & Medicinal Chemistry Letters, Vol. 11, No. 21, pages 2803 - 2805 (2001)	
		MCINTEE et al., "Probing the Mechanism of Action and Decomposition of Amino Acid Phosphomonoester Amidates of Antiviral Nucleoside Prodrugs," J. Med. Chem., Vol. 40, No. 21, pages 3323 - 3331 (1997)	
		MEIER et al., "Cyclic Saligenyl Phosphotriesters of 2',3' -Dideoxy-2',3'-didehydrothymidine (d4T) - A New Pro-Nucleotide Approach," Bioorg. & Med. Chem. Lett., Vol. 7, No. 2, pages 99 - 104, (1997)	
		MEYERS et al., "Molecular Characterization of Pestiviruses," Advance in Virus Research, Vol. 47, pages 53 - 119 (1996)	
		MITCHELL et al., "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4- acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate," J. Chem. Soc. Perkin. Trans. 1, pages 2345 - 2353 (1992)	
		MOENNING et al., "The Pestiviruses," Advances in Virus Research, Vol. 41, pages 53 - 99 (1992)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 25 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		MONATH, T. P., M.D., "Japanese Encephalitis - A Plague of the Orient," N. Engl. J. Med., Vol. 319, No. 10, pages 641 - 643 {September 8, 1988)	
		MURAKAMI et al., "Mechanism of Activation of beta-D-2' -Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of hepatitis C Virus NS5B RNA Polymerase," Antimicrobial Agents and Chemotherapy, Vol. 51, No. 2, pages 503 - 509 (February 2007)	
		MURAKAMI, E., et al., "The Mechanism of Action of beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcy1idine Involves a SecondMetabolic Pathway Leading to beta-D-2'-Deoxy-2'-ftuoro-2'-C-methyluridine 5'-Triphosphate, a Potent Inhibitor of the HCV RNA-Dependent RNA Polymerase," 14th International Symposium on Hepatitis C Virus and Related Viruses, Glasgow, Scotland (September 2007)	
		MURAKAMI et al., "The Mechanism of Action of beta-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to beta-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase," Antimicrobial Agents and Chemotherapy, Vol. 52, No. 2, pages 458 - 464 (2008)	
		NAKAYAMA et al., "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc. (1990) 112:6936-6942	
		NEIDLEIN et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphoni c Dichlorides: Application to the Synthesis of Cyclic Phosphonic Diesters and Cyclic Monoester Amides," Heterocycles, Vol. 35, No. 2, pages 1185 - 1203 (1993)	
		NELSON et al., "The Question of Chair-twist Equilibria for the Phosphate Rings of Nucleoside Cyclic 3',5'-Monophosphates. 1H NMR and X-ray Crystallographic Study of Diastereomers of Thymidine Phenyl Cyclic 3',5'-Monophosphate," J. Am. Chem. Soc., Vol. 109, No. 13, pages 4058 - 4064 (1987)	
		NI et al., "Progress and development of small molecule HCV antivirals," Current Opinion in Drug Discovery & Development, Vol. 7, No. 4, pages 446 - 459 (2004)	
		NIFANTYEV et al., "Synthesis and Structure of Some Stable Phospholane-Phospholanes," Phosphorus, Sulfur, and Silicon, Vol. 113, pages 1 - 13 (1996)	
		NOVAK, J. J. K., "Chiroptical Properties of 2-Methyl-1,4-Lactones; Revised Absolute Configuration of 2-Deoxy-2-C- Methyl-erythro-D-Pentono-1,4-Lactones," Collection Czechoslov. Chem. Commun., Vol. 39, pages 869 - 882 (1974)	
		NOVAK, J. J. K., "Nucleic Acid Components and Their Analogues CXLIII. Nucleosides Derived from 2-Deoxy-2(R)-C-Methyl-erythro-D-Pentose," Collection Czechoslov. Chem. Commun., Vol. 36, pages 3670 - 3677 (1971)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 26 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		OISHI et al., "Asymmetric Dihydroxylation of Chiral Olefins. High Control of Diastereofacial Selection," Tet. Lett., Vol. 34, No. 22, pages 3573 - 3576 (1993)	
		OLSEN et al., "2'-Modified Nucleoside Analogs as Inhibitors of Hepatitis C RNA Replication," Program and Abstracts, 16th International Conference on Antiviral Research, Abstract No. 121, p. A76 (April 27 - May 1, 2003)	
		OTTO, M., "Evaluation of Nucleoside Analogs in the Hepatitis C Virus Replicon System," Framing the Knowledge of Therapeutics for Viral Hepatitis, IHL Press, First Edition, pages 247 - 261 (2006)	
		Partial International Search Report issued in International Application No. PCT/US2009/069475 (7 pages)	
		PERRONE et al. "Application of the Phosphoramidate ProTide Approach to 4'-Azidouridine Confers Sub-micromolar Potency versus Hepatitis C Virus on an Inactive Nucleoside," J. Med. Chem., Vol. 50, No. 8, 1840 - 1849 (2007)	
		PERRONE et al., "First Example of Phosphoramidate Approach Applied to a 4'-Substituted Purine Nucleoside (4'-Azidoadenosine): Conversion of an Inactive Nucleoside to a Submicromolar Compound versus Hepatitis C Virus," J. Med. Chem., Vol. 50, No. 22, pages 5463 - 5470 (2007)	
		PIANTADOSI et al., "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity," J. Med. Chem., Vol. 34, No. 4, pages 1408 - 1414 (1991)	
		PIERRA et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrug of the Potent Anti-HGV Agent 2'-C-Methylcytidine," J. Med. Chem., Vol. 49, No. 22, pages 6614 - 6620 (2006)	
		POGAM et al., "No Evidence of R7128 Drug Resistance After Up to 4 Weeks Treatment of GT1, 2 and 3 Hepatitis C Virus Infected Individuals", 44th Annual Meeting of European Association for the Study of the Liver {EASL), Copenhagen, Denmark {April 22 - 26, 2009)	
		RAY et al., "Intracellular Metabolism of the Nucleotide Prodrugs GS-9131, a Potent Anti-Human Immunodeficiency Virus Agent," Antimicrobial Agents and Chemotherapy, Vol. 52, No. 2, pages 648 - 654 (2008)	
		REMY et al., "Studies on Flourinated Pyrimidines. XIV. The Synthesis of Derivatives of 5-Fluoro-2'-deoxyuridine 5'- Phosphate and Related Compounds," J. Org. Chem., Vol. 27, No. 7, pages 2491 - 2500 (1962)	
		Response filed October 25, 2010 at the EPO for European patent application No. EP08732818.3	
		Response to non-final Office Action dated October 1, 2009 for U.S. Application No. 12/142,554	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 27 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		RICE, C. M., "Flaviviridae: The Viruses and Their Replication," Fields Virology, 3rd Edition, Vol. 1, pages 931 - 959 (1996)	
		SABOULARD et al., "Characterization of the Activation Pathway of Phosphoramidate Triester Prodrugs of Stavudine and Zidovudine," Mol. Pharmacol., Vol. 56, pages 693 - 704 (1999)	
		SCHULTZ, C., "Prodrugs of Biologically Active Phosphate Esters" Bioorg. and Med. Chem., Vol. 11, pages 885 - 898 (2003)	
		SHIH et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem., Acad. Sin., Vol. 41, pages 9 -16, (March 1994)	
		SICCARDI et al., "Stereoselective and Concentration-Dependent Polarized Epithelial Permeability of a Series of Phosphoramidate Triester Prodrugs of d4T: An in Vitro Study in Caco-2 and Madin-Darby Canine Kidney Cell Monolayers," J. Pharmacol. and Exp. Ther., Vol. 307, No. 3, pages 1112 - 1119 (2003)	
		SICCARDI et al., "Stereospecific chemical and enzymatic stability of phosphoramidate triester prodrugs of d4T in vitro," European Journal of Pharmaceutical Sciences, Vol. 22, pages 25 - 31 (2004)	
		SIDDIQUI et al., "Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR," J. Med. Chem., Vol. 42, No. 20, pages 4122 - 4128 (1999)	
		SIDDIQUI et al., "Enhancing the Aqueous Solubility of d4T-based Phosphoramidate Prodrugs," Bioorg. and Med. Chem. Lett., Vol. 10, pages 381 - 384 (2000)	
		SIDDIQUI et al., "The Presence of Substituents on the Aryl Moiety of the Aryl Phosphoramidate Derivatives of d4T Enhances Anti-HIV Efficacy in Cell Culture: A Structure-Activity Relationship," J. Med. Chem. (1999) 42:393-399.	
		SMIRRNOV et al., "A Fluorescent Study of Tryptophan Derivatives of Oligonucleotides and Their Helical Complexes with Polyuridylic," FEBS Letters, Vol. 51. No. 1, pages 211 - 214 (1975)	
		SOFIA et al., "beta-D-2'-Deoxy-2'-C-methyluridine Phosphoramidates: Potent and Selective Inhibitors of HGV RNA Replication", Poster #P-259, 14th International Symposium on Hepatitis C Virus and Related Viruses, Glasgow, Scotland, UK (September 9 to 13, 2007)	
		SOFIA et al., "beta-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine Phosphoramidates: Potent and Selective Inhibitors of HGV RNA Replication", 2nd International Workshop on HGV, Poster #7 (October 31, 2007)	
		SOFIA, M.J., "beta-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine Phosphoramidates: Potent and Selective Inhibitors of HGV RNA Replication", 2nd International Workshop on HCV--Resistance and New Compounds (October 31, 2007)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 28 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		SOFIA, M.J., "R7128, A Potent and Selective Nucleoside Inhibitor of HGV NS5B Polymerase: An Overview of Clinical Efficacy and Progress Toward Second Generation Inhibitors", HGV Drug Discovery 2008, Chicago, IL {April 28, 2008)	
		SONG et al., "Pharmacokinetics of Amino Acid Phosphoramidate Monoesters of Zidovudine in Rats," Antimicrobial Agents and Chemotherapy, Vol. 46, No. 5, pages 1357 - 1363 (2002)	
		STARRETT, Jr. et al., "Synthesis, Oral Bioavailability Determination, and In Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., Vol. 37, No. 12, pages 1857 - 1864 (1994)	
		STELLA, V. J., "Prodrugs as Therapeutics," Expert opinion on therapeutic patents, Vol. 14, No. 3, pages 277 - 280 (March 2004)	
		STUYVER et al., "Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites," J. Viral., Vol. 77, No. 19, pages 10689 - 10694 (2003)	
		STUYVER et al., "Inhibition of hepatitis C replicon RNA synthesis by B-D-2'-deoxy-2'-fluoro-2'-C-methlcytidine: a specific inhibitor of hepatitis C virus replication," Antiviral Chemistry & Chemotherapy, Vol. 17, No. 2, pages 79 - 87 (2006)	
		STUYVER et al., "Inhibition of the Subgenomic Hepatitis C Virus Replicon in Huh-7 Cells by 2'-Deoxy-2'-Fluorocytidine," Antimicrobial Agents and Chemotherapy, Vol. 48, No. 2, pages 651 - 654 (2004)	
		STUYVER et al., "Ribonucleoside Analogue that Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture," Antimicrobial Agents and Chemotherapy, Vol. 47, No. 1, pages 244 - 254 (2003)	
		TAN et al., "Hepatitis C Therapeutics: current Status and Emerging Strategies," Nature Reviews, Vol. 1, pages 867 - 881 (2002)	
		TOMEI et al., "NS3 Is a Serine Protease Required for Processing of Hepatitis C Virus Polyprotein," J. Viral., Vol. 67, No. 7, pages 4017 - 4026 {1993)	
		U.S Application No. 10/828,753, Final Office Action Rejection, mailed 02/26/2008	
		U.S Application No. 11/353,597, Non-Final Office Action Rejection, mailed 10/02/2007	
		U.S Application No. 11/353,597, Non-Final Office Action Rejection, mailed 07/17/2008	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 29 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		U.S Application No. 11/635,898, Pending claims filed on 12/24/2009	
		U.S Application No. 12/142,554, Non-Final Office Action Rejection, mailed 10/01/2009	
		U.S. Application No. 10/828,753, Non-Final Office Action Rejection, mailed 03/30/2007	
		U.S. Application No. 11/225,425, Final Office Action Rejection, mailed 02/18/2010	
		U.S. Application No. 11/225,425, Non-Final Office Action Rejection, mailed 11/13/2008	
		U.S. Application No. 11/225,425, Non-Final Office Action Rejection, mailed 07/07/2009	
		U.S. Application No. 11/353,597, Final Office Action Rejection, mailed 12/02/2008	
		U.S. Application No. 11/635,898, Non-Final Office Action Rejection, mailed 07/28/2009	
		U.S. Application No. 11/854,218, Non-Final Office Action Rejection, mailed 10/01/2009	
		U.S. Application No. 12/142,536, Non-Final Office Action Rejection, mailed 10/02/2009	
		U.S. Application No. 12/240,342, Non-Final Office Action Rejection, mailed 10/01/2009	
		U.S. Application No. 12/553,483, Non-Final Office Action Rejection, mailed 12/17/2009	
		U.S. Application No. 13/099,671, claims filed September 4, 2012	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 30 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		U.S. Patent Application No. 13/956, 195, as filed July 31, 2013	
		U.S. Patent Application No. 14/013,237, as filed Aug. 29, 2013	
		U.S. Patent Application No. 14/013,237, as filed Aug. 29, 2013	
		U.S. Patent Application No. 13/925,078, as filed Jun. 24, 2013	
		U.S. Provisional Patent Application No. 60/392,350, filed on June 28, 2002	
		U.S. Provisional Patent Application No. 60/392,351, filed on June 28, 2002	
		UCHIAAMA et al., "O-Selective Phosphorylation of Nucleosides without N-Protection," J. Org. Chem. (1993) 58:373-379	
		UCKUN et al., "In Vivo Pharmacokinetics and Toxicity Profile of the Anti-HIV Agent Stampidine in Dogs and Feline Immunodeficiency Virus-infected Cats," Arzneim.-Forsch./Drug Res., Vol. 56, No. 2a, pages 176 - 192 (2006)	
		VALETTE et al., "Decomposition Pathways and in Vitro HIV Inhibitory Effects of IsoddA Pronucleotides: Toward aRational Approach for Intracellular Delivery of Nucleoside 5'-Monophosphates," J. Med. Chem., Vol. 39, No. 10, pages 1981 - 1990 (1996)	
		VENKATACHALAM et al., "Rational Drug Design of Multifunctional Phosphoramidate Substituted Nucleoside Analogs," Current Pharmaceutical Design, Vol. 10, No. 15, pages 1713 - 1726 (2004)	
		VENKATACHALAM et al., "Synthesis and metabolism of naphthyl substituted phosphoramidate derivatives of stavudine," Bioorg. and Med. Chem., Vol. 14, pages 5161 - 5177 (2006)	
		WAGNER et al., "Antiviral Nucleoside Drug Delivery via Amino Acid Phosphoramidates," Nucleosides, Nucleotides and Nucleic Acids, Vol. 18, No. 4 & 5, pages 913 - 919 (1999)	
		WALKER et al., "Promising candidates for the treatment of chronic hepatitis C," Expert Opin. Investig. Drugs, Vol. 12, No. 8, pages 1269 - 1280 (2003)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 31 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		WARRENER et al., "Pestivirus NS3 (p80) Protein Possesses RNA Helicase Activity," J. Viral., Vol. 69, No. 3, pages 1720 - 1726 (1995)	
		WISKERCHEN et al., "Pestivirus Gene Expression: Protein p80 of Bovine Viral Diarrhea Virus Is a Proteinase Involved in Polyprotein Processing, Virology, Vol. 184, pages 341 - 350 (1991)	
		WOLFF, "Burger's Medicinal Chemistry and Drug Discovery," Fifth Edition, Vol. 1, pages 975 - 977 (1995)	
		WOZNIAK et al., "The stereospecific synthesis of P-chiral biophosphates and their analogues by the Stec reaction," Chem. Soc. Rev. (2003) 32:158-169	
		Written Opinion of the International Searching Authority issued in International Application No. PCT/US2004/012472 (7 pages)	
		Written Opinion of the International Searching Authority issued in the International Application No. PCT/US/2008/058183 (12 pages)	
		Written Opinion of the International Searching Authority issued in International Application No. PCT/US2004/012472 (7 pages)	
		Written Opinion of the International Searching Authority issued in the International Application No. PCT/US/2008/058183 (12 pages)	
		WU et al., "Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug," J. Med. Chem., Vol. 50, No. 15, pages 3743 - 3746 (2007)	
		WU et al., "Targeting NS5B RNA-Dependent RNA Polymerase For Anti-HCV Chemotherapy," Current Drug Targets - Infectious Disorders, Vol. 3, No. 3, pages 207 - 219 {2003)	
		XIAO-LING et al., "Study on the Chirality of Sulfur in Ethyl (2S, 3R,4R)-4,5-0-Isopropylidene-2,3-sulfinyl-2,3,4,5-tetrahydroxy-pentanoate", Acta Chimica Sinica, Vol. 55, pages 600 - 604 (1997)	
		XIAO-LING et al., "The Synthesis of (2S,3R)-Sphingosine from D-Mannitol", Acta Chimica Sinica, Vol. 54, pages 826 - 832 (1996)	
		XU et al., "Bovine Viral Diarrhea Virus NS3 Serine Proteinase: Polyprotein Cleavage Sites, Cofactor Requirements, and Molecular Model of an Enzyme Essential for Pestivirus Replication," J. Viral., Vol. 71, No. 7, pages 5312 - 5322 (1997)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 32 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		YUAN et al., "Expression, Purification, and Partial Characterization of HCV RNA Polymerase," Biochemical and Biophysical Research Communications, Vol. 232, No. 1, pages 231 - 235 (1997)	
		YUODKA et al., "Oligonucleotides and Polynucleotides. XXVI. Synthesis of Esters of Nucleotidyl- and Oligonucleotidyl- (5' -N)-(Amino Acid)S and -Peptides," Soviet Journal of Bioorganic Chemistry, Vol. 2, No. 11 pages 1089 - 1094(1976) Translated from Russian	
		ZHONG et al., "Identification and characterization of an RNA-Dependent RNA Polymerase Activity within the Nonstructural Protein 5B Region of Bovine Viral Diarrhea Virus," J. Viral., Vol. 72, No. 11, pages 9365 - 9369 (1998)	
		ZON, G., "4 Cyclophosphoamide Analogues," Progress in Medicinal Chemistry, vol. 19, pp. 205-246 (1982)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Electronic Acknowledgement Receipt

EFS ID:	20491309
Application Number:	14254737
International Application Number:	
Confirmation Number:	1596
Title of Invention:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
First Named Inventor/Applicant Name:	Jinfa Du
Customer Number:	117796
Filer:	Neeta C. Thakur/Aubrett Baker
Filer Authorized By:	Neeta C. Thakur
Attorney Docket Number:	37JD-199059-US6
Receipt Date:	22-OCT-2014
Filing Date:	16-APR-2014
Time Stamp:	19:23:22
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		37JD-199059-US6_Amendment.pdf	149813 f9bac7e716d1cf5725bcaa84a8e97375e5b031d3	yes	7

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment after Notice of Allowance (Rule 312)	1	1
	Specification	2	6
	Applicant Arguments/Remarks Made in an Amendment	7	7

Warnings:					
Information:					
2	Transmittal Letter	37JD-199059-US6_Communication.pdf	81041 ea615b56947aa945acf85396a64888bd48803a5d	no	2
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Form (SB08)	37JD-199059-US6_SB08.pdf	429852 00d6dfd5943c4c2d58af2f039be10ce932f80d7c	no	32
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
		Total Files Size (in bytes):	660706		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

<u>New Applications Under 35 U.S.C. 111</u>
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

<u>National Stage of an International Application under 35 U.S.C. 371</u>
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

<u>New International Application Filed with the USPTO as a Receiving Office</u>
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	04/16/2014	Jinfa Du	37JD-199059-US6	1596

7590 10/29/2014

Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

EXAMINER	
LEWIS, PATRICK T	

ART UNIT	PAPER NUMBER
1672	

NOTIFICATION DATE	DELIVERY MODE
10/29/2014	ELECTRONIC

NOTICE OF NON-COMPLIANT INFORMATION DISCLOSURE STATEMENT

An Information Disclosure Statement (IDS) filed 10-22-14 in the above-identified application fails to meet the requirements of 37 CFR 1.97(d) for the reason(s) specified below. Accordingly, the IDS will be placed in the file, but the information referred to therein has not been considered.

The IDS is not compliant with 37 CFR 1.97(d) because:

☒ The IDS lacks a statement as specified in 37 CFR 1.97(e).

☐ The IDS lacks the fee set forth in 37 CFR 1.17(p).

☐ The IDS was filed after the issue fee was paid. Applicant may wish to consider filing a petition to withdraw the application from issue under 37 CFR 1.313(c) to have the IDS considered. See MPEP 1308.

Elmer Beyda

571-272-4200 or 1-888-786-0101
Application Assistance Unit
Office of Data Management

FORM PTOM327-B (Rev. 02/08)

Gilead Exhibit 2026
PGR2023-00046 - Page 001932

OK TO ENTER: /P.L./ (10/28/2014)

Atty. Docket No: 37JD-199059-US6

OK TO ENTER: /P.L./ (10/28/2014)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Jinfa Du, et al.
Title:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
Appl. No.	14/254,737
Filing Date	04/16/2014
Examiner:	LEWIS, PATRICK T.
Art Unit:	1672
Confirmation No.:	1596

AMENDMENT UNDER 37 CFR 1.312

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

Applicant acknowledges receipt of a Notice of Allowance in the above-captioned application. Prior to payment of the issue fee, please amend the application as follows:

Amendments to the Specification begin on page 2 of this document.

Remarks/Arguments begin on page 7 of this document.

Please amend the application as follows:

Gilead Exhibit 2026
PGR2023-00046 - Page 001933

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	04/16/2014	Jinfa Du	37JD-199059-US6	1596

117796 7590 10/30/2014

Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

EXAMINER	
LEWIS, PATRICK T	
ART UNIT	**PAPER NUMBER**
1672	

NOTIFICATION DATE	DELIVERY MODE
10/30/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

svipdocketing@sheppardmullin.com
ltanner@sheppardmullin.com
CCarter@sheppardmullin.com

Response to Rule 312 Communication	Application No.	Applicant(s)
	14/254,737	DU ET AL.
	Examiner	Art Unit
	PATRICK LEWIS	1672

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address –

1. ☒ The amendment filed on *22 October 2014* under 37 CFR 1.312 has been considered, and has been:

a) ☒ entered.

b) ☐ entered as directed to matters of form not affecting the scope of the invention.

c) ☐ disapproved because the amendment was filed after the payment of the issue fee.
Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☐ entered in part. See explanation below.

/PATRICK LEWIS/
Primary Examiner, Art Unit 1672

Gilead Exhibit 2026
PGR2023-00046 - Page 001935

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 1 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		RE29835	1978-11-14	WITKOWSKI ET AL.	
		3798209	1974-03-19	WITKOWSKI ET AL.	
		3852267	1974-12-03	MEYER, JR. ET AL.	
		4814477	1989-03-21	WIJNBERG ET AL.	
		4957924	1990-09-18	BEAUCHAMP	
		5026687	1991-06-25	YARCHOAN ET AL.	
		5118820	1992-06-02	HERTEL	
		5149794	1992-09-22	YATVIN ET AL.	
		5157027	1992-10-20	BILLER ET AL.	
		5192549	1993-03-09	BARENOLZ ET AL.	
		5194654	1993-03-16	HOSTETLER ET AL.	
		5223263	1993-06-29	HOSTETLER ET AL.	
		5256641	1993-10-26	YATVIN ET AL.	
		5256798	1993-10-26	CHOU ET AL.	
		5372808	1994-12-13	BLATT ET AL.	
		5376380	1994-12-27	KIKUCHI ET AL.	
		5405598	1995-04-11	SCHINAZI ET AL.	
		5411947	1995-05-02	HOSTETLER ET AL.	
		5420266	1995-05-30	BRITTON ET AL.	
		5426183	1995-06-20	KJELL	
		5453499	1995-09-26	CHOU ET AL.	
		5462724	1995-10-31	SCHINAZI ET AL.	
		5463092	1995-10-31	HOSTETLER ET AL.	
		5496546	1996-03-05	WANG ET AL.	
		5538865	1996-07-23	REYES ET AL.	
		5543389	1996-08-06	YATVIN ET AL.	
		5543390	1996-08-06	YATVIN ET AL.	
		5543391	1996-08-06	YATVIN ET AL.	
		5554728	1996-09-10	BASAVA ET AL.	
		5610054	1997-03-11	DRAPER	
		5633358	1997-05-27	GRUETZKE ET AL.	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 2 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		5633388	1997-05-27	DIANA ET AL.	
		5676942	1997-10-14	TESTA ET AL.	
		5703058	1997-12-30	SCHINAZI ET AL.	
		5711944	1998-01-27	GILBERT ET AL.	
		5725859	1998-03-10	OMER	
		5738845	1998-04-14	LMAKAWA	
		5738846	1998-04-14	GREENWALD ET AL.	
		5747646	1998-05-05	HAKIMI ET AL.	
		5767097	1998-06-16	TAM	
		5792834	1998-08-11	HAKIMI ET AL.	
		5830455	1998-11-03	VALTUENA ET AL.	
		5830905	1998-11-03	DIANA ET AL.	
		5834594	1998-11-10	HAKIMI ET AL.	
		5837257	1998-11-17	TSAI ET AL.	
		5846964	1998-12-08	OZEKI	
		5849696	1998-12-15	CHRETIEN ET AL.	
		5869253	1999-02-09	DRAPER	
		5891874	1999-04-06	COLACINO ET AL.	
		5905070	1999-05-18	SCHINAZI ET AL.	
		5908621	1999-06-01	GLUE ET AL.	
		5922757	1999-07-13	CHOJKIER	
		5928636	1999-07-27	ALBER ET AL.	
		5942223	1999-08-24	BAZER ET AL.	
		5980884	1999-11-09	BLATT ET AL.	
		5990276	1999-11-23	ZHANG ET AL.	
		6004933	1999-12-21	SPRUCE ET AL.	
		6034134	2000-03-07	GOLD ET AL.	
		6043077	2000-03-28	BARBER ET AL.	
		6056961	2000-05-02	LAVIE ET AL.	
		6060080	2000-05-09	KIKUCHI ET AL.	
		6090932	2000-07-18	MCGEE ET AL.	
		6130326	2000-10-10	RAMASAMY ET AL.	
		6132763	2000-10-17	FISHER	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 3 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		6156501	2000-12-05	MCGALL ET AL.	
		6180134	2001-01-30	ZALIPSKY ET AL.	
		6232300	2001-05-15	SCHINAZI ET AL.	
		6239159	2001-05-29	BROWN ET AL.	
		6348587	2002-02-19	SCHINAZI ET AL.	
		6372883	2002-04-16	ATTWOOD ET AL.	
		6391859	2002-05-21	SCHINAZI ET AL.	
		6410531	2002-06-25	LLINAS-BRUNET ET AL.	
		6420380	2002-07-16	LLINAS-BRUNET ET AL.	
		6455513	2002-09-24	MCGUIGAN ET AL.	
		6455690	2002-09-24	TAM ET AL.	
		6475985	2002-11-05	WAGNER ET AL.	
		6479463	2002-11-12	WANG ET AL.	
		6495677	2002-12-17	RAMASAMY ET AL.	
		6509320	2003-01-21	WANG ET AL.	
		6534523	2003-03-18	LLINAS-8RUNET ET AL.	
		6552183	2003-04-22	RAMASAMY ET AL.	
		6555677	2003-04-29	PETRILLO ET AL.	
		6573248	2003-06-03	RAMASAMY ET AL.	
		6642206	2003-11-04	RAMASAMY ET AL.	
		6660721	2003-12-09	DEVOS ET AL.	
		6677314	2004-01-13	KLECKER ET AL.	
		6677315	2004-01-13	KLECKER ET AL.	
		6680303	2004-01-20	SCHINAZI ET AL.	
		6682715	2004-01-27	KLECKER ET AL.	
		6683045	2004-01-27	KLECKER ET AL.	
		6703374	2004-03-09	KLECKER ET AL.	
		6753309	2004-06-22	KLECKER ET AL.	
		6777395	2004-08-17	BHAT ET AL.	
		6784166	2004-08-31	DEVOS ET AL.	
		6787305	2004-09-07	LI ET AL.	
		6787526	2004-09-07	BRYANT ET AL.	
		6815542	2004-11-09	HONG ET AL.	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 4 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		6846810	2005-01-25	MARTIN ET AL.	
		6897201	2005-05-24	BOYER ET AL.	
		6908924	2005-06-21	WATANABE ET AL.	
		6911424	2005-06-28	SCHINAZI ET AL.	
		6914054	2005-07-05	SOMMADOSSI ET AL.	
		6962991	2005-11-08	DEMPCY ET AL.	
		7018985	2006-03-28	BOYER ET AL.	
		7018989	2006-03-28	MCGUIGAN ET AL.	
		7081449	2006-07-25	PIETRZKOWSKI ET AL.	
		7105499	2006-09-12	CARROLL ET AL.	
		7148206	2006-12-12	SOMMADOSSI ET AL.	
		7163929	2007-01-16	SOMMADOSSI ET AL.	
		7202224	2007-04-10	ELDRUP, ET AL.	
		7217523	2007-05-15	WAGNER	
		7268119	2007-09-11	COOK ET AL.	
		7307065	2007-12-11	SCHINAZI ET AL.	
		7365057	2008-04-29	LACOLLA ET AL.	
		7390791	2008-06-24	BECKER, ET AL.	
		7754699	2010-07-13	CHUN ET AL.	
		7429572	2008-09-30	CLARK	
		7601820	2009-10-13	WANG ET AL.	
		7879815	2011-02-01	MACCOSS ET AL.	
		7964580	2011-06-21	SOFIA ET AL.	
		8148349	2012-04-03	MEPPEN ET AL.	
		8173621	2012-05-08	DU, ET AL.	
		8334270	2012-12-18	SOFIA, ET AL.	
		8551973	2013-10-08	BAO ET AL.	
		20070087960	2007-04-19	STORER ET AL.	
		2009280084	2009-11-12	SCHINAZI ET AL.	
		20010034440	2001-10-25	SHEPARD ET AL.	
		20020058635	2002-05-16	AVERETT	
		20020198173	2002-12-26	SCHINAZI ET AL.	
		20030060400	2003-03-27	LACOLLA ET AL.	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 5 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		20030120071	2003-06-26	MCGUIGAN ET AL.	
		20030144502	2003-07-31	PIETRZKOWSKI ET AL.	
		20030153744	2003-08-14	MEKOUAR ET AL.	
		20030050229	2003-03-13	SOMMADOSSI ET AL.	
		20030187018	2003-10-02	LLINAS-BRUNET ET AL.	
		20040006007	2004-01-08	GOSSELIN ET AL.	
		20040014108	2004-01-22	ELDRUP ET AL.	
		20040023240	2004-02-05	MARLIERE ET AL.	
		20040023901	2004-02-05	COOK ET AL.	
		20040059104	2004-03-25	COOK ET AL.	
		20040063622	2004-04-01	SOMMADOSSI ET AL.	
		20040067901	2004-04-08	BHAT ET AL.	
		20040072788	2004-04-15	BHAT ET AL.	
		20040097461	2004-05-20	SOMMADOSSI ET AL.	
		20040097462	2004-05-20	SOMMADOSSI ET AL.	
		20040101535	2004-05-27	SOMMODOSSI ET AL.	
		20040102414	2004-05-27	SOMMADOSSI ET AL.	
		20040110717	2004-06-10	CARROLL ET AL.	
		20040167140	2004-08-26	SCHINAZI ET AL.	
		20040191824	2004-09-30	DEMPCY ET AL.	
		20040214844	2004-10-28	OTTO ET AL.	
		20040229839	2004-11-18	BABU ET AL.	
		20040229840	2004-11-18	BHAT ET AL.	
		20040248892	2004-12-09	WANG	
		20040254141	2004-12-16	SCHINAZI ET AL.	
		20040259934	2004-12-23	OLSEN ET AL.	
		20040265969	2004-12-30	LI ET AL.	
		20040266996	2004-12-30	RABI	
		20050009737	2005-01-13	CLARK	
		20050020825	2005-01-27	STORER ET AL.	
		20050026853	2005-02-03	MEKOUAR ET AL.	
		20050031588	2005-02-10	SOMMADOSSI ET AL.	
		20050059632	2005-03-17	STORER ET AL.	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 6 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		20050075309	2005-04-07	STORER ET AL.	
		20050080034	2005-04-14	STANDRING ET AL.	
		20050090660	2005-04-28	WATANABE ET AL.	
		20050124532	2005-06-09	SOMMADOSSI ET AL.	
		20050130931	2005-06-16	BOYER ET AL.	
		20050137161	2005-06-23	SOMMADOSSI ET AL.	
		20050148534	2005-07-07	CASTELLINO ET AL.	
		20050154056	2005-07-14	YANG ET AL.	
		20050164960	2005-07-28	OLSEN ET AL.	
		20050215513	2005-09-29	BOOJAMRA ET AL.	
		20050227947	2005-10-13	CHEN ET AL.	
		20050261237	2005-11-24	BOOJAMRA ET AL.	
		20050267018	2005-12-01	BLATT ET AL.	
		20060003951	2006-01-05	MAKOUAR ET AL.	
		20060014943	2006-01-19	DEMPCY ET AL.	
		20060035866	2006-02-16	CANNIZZARO ET AL.	
		20060040890	2006-02-23	MARTIN ET AL.	
		20060040927	2006-02-23	BLAKE ET AL.	
		20060040944	2006-02-23	GOSSELIN ET AL.	
		20060079478	2006-04-13	BOOJAMRA ET AL.	
		20060110727	2006-05-25	MCGALL ET AL.	
		20060199738	2006-09-07	OTSUBO ET AL.	
		20060122146	2006-06-08	CHUN ET AL.	
		20060122154	2006-06-08	OLSEN ET AL.	
		20060142238	2006-06-29	MCGUIGAN	
		20060166964	2006-07-27	HUDYMA ET AL.	
		20060194749	2006-08-31	KEICHER ET AL.	
		20060199783	2006-09-07	WANG ET AL.	
		2006/116557	2006-11-02	GENELABS TECHNOLOGIES, INC	
		20060241064	2006-10-26	ROBERTS ET AL.	
		20060276511	2006-12-07	SERRANO-WU ET AL.	
		20060293306	2006-12-28	BEAULIEU ET AL.	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 7 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		20070015905	2007-01-18	LACOLLA ET AL.	
		20070037735	2007-02-15	GOSSELIN ET AL.	
		20070037773	2007-02-15	SOMMADOSSI ET AL.	
		20070042939	2007-02-22	LACOLLA ET AL.	
		20070042988	2007-02-22	KLUMPP ET AL.	
		20070042990	2007-02-22	GOSSELIN ET AL.	
		20070049754	2007-03-01	BOOJAMRA ET AL.	
		20070060498	2007-03-15	GOSSELIN ET AL.	
		20070060541	2007-03-15	GOSSELIN ET AL.	
		20070197463	2007-08-23	CHUN ET AL.	
		20070225249	2007-09-27	SHI	
		20080070861	2008-03-20	CLARK	
		20080253995	2008-10-16	CLARK	
		20070265222	2007-11-15	MACCOSS ET AL.	
		20070275912	2007-11-29	BHAT ET AL.	
		20070275947	2007-11-29	BERGSTROM	
		20090137521	2009-05-28	HAMILTON ET AL.	
		20090176732	2009-07-09	BEIGELMAN ET AL.	
		20090004135	2009-01-01	CLARK	
		20090036666	2009-02-05	CLARK	
		20090233879	2009-09-17	REDDY ET AL.	
		20090306007	2009-12-10	WAGNER	
		20100029008	2010-02-04	STUTZ ET AL.	
		20100035835	2010-02-11	NARJES ET AL.	
		20100081628	2010-04-01	DU, ET AL.	
		20100137576	2010-06-03	STEC ET AL.	
		20100152128	2010-06-17	ATTENNI ET AL.	
		20100173863	2010-07-08	SCHINAZI ET AL.	
		20100227801	2010-09-09	HOPKINS ET AL.	
		20100048917	2010-02-25	WANG ET AL.	
		20100279973	2010-11-04	CHUN; BYOUNG-KWON; ET AL.	
		20100286083	2010-11-11	BAO; DONGHUI; ET AL.	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 8 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		20100298257	2010-11-25	ROSS; BRUCE; ET AL.	
		20100316594	2010-12-16	SOMMADOSSI ET AL.	
		20110015146	2011-01-20	SOFIA; MUCHAEL JOSEPH; ET AL.	
		20110124592	2011-05-26	MCGUIGAN ET AL.	
		20110245484	2011-10-10	ROSS; BRUCE S.; ET AL.	
		20110251152	2011-10-13	ROSS; BRUCE S.; ET AL.	
		20120107278	2012-05-03	BERREY; MIRIAM MICHELLE; ET AL.	
		20110257122	2011-10-20	SOFIA ET AL.	
		20130109647	2013-05-02	BERREY	
		20130136776	2013-05-30	CLEARY	
		20130029929	2013-01-31	SOFIA ET AL.	
		20130165401	2013-06-27	ROSS ET AL.	
		20130165644	2013-06-27	ROSS ET AL.	
		20130288997	2013-10-31	ROSS ET AL.	
		20130310551	2013-11-21	ROSS ET AL.	
		20130109647	2013-05-02	BERREY	
		20130136776	2013-05-30	CLEARY	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Application Document Serial Number-Kind Code[2] (*if known*)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		CN 101108870	2008-01-23	YIXIN LENG		
		DE 199 14 474	1999-10-07	HOFFMANN LA-ROCHE AG		
		EP 0 180 276	1986-05-07	OCE ANDENO BV		

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 9 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		EP 0 350 287	1990-01-10	VICAL, INC.		
		EP 1 828 217	2007-09-05	FEBIT BIOTECH GMBH		
		EP 1 881 001	2008-01-23	TIBOTEC PHARM, LTD.		
		EP 2 097 430	2009-09-09	CT BADAN MOLEKULAR I MAKRO		
		EP 2 124 555	2009-12-02	MERCK & CO, INC.		
		EP 2 207 786	2012-03-07	EISAI, INC.		
		JP 5 238939	1993-09-17	NODA SANGYO KAGAKU KENKYUSHO KIKKOMAN CORP		
		WO 1989/002733	1989-04-06	UNIV CALIFORNIA		
		WO 1990/000555	1990-01-25	VICAL, INC.		
		WO 1991/016920	1991-11-14	VICAL, INC.		
		WO 1991/018914	1991-12-12	VICAL, INC.		
		WO 1991/019721	1991-12-26	GLAZIER ARNOLD		
		WO 1993/000910	1993-01-21	VICAL, INC.		
		WO 1994/026273	1994-11-24	HOSTETLER KARL Y		
		WO 1995/013090	1995-05-18	ENZON, INC.		
		WO 1995/024185	1995-09-14	ISIS PHARMACEUTICALS, INC.		
		WO 1996/015132	1996-05-23	UNIV CALIFORNIA		
		WO 1996/032403	1996-10-17	SCHERING AG		
		WO 1997/012033	1997-04-03	UNIV EMORY		
		WO 1997/036554	1997-10-09	VIROPHARMA, INC.		
		WO 1998/016184	1998-04-23	ICN PHARMACEUTICALS		
		WO 1998/017679	1998-04-30	VERTEX PHARMA		
		WO 1998/022496	1998-05-28	HOFFMANN LA-ROCHE AG		
		WO 1999/007734	1999-02-18	BOEHRINGER INGELHEIM, LTD.		
		WO 1999/015194	1999-04-01	SCHERING CORP.		
		WO 1999/032139	1999-07-01	ENZON, INC.		
		WO 1999/032140	1999-07-01	ENZON, INC.		

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 10 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 1999/043691	1999-09-02	UNIV EMORY UNIV GEORGIA RES FOUND		
		WO 1999/059621	1999-11-25	SCHERING CORP.		
		WO 1999/064016	1999-12-16	HOFFMANN LA-ROCHE AG		
		WO 2000/006529	2000-02-10	ANGELETII P IST RICHERCHE BIO		
		WO 2000/009531	2000-02-24	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2000/037110	2000-06-29	SCHERING CORP		
		WO 2001/009121	2001-02-08	BASF AG		
		WO 2001/032153	2001-05-10	BIOCHEM PHARMA, INC.		
		WO 2001/060315	2001-08-23	IAF BIOCHEM INT		
		WO 2001/081359	2001-11-01	SCHERING CORP.		
		WO 2001/090121	2001-11-29	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2001/091737	2001-12-06	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2001/092282	2001-12-06	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2001/096353	2001-12-20	NOVIRIO PHARMACEUTICALS, LTD.		
		WO 2001/079246	2001-10-25	PHARMASSET, LTD.		
		WO 2002/008187	2002-01-31	SCHERING CORP. CORVAS INT. INC.		
		WO 2002/018404	2002-03-07	HOFFMANN LA-ROCHE AG		
		WO 2002/032414	2002-04-25	SCHERING CORP.		
		WO 2002/032920	2002-04-25	PHARMASSET LTD.		
		WO 2002/048116	2002-06-20	BRISTOL-MYERS SQUIBB PHARMA CO		
		WO 2002/048157	2002-06-20	BRISTOL-MYERS SQUIBB PHARMA CO		
		WO 2002/048165	2002-06-20	PHARMASSET LTD.		
		WO 2002/048172	2002-06-20	SCHERING CORP.		
		WO 2002/057287	2002-07-25	MERCK & CO., INC.		
		WO 2002/057425	2002-07-25	MERCK & CO., INC.		
		WO 2002/060926	2002-08-08	SQUIBB BRISTOL MYERS CO.		
		WO 2002/008198	2002-01-31	SCHERING CORP.		

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 11 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2002/008251	2002-01-31	CORVAS INT., INC. [US]		
		WO 2002/008256	2002-01-31	SCHERING CORP [US] CORVAS INT., INC.		
		WO 2002/100415	2002-12-19	F. HOFFMANN-LA ROCHE AG		
		WO 2003/000713	2003-01-03	GLAXO GROUP LTD.		
		WO 2003/006490	2003-01-23	VERTEX PHARMA., INC.		
		WO 2003/010141	2003-02-06	BOEHRINGER INGELHEIM CA LTD.		
		WO 2003/024461	2003-03-27	SCHERING CORP.		
		WO 2003/026589	2003-04-03	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2003/037895	2003-05-08	GLAXO GROUP LTD.		
		WO 2003/051899	2003-06-26	RIBAPHARM INC.		
		WO 2003/053989	2003-07-03	MRC TECHNOLOGY LTD.		
		WO 2003/061576	2003-07-31	RIBAPHARM INC.		
		WO 2003/062256	2003-07-31	RIBAPHARM INC.		
		WO 2003/064456	2003-08-07	BOEHRINGER INGELHEIM INT		
		WO 2003/068244	2003-08-21	MERCK & CO., INC.		
		WO 2003/101993	2003-12-11	NEOGENESIS PHARMACEUTICALS INC.		
		WO 2003/104250	2003-12-18	KYLIX B V		
		WO 2003/105770	2003-12-24	MERCK & CO., INC.		
		WO 2003/106477	2003-12-24	ISIS PHARMACEUTICALS INC.		
		WO 2004/000858	2003-12-31	MERCK & CO,. INC.		
		WO 2004/002422	2004-01-08	IDENIX CAYMAN LTD UNIV DEGLI STUDI DI CAGLIARI		
		WO 2004/002940	2004-01-08	PHARMACIA & UPJOHN CO.		
		WO 2004/002944	2004-01-08	PHARMACIA & UPJOHN CO.		
		WO 2004/002977	2004-01-08	PHARMACIA & UPJOHN CO.		
		WO 2004/002999	2004-01-08	IDENIX CAYMAN LTD.		
		WO 2004/003000	2004-01-08	IDENIX CAYMAN LTD CENTRE NAT RECH SCIENT		

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 12 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2004/003138	2004-01-08	MERCK & CO., INC.		
		WO 2004/007512	2004-01-22	MERCK & CO., INC.		
		WO 2004/009020	2004-01-29	MERCK & CO., INC.		
		WO 2004/009610	2004-01-29	PTC THERAPEUTICS INC.		
		WO 2004/011478	2004-02-05	MICROLOGIX BIOTECH INC.		
		WO 2004/035571	2004-04-29	RIGEL PHARMACEUTICALS INC.		
		WO 2004/041201	2004-05-21	VIROPHARMA INC [US] WYETH CORP.		
		WO 2004/046331	2004-06-03	IDENIX CAYMAN LTD.		
		WO 2004/065367	2004-08-05	BOEHRINGER INGELHEIM INT		
		WO 2004/080466	2004-09-23	RIBAPHARM INC.		
		WO 2004/094452	2004-11-04	SQUIBB BRISTOL MYERS CO.		
		WO 2004/096210	2004-11-11	GLAXO GROUP LTD.		
		WO 2004/096234	2004-11-11	GILEAD SCIENCES INC.		
		WO 2004/096235	2004-11-11	GILEAD SCIENCES INC.		
		WO 2004/096286	2004-11-11	GILEAD SCIENCES INC.		
		WO 2004/106356	2004-12-09	UNIV. SYDDANSK		
		WO 2004/014313	2004-02-19	SQUIBB BRISTOL MYERS CO.		
		WO 2004/014852	2004-02-19	SQUIBB BRISTOL MYERS CO.		
		WO 2005/002626	2005-01-13	GILEAD SCIENCES INC.		
		WO 2005/003147	2005-01-13	PHARMASSET LTD.		
		WO 2005/007810	2005-01-27	GRINSTAFF MARK W		
		WO 2005/009418	2005-02-03	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2005/012327	2005-02-10	UNIV. COLLEGE CARDIFF CONSULTANTS LTD.		
		WO 2005/020884	2005-03-10	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2005/021568	2005-03-10	BIOTA INC.		
		WO 2005/028502	2005-03-31	VERTEX PHARMA INC.		
		WO 2005/037214	2005-04-28	INTERMUNE INC.		
		WO 2005/067900	2005-07-28	ACHILLION PHARMACEUTICALS INC.		
		WO 2005/072361	2005-08-11	MERCK & CO., INC.		

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 13 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2005/082144	2005-09-09	US GOV HEALTH & HUMAN SERV		
		WO 2005/087788	2005-09-22	UNIV. CALIFORNIA		
		WO 2005/095403	2005-10-13	INTERMUNE INC.		
		WO 2005/103045	2005-11-03	GLAXO GROUP LTD.		
		WO 2005/123087	2005-12-29	MERCK & CO., INC.		
		WO 2006/000922	2006-01-05	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2006/012078	2006-02-02	MERCK & CO., INC.		
		WO 2006/012440	2006-02-02	PHARMASSET INC.		
		WO 2006/020082	2006-02-23	SQUIBB BRISTOL MYERS CO.		
		WO 2006/029081	2006-03-16	NEOPHARM INC.		
		WO 2006/031725	2006-03-23	PHARMASSET INC.		
		WO 2006/035061	2006-04-06	TIBOTEC PHARM LTD.		
		WO 2006/037028	2006-04-06	IDENIX CAYMAN LTD CENTRE NAT DE LA RECH SCIENT		
		WO 2006/050161	2006-05-11	BIOCRYST PHARMACEUTICALS, INC.		
		WO 2006/063149	2006-06-15	UNIV. MINNESOTA		
		WO 2006/063717	2006-06-22	UNIV. KARLSRUHE		
		WO 2006/065335	2006-06-22	MERCK & CO., INC.		
		WO 2006/065590	2006-06-22	XTL BIOPHARMACEUTICAL S INC.		
		WO 2006/093801	2006-09-08	ABBOTT LAB		
		WO 2006/100310	2006-09-28	TIBOTEC PHARM LTD.		
		WO 2006/120251	2006-11-16	IBOTEC PHARM LTD [IE]		
		WO 2006/120252	2006-11-16	TIBOTEC PHARM LTD.		
		WO 2006/121820	2006-11-16	VALEANT RES & DEV		
		WO 2007/002602	2007-01-04	DEPUY SPINE INC.		
		WO 2007/014920	2007-02-08	TIBOTEC PHARM., LTD.		
		WO 2007/014921	2007-02-08	TIBOTEC PHARM., LTD.		
		WO 2007/014922	2007-02-08	TIBOTEC PHARM., LTD.		

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 14 of 32

Complete if Known

Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2007/014925	2007-02-08	TIBOTEC PHARM., LTD.		
		WO 2007/014926	2007-02-08	TIBOTEC PHARM., LTD.		
		WO 2007/015824	2007-02-08	INTERMUNE INC.		
		WO 2007/020193	2007-02-22	F. HOFFMANN-LA ROCHE AG		
		WO 2007/027248	2007-03-08	VALEANT RES & DEV		
		WO 2007/039142	2007-04-12	GLAXO GROUP LTD.		
		WO 2007/039145	2007-04-12	GLAXO GROUP LTD.		
		WO 2007/065829	2007-06-14	F. HOFFMANN-LA ROCHE AG		
		WO 2007/070556	2007-06-21	GENELABS TECH INC.		
		WO 2007/076034	2007-07-05	ABBOTT LA		
		WO 2007/088148	2007-08-09	SMITHKLINE BEECHAM CORP.		
		WO 2007/093901	2007-08-23	PFIZER LTD.		
		WO 2007/095269	2007-08-23	MERCK & CO., INC.		
		WO 2007/092000	2007-08-16	SQUIBB BRISTOL MYERS CO.		
		WO 2008/010921	2008-01-24	GILEAD SCIENCES INC.		
		WO 2008/045419	2008-04-17	PHARMASSET INC.		
		WO 2008/048128	2008-04-24	CT BADAN MOLEKULAR I MAKRO		
		WO 2008/062206	2008-05-29	UNIV. COLLEGE CARDIFF CONSULTANT LTD.		
		WO 2008/079206	2008-07-03	MERCK & CO., INC.		
		WO 2008/082601	2008-07-10	IDENIX PHARMACEUTICALS INC.		
		WO 2008/085508	2008-07-17	MERCK & CO., INC.		
		WO 2008/142055	2008-11-27	ANGELETII P IST RICHERCHE BIO		
		WO 2009/052287	2009-04-23	EISAL CORP OF NORTH AMERICA		
		WO 2009/115893	2009-09-24	HETERO RESEARCH FOUNDATION		
		WO 2009/120878	2009-10-01	ALNYLAM PHARMACEUTICALS INC.		
		WO 2009/129120	2009-10-22	RFS PHARMA LLC		
		WO 2009/152095	2009-12-17	PHARMASSET INC.		
		WO 2010/042834	2010-04-15	ANADYS PHARMACEUTICALS INC.		

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 15 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] Number[4] Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO 2010/080878	2010-07-15	SCYNEXIS INC.		
		WO 2010/075554	2010-07-01	PHARMASSET INC.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		ABRAHAM et al., "Synthesis and Biological Activity of Aromatic Amino Acid Phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-Arabinofuranosylcytosine: Evidence of Phosphoramidase Activity," J. Med. Chem., Vol. 39, No. 23, pages 4569 - 4575, (1996)	
		ABRAHAM et al., "Synthesis, Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir," Nucleosides, Nucleotides and Nucleic Acids, Vol. 16, No. 10, pages 2079 - 2092 (1997)	
		AQUARO et al., "Activities of Masked 2',3'-Dideoxynucleoside Monophosphate Derivaties Against Human Immunodeficiency Virus in Resting Macrophages," Antimicrobial Agents and Chemotherapy, Vol. 44, No. 1, pages 173-177 (2000)	
		ASIF et al., "Pharmacokinetics of the Antiviral Agent B-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine in Rhesus Monkeys," Antimicrobial Agents and Chemotherapy, Vol. 51, No. 8, pages 2877 - 2882 (2007)	
		BALZARINI et al., "Mechanism of anti-HIV action of masked alaninyl d4t-MP derivatives," Proc. Natl. Acad. Sci., Vol. 93, pages 7295 - 7299 (1996)	
		BANKER et al., "Prodrugs," Modern Pharmaceutics, Third Edition, Revised and Expanded," pages 451 and 596 (1996)	
		BARTENSCHLAGER et al., "Kinetic and Structural Analyses of Hepatitis C Virus Polyprotein Processing," J. Virol., Vol. 68, No. 8, pages 5045 - 5055 (1994)	
		BARTENSCHLAGER et al., "Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions," J. Virol., Vol. 67, No. 7, pages 3835 - 3844 (1993)	
		BASCHANG et al., "Neue Derivate von Thymidin-3',5'-cyclophosphat," Angew. Chem., Vol. 85, No. 1, pages 44 - 45 (1973)	
		BATTAGLIA et al., "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection," The Annals of Pharmacotherapy, Vol. 34, No. 4, pages 487 - 494 (2000)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 16 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		BAZAN et al., "Detection of a Trypsin-like Serine Protease Domain in Flaviviruses and Pestiviruses," Virology, Vol. 171, pages 637 - 639 (1989)	
		BEAULIEUet al., "Inhibitors of the HGV NS5B polymerase: New hope for the treatment of hepatitis C infections," Current Opinion in Investigational Drugs, Vol. 5, No. 8, pages 838 - 850 (2004)	
		BEHRENS et al., "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus," The EMBO Journal, Vol. 15, No. 1, pages 12 - 22 (1996)	
		BERENGUER, M., Hepatitis C virus in the transplant setting, Antiviral Therapy, Vol. 3, Supplement 3, pages 125 - 136 (1998)	
		BHAT et al., "Synthesis and Pharmacokinetic Properties of Nucleoside Analogues as Possible Inhibitors of HCV RNA Replication," (Oral Session V: Hepatitis C Virus, Flaviviruses), 16th International Conference on Antiviral Research, Abstract No. 120, p. A75 (April 27 - May 1, 2003)	
		BROEDERS et al., "A 400- and 600-Mhz 'H NMR Confromational Study on Nucleoside Cyclic 3', 5' PV-TBP Systems. Conformational Transmission Induces Diequatorial Orientation of the 3', 5'-Dioxaphosphorinane Ring in a Nonchair Confirmation," J. Am. Chem. Soc., Vol. 112, No. 21, pages 7475 - 7482 (1990)	
		CALISHER et al., "Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera," J. Gen. Virol., Vol. 70, pages 37 - 43 (1989)	
		CARROLL et al., "Nucleoside Analog Inhibitors of Hepatitis C Virus Replication," Infectious Disorders - Drug Targets, Vol. 6, No. 1, pages 17 - 29 (2006)	
		CHANG et al., "Amino Acid Phosphoramidate Monoesters of 3'-Azido-3'-deoxythymidine: Relationship between Antiviral Potency and Intracellular Metabolism," J. Med. Chem., Vol. 44, No. 2, pages 223 - 231 (2001)	
		CHAPMAN et al., "Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340," Nucleosides, Nucleotides & Nucleic Acids, Vol. 20, No. 4 - 7, pages 621 - 628 (2001)	
		CHAPMAN et al., "Purification of PMPA Amidate Prodrugs by SMB Chromatography and X-Ray Crystallography of the Diastereomerically Pure GS-7340," Nucleosides, Nucleotides & Nucleic Acids, Vol. 20, No. 4 - 7, pages 1085 - 1090 (2001)	
		CHEN et al., "In Vivo Pharmacokinetics and Metabolism of Anti-Human Immunodeficiency Virus Agent D4t-5'-[P-Bromophenyl Methoxyalaninyl Phosphate] {Sampidine) In Mice," Drug Metabolism and Disposition, Vol. 29, No. 7, pages 1035 - 1041 (2001)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 17 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		CHEN et al., "Metabolism of Stavudine-5'-[P-Bromophenyl Methoxyalaninyl Phosphate], Stampidine, in Mice, Dogs, and Cats," Drug Metabolism and Disposition, Vol. 30, No. 12, pages 1523 - 1531 (2002)	
		CHOU et al., "Evidence that Human Histidine Triad Nucleotide Binding Protein 3 (Hint3) is a Distinct Branch of the Histidine Triad (HIT) Superfamily," J. Mol. Biol., Vol. 373, pages 978 - 989 (2007)	
		CHOU et al., "Phosphoramidate Pronucleotides: A Comparison of the Phosphoramidase Substrate Specificity of Human and Escherichia coli Histidine Triad Nucleotide Binding Proteins," Molecular Pharmaceutics, Vol. 4, No. 2, pages 208 - 217 (2006)	
		CHU et al., "Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the Fungus Penicillium Griseofulvum," Bioorg. & Med. Chem. Lett., Vol. 9, pages 1949 - 1952 (1999)	
		CHU et al., "Structure of Sch 68631: A New Hepatitis C Virue Proteinase Inhibitor from Streptomyces sp." Tet. Lett., Vol. 37, No. 40, pages 7229 - 7232 (1996)	
		CIHLAR et al. "Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131," Antimicrobial Agents and Chemotherapy, Vol. 52, No. 2, pages 655 - 665 (2008)	
		Claims of U.S. Patent Application No. 13/956,195 as amended Oct. 21, 2013	
		Claims of U.S. Patent Application No. 14/013,237 as amended Aug. 30, 2013	
		CLARK et al., "Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication," J. Med. Chem., Vol. 48, No. 17, pages 5504 - 5508 {2005)	
		CONGIATU et al. "Molecular Modeling Studies on the Binding of Some Protides to the Putative Human Phosphoramidase Hint1," Nucleosides, Nucleotides and Nucleic Acids, Vol. 26, pages 1121 - 1124 (2007)	
		CONGIATU et al., "Naphthyl Phosphoramidate Derivatives of BVdU as Potential Anticancer Agents: Design, Synthesis and Biological Evaluation," Nucleosides, Nucleotides, and Nucleic Acids, Vol. 24, No. 5 - 7, pages 485 - 489 (2005)	
		CURLEY et al., "Synthesis and anti-HIV evaluation of some phosphoramidate derivatives of AZT: studies on the effect of chain elongation on biological activity," Antiviral Research, Vol. 14, pages 345 - 356 (1990)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 18 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		DAVIS, G. L., "Current Therapy for Chronic Hepatitis C," Gastroenterology, Vol. 118, No. 2, pages S104 - S114 (2000)	
		D'CRUZ et al., "Stampidine: a selective oculo-genital microbicide," Journal of Antimicrobial Chemotherapy, Vol. 56, pages 10 - 19 (2005)	
		DE LOMBAERT et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors," J. Med. Chem., Vol. 37, No. 4, pages 498 - 511 (1994)	
		DRONTLE et al., "Designing a Pronucleotide Stratagem: Lessons from Amino Acid Phosphoramidates of Anticancer and Antiviral Pyrimidines," MiniReviews in Medicinal Chemistry, Vol. 4, No. 4, pages 409 - 419 (2004)	
		DUMEZ et al., "Large-Scale Synthesis and Formulation of GMP-Grade Stampidine, a New Anti-HIV Agent," Arzneim.-Forsch./Drug Res. (2006) 56(2a):136-151.	
		ECKART et al., "The Hepatitis C Virus Encodes a Serine Protease Involved in Processing of the Putative Nonstructural Proteins from the Viral Polyprotein Precursor," Biochemical and Biophysical Research Communications, Vol. 192, No. 2, pages 399 - 406 (1993)	
		EDMUNDSON et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2-dioxaphosphorinane Series. X-Ray Molecular Structure of cis-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide," J. Chem. Research (S), pages 122 - 123 (1989)	
		EGRON et al., "S-Acyl-2-thioethyl Phosphoramidate Diester Derivatives as Mononucleotide Prodrugs" J. Med. Chem., Vol. 46, No. 21, pages 4564 - 4571 (2003)	
		EISENBERG et al., "Metabolism of GS-7340, A Novel Phenyl Monophosphoramidate Intracellular Prodrug of PMPA, In Blood," Nucleosides, Nucleotides & Nucleic Acids, Vol. 20, No. 4 - 7, pages 1091 - 1098 (2001)	
		ELDRUP et al., "Oral Session V: Hepatitis C Virus, Flaviviruses," Program and Abstracts, The Sixteenth International Conference on Antiviral Research, page A75, Abstract 119 (April 27 to May 1, 2003)	
		ELDRUP et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase," J. Med. Chem., Vol. 47, No. 9, pages 2283 - 2295 (2004)	
		ENGELS et al., "Ctclophosphate, III. Synthese und Eignschaften von Uridin-3',5'-cyclophosphat-estern," Chemische Berichte, Vol. 110, No. 6, pages 2019 - 2027 (1977)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 19 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		Extended search report includes the supplementary European search report issued in European Application No. 05775359.2 dated September 15, 2010 (9 pages)	
		FAILLA et al., "Both NS3 and NS4A are Required for Proteolytic Processing of Hepatitis C Virus Nonstructural Proteins," J. Virol., Vol. 68, No. 6, pages 3753 - 3760 (1994)	
		FARQUHAR et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem., Vol. 26, No. 8, pages 1153 - 1158 (1983)	
		FARQUHAR et al., "Synthesis of Biological Evaluation of 9-[5'-(2-0xo-1,3,2-oxazaphosphorinan-2-yl)-beta-D-arabinosyl] adenine and 9-[5'-(2-0xo-1,3,2-dioxaphosphorinan-2-yl)-beta-D-arabinosyl]adenine: Potential Neutral Precursors of 9- [beta-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem., Vol. 28, No. 9, pages 1358 - 1361 (1985)	
		FREED et al., "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells," Biochemical Pharmacology, Vol. 38, No. 19, pages 3193 - 3198 (1989)	
		GILLESPIE, S., et al., "Stereoselective Inhibition of Cholesterol Esterase by Enantiomeric Phosphonates," Phosphorous, Sulfur and Silicon, 1997, 122: 205-208	
		GOEKJIAN et al., "Synthesis of Fluorinated Marcocyclic Bis(indolyl)maleimides as Potential 19F NMR Probes for Protein Kinase C," J. Org. Chem. Vol., 64., No. 12, pages 4238 - 4246 (1999)	
		GORBALENYA et al., "A conserved NTP-motif in putative helicases," Nature, Vol. 333, page 22 (1988)	
		GORBALENYA et al., "N-terminal domains of putative helicases of flavi-and pestiviruses may be serine proteases," Nucleic Acids Research, Vol. 17, No. 10, pages 3889 - 3897 (1989)	☐
		GRAKOUI et al., "A second hepatitis C virus-encoded proteinase," Proc. Natl. Acad. Sci., Vol. 90, pages 10583 - 10587 (1993)	☐
		GRAKOUI et al., "Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase- Dependent Polyprotein Clevage Sites," J. Viral., Vol. 67, No. 5, pages 2832 - 2843 (1993)	☐
		GRIFFITH et al., "HCV Anti-viral Agents," Annual Reports in Medicinal Chemistry, Vol. 39, pages 223 - 237 (2004)	☐

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 20 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		GROMOVA et al., "Optical Rotatory Dispersion and Circular Dichroism of Mono- and Oligonucleotide-Amino Acids (Amidates)," Biochim. Biophys. Acta., Vol. 240, No. 1, pages 1 - 11 (1971)	
		GUDMUNDSSON et al., "Phosphoramidate Protides of 2',3'-Dideoxy-3'-fluoroadenosine and Related Nucleosides with Potent Activity Against HIV and HBV," Nucleosides, Nucleotides & Nucleic Acids (2003) 22 (10):1953-1961	
		GUDMUNDSSON et al., "Phosphoramidate Protides of Carbocyclic 2',3'-Dideoxy-3'-didehydro-7-Deazaadenosine with Potent Activity Against HIV and HBV", Nucleosides, Nucleotides and Nucleic Acids (2004), 23(12): 1929-1937	
		GUNIC et al., "6-Hydrazinopurine 2'-methyl ribonucleosides and their 5'-monophosphate prodrugs as potent hepatitis C virus inhibitors," Bioorg. & Med. Chem. Lett., Vol. 17, pages 2456 - 2458 (2007)	
		HALSTEAD, S. B., "Pathogenesis of Dengue: Challenges to Molecular Biology," Science, Vol. 239, pages 476 - 481 (1988)	
		HALSTEAD, S. B., "Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XI. Dengue," Review of Infectious Diseases, Vol. 6, No. 2, pages 251 - 263 (1984)	
		HARRIS et al., "Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine," Antiviral Chemistry & Chemotherapy, Vol 12, No. 5, pages 293 - 300 (2001)	
		HERNANDEZ et al., "Synthesis of Highly Functionalized Chiral Nitriles by Radical Fragmentation of beta-Hydroxy Azides. Convenient Transformation of Aldononitriles into 1,4- and 1,5-Iminoalditols," J. Org. Chem., Vol. 69. No. 24, pages 8437 - 8444 (2004)	
		HERTEL et al., "Synthesis of 2-Deoxy-2,2-difluoro-D-ribose and 2-Deoxy-2,2-difluoro-D-ribofuranosyl Nucleosides," J. Org. Chem., Vol. 53, No. 11, pages 2406 - 2409 (1988)	
		HIJIKATA et al., "Two Distinct Proteinase Activities required for the Processing of a Putative Nonstructural Precursor Protein of Hepatitis C Virus," J. Viral., Vol. 67, No. 8, pages 4665 - 4675 (1993)	
		HOSTETTLER et al., "Greatly Enhanced Inhibition of Human Immunodeficiency Virus Type 1 Replication in CEM and HT4-6C Cells by 3' -Deoxythymidine Diphosphate Dimyristoylglycerol, a Lipid Prodrug of 3' -Deoxythymidine," Antimicrobial Agents and Chemotherapy," Vol. 36, No. 9, pages 2025 - 2029 (1992)	
		HOSTETTLER et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and other Antiviral Nucleosides," J. Biol. Chem., Vol. 265, No. 11, pages 6112 - 6117 (1990)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 21 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		HOWES et al., "The Regiospecific One-Pot Phosphorylation of Either the 5'- or 2'-Hydroxyl in 3'-Deoxycytidines Without Protection: Critical Role of the Base," Nucleosides, Nucleotides, and Nucleic Acids, Vol. 22, No. 5 - 8, pages 687 - 689 (2003)	
		HUNSTON et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem., Vol. 27, No. 4, pages 440 - 444 (1984)	
		International Preliminary Examination Report along with Written Opinion of the International Searching Authority issued in International PCT application No. PCT/US2008/058183 issued April 7, 2010 (17 pages)	
		~~International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued in International Application No. PCT/US2005/025916 (4 pages~~)	
		~~International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued in International Application No. PCT/US2005/022406 (4 pages~~)	
		~~International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued in International Application No. PCT/EP2006/069060 (13 pages~~)	
		~~International Preliminary Report on Patentability and Written Opinion of the International Searching Authority issued in International Application No. PCT/US2004/012472 (8 pages~~)	
		~~International Search Report and Written Opinion of the International Searching Authority issued in International Application No. PCT/US2009/060475 (21 pages~~)	
		~~International Search Report and Written Opinion of the International Searching Authority issued in PCT/US2010/035641 (22 pages.)~~	
		International Search Report issued in International Application No. PCT/US2005/025916 mailed June 15, 2006	
		International Search Report issued in International Application No. PCT/US2004/012472 mailed December 30, 2004 (4 pages)	
		~~International Search Report issued in International Application No. PCT/US2009/046619 (4 pages)~~	
		International Search Report issued in International Application No. PCT/EP2006/069060 mailed January 30, 2007 (4 pages)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 22 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		International Search Report issued in International Application No. PCT/US2005/032406 mailed May 8, 2008 (3 pages)	
		International Search Report issued in International PCT application No. PCT/US2008/058183 mailed March 31, 2010 (7 pages)	
		~~Invitation to Pay Additional Fees & Partial International Search Report issued in International Application No. PCT/US2010/035641 (10 pages)~~	
		IYER et al., "Synthesis, in Vitro Anti-Breast Cancer Activity, and Intracellular Decomposition of Amino Acid Methyl Ester and Alkyl Amide Phosphoramidate Monoesters of 3'-Azido-3'-deoxythymidine (AZT)," J. Med. Chem., Vol. 43, No. 11, pages 2266 - 2274 (2000)	
		JIN et al., "Expression, Isolation, and characterization of the Hepatitis C Virus ATPase/RNA Helicase," Archives of Biochemistry and Biophysics, Vol. 323, No. 1, pages 47 - 53 (1995)	
		JONES et al., "Minireview: Nucleotide Prodrugs," Antiviral Research, Vol. 27, No. 1 - 2pages 1 - 17 (1995)	
		JUODKA et al., "Oligonucleotides and Nucleotide-Peptides. XXXIV. Synthesis and Some Properties of Complex Nucleotidyl (Oligonucleotidyl)-(P-N)-Amino Acids (Peptides) and Their Ethyl Esters," J. Carbohydrates Nucleosides Nucleotides, Vol. 6, No. 4, pages 333 - 357 (1979)	
		JUODKA et al., "Oligonucleotides and Nucleotide-Peptides. XXXVII. On the Mechanism of Hydrolysis of Uridylyl-(5'-N)- Amino Acids. Intramolecular Catalysis by the alpha-Carboxyl Group of Amino Acids," J. Carbohydrates Nucleosides Nucleotides, Vol. 8, No. 6, pages 519 - 535 (1981)	
		JUODKA et al., "Oligonucleotides and Nucleotide-Peptides. XXXV. Some Properties of Nucleotidyl-(5'-N)-Amino Acid Esters Differing In Amino Acid and Nucleotide Components," J. Carbohydrates Nucleosides Nucleotides, Vol. 8, No. 1, pages 19 - 39 (1981)	
		KOTRA et al., "Structure-Activity Relationships of 2'-Deoxy-2' ,2'-difluoro-L-erythro-pentofuranosyl Nucleosides," J. Med. Chem., Vol. 40, No. 22, pages 3635 - 3644 (1997)	
		KHAMNEI et al., "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs," J. Med. Chem., Vol. 39, No. 20, pages 4109 - 4115 (1996)	
		KIM et al., "C-Terminal Domain of the Hepatitis C Virus NS3 Protein Contains an RNA Helicase Activity," Biochemical and Biophysical Research Communications, Vol. 215, No. 1, pages 160 - 166 (1995)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 23 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		KIM et al., "Monitoring the Intracellular Metabolism of Nucleoside Phosphoramidate Pronucleotides by 31P NMR," Nucleosides, Nucleotides and Nucleic Acid, Vol. 23, No. 1 & 2, pages 483 - 493 (2004)	
		KOONIN et al., "Evolution and Taxonomy of Positive-Strand RNA Viruses: Implications of Comparatives Analysis of Amino Acid Sequences," Critical Reviews in Biochemistry and Molecular Biology, Vol. 28, No. 5, pages 375 - 430 (1993)	
		KRYUCHKOV et al., "Influence of Solvent on the Strength of Cyclic Oxygen-Containing Phosphorus Acids," Bulletin of the Academy of Sciences of the USSR. Division of Chemical Science, Vol. 36, No. 6, Part 1, pages 1145 - 1148 (1987) Translated from Russian	
		KUCERA et al., "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation," Aids Research and Human Retroviruses, Vol. 6, No. 4, pages 491 - 501 (1990)	
		LACKEY et al., "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase," Biochemical Pharmacology, Vol. 61, No. 2, pages 179 - 189 (2001)	
		LEE et al., "Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue," Antimicrobial Agents and Chemotherapy, Vol. 49, No. 5, pages 1898 - 1906 (2005)	
		LEHSTEN et al., "An Improved Procedure for the Synthesis of Nucleoside Phosphoramidates," Organic Process Research and Development, Vol. 6, pages 819 - 822 (2002)	
		LI et al., "Synthesis of the Phosphoramidite Derivative of 2'-Deoxy-2'-C-beta-methyl cytidine", J. Org. Chem., Vol. 68, No. 17, pages 6799 - 6802 (2003)	
		LOHMANN et al., "Biochemical Properties of Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase and Identification of Amino Acid Sequence Motifs Essential for Enzymatic Activity," J. Viral., Vol. 71, No. 11, pages 8416 - 8428 (1997)	
		LOPEZ-APARICIO et al., "Synthesis of Saccharinic Acid Derivatives," Carbohydrate Research, Vol. 129, pages 99 - 109 (1984)	
		MA et al., "Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor B-D-2'-Deoxy-2-Fluoro-2'-C-Methylcytidine {PSI-6130) and Identification of a Novel Active 5'-Triphosphate Species," J. Biol. Chem., Vol. 282, No. 41, pages 29812 - 29820 (October 12, 2007)	
		MCGUIGAN et al., "Application of Phosphoramidate Pronucleotides Technology to Abacavir Leads to a Significant Enhancement of Antiviral Potency," J. Med. Chem., Vol. 48, No. 10, pages 3504 - 3515 (2005)	
		MCGUIGAN et al., "Application of Phosphoramidate ProTide Technology Significantly Improves Antiviral Potency of Carbocyclic Adenosine Derivatives," J. Med. Chem., Vol. 49, No. 24, pages 7215 - 7226 (2006)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 24 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		MCGUIGAN et al., "Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT," Antiviral Research, Vol. 17, pages 311 - 321 (1992)	
		MCGUIGAN et al., "Aryl Phosphoramidate Derivatives of d4T Have Improved Anti-HIV Efficacy in Tissue Culture and May Act by the Generation of a Novel Intracellular Metabolite," J. Med. Chem., Vol. 39, No. 8, pages 1748 – 1753 {1996)	
		MCGUIGAN et al., "Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a rapid predictive test for antiviral potency," Antiviral Chemistry and Chemotherapy, Vol 9, pages 109 - 115 (1998)	
		MCGUIGAN et al., "Synthesis and evaluation of some novel phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT) as anti-HIV compounds," Antiviral Chemistry and Chemotherapy, Vol. 1, No. 2, pages 107 - 113 (1990)	
		MCGUIGAN et al., "Synthesis and evaluation of some novel phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT) as anti-HIV compounds," Antiviral Chemistry and Chemotherapy, Vol. 1, No.2, pages 107-113 (1990)	
		MCGUIGAN et al., "Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T)," Antiviral Chemistry & Chemotherapy, Vol. 9, pages 473 - 479 (1998)	
		MCINTEE et al., "Amino Acid Phosphoramidate Nucleosides: Potential ADEPT/GDEPT Substrates," Bioorganic & Medicinal Chemistry Letters, Vol. 11, No. 21, pages 2803 - 2805 (2001)	
		MCINTEE et al., "Probing the Mechanism of Action and Decomposition of Amino Acid Phosphomonoester Amidates of Antiviral Nucleoside Prodrugs," J. Med. Chem., Vol. 40, No. 21, pages 3323 - 3331 (1997)	
		MEIER et al., "Cyclic Saligenyl Phosphotriesters of 2',3' -Dideoxy-2',3'-didehydrothymidine (d4T) - A New Pro-Nucleotide Approach," Bioorg. & Med. Chem. Lett., Vol. 7, No. 2, pages 99 - 104, (1997)	
		MEYERS et al., "Molecular Characterization of Pestiviruses," Advance in Virus Research, Vol. 47, pages 53 - 119 (1996)	
		MITCHELL et al., "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4- acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate," J. Chem. Soc. Perkin. Trans. 1, pages 2345 - 2353 (1992)	
		MOENNING et al., "The Pestiviruses," Advances in Virus Research, Vol. 41, pages 53 - 99 (1992)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 25 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		MONATH, T. P., M.D., "Japanese Encephalitis - A Plague of the Orient," N. Engl. J. Med., Vol. 319, No. 10, pages 641 - 643 {September 8, 1988)	
		MURAKAMI et al., "Mechanism of Activation of beta-D-2' -Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of hepatitis C Virus NS5B RNA Polymerase," Antimicrobial Agents and Chemotherapy, Vol. 51, No. 2, pages 503 - 509 (February 2007)	
		MURAKAMI, E., et al., "The Mechanism of Action of beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcy1idine Involves a SecondMetabolic Pathway Leading to beta-D-2'-Deoxy-2'-ftuoro-2'-C-methyluridine 5'-Triphosphate, a Potent Inhibitor of the HCV RNA-Dependent RNA Polymerase," 14th International Symposium on Hepatitis C Virus and Related Viruses, Glasgow, Scotland (September 2007)	
		MURAKAMI et al., "The Mechanism of Action of beta-D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to beta-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase," Antimicrobial Agents and Chemotherapy, Vol. 52, No. 2, pages 458 - 464 (2008)	
		NAKAYAMA et al., "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc. (1990) 112:6936-6942	
		NEIDLEIN et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphoni c Dichlorides: Application to the Synthesis of Cyclic Phosphonic Diesters and Cyclic Monoester Amides," Heterocycles, Vol. 35, No. 2, pages 1185 - 1203 (1993)	
		NELSON et al., "The Question of Chair-twist Equilibria for the Phosphate Rings of Nucleoside Cyclic 3',5'-Monophosphates. 1H NMR and X-ray Crystallographic Study of Diastereomers of Thymidine Phenyl Cyclic 3',5'-Monophosphate," J. Am. Chem. Soc., Vol. 109, No. 13, pages 4058 - 4064 (1987)	
		NI et al., "Progress and development of small molecule HCV antivirals," Current Opinion in Drug Discovery & Development, Vol. 7, No. 4, pages 446 - 459 (2004)	
		NIFANTYEV et al., "Synthesis and Structure of Some Stable Phospholane-Phospholanes," Phosphorus, Sulfur, and Silicon, Vol. 113, pages 1 - 13 (1996)	
		NOVAK, J. J. K., "Chiroptical Properties of 2-Methyl-1,4-Lactones; Revised Absolute Configuration of 2-Deoxy-2-C- Methyl-erythro-D-Pentono-1,4-Lactones," Collection Czechoslov. Chem. Commun., Vol. 39, pages 869 - 882 (1974)	
		NOVAK, J. J. K., "Nucleic Acid Components and Their Analogues CXLIII. Nucleosides Derived from 2-Deoxy-2(R)-C-Methyl-erythro-D-Pentose," Collection Czechoslov. Chem. Commun., Vol. 36, pages 3670 - 3677 (1971)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 26 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		OISHI et al., "Asymmetric Dihydroxylation of Chiral Olefins. High Control of Diastereofacial Selection," Tet. Lett., Vol. 34, No. 22, pages 3573 - 3576 (1993)	
		OLSEN et al., "2'-Modified Nucleoside Analogs as Inhibitors of Hepatitis C RNA Replication," Program and Abstracts, 16th International Conference on Antiviral Research, Abstract No. 121, p. A76 (April 27 - May 1, 2003)	
		OTTO, M., "Evaluation of Nucleoside Analogs in the Hepatitis C Virus Replicon System," Framing the Knowledge of Therapeutics for Viral Hepatitis, IHL Press, First Edition, pages 247 - 261 (2006)	
		~~Partial International Search Report issued in International Application No. PCT/US2009/069475 (7 pages)~~	
		PERRONE et al. "Application of the Phosphoramidate ProTide Approach to 4'-Azidouridine Confers Sub-micromolar Potency versus Hepatitis C Virus on an Inactive Nucleoside," J. Med. Chem., Vol. 50, No. 8, 1840 - 1849 (2007)	
		PERRONE et al., "First Example of Phosphoramidate Approach Applied to a 4'-Substituted Purine Nucleoside (4'-Azidoadenosine): Conversion of an Inactive Nucleoside to a Submicromolar Compound versus Hepatitis C Virus," J. Med. Chem., Vol. 50, No. 22, pages 5463 - 5470 (2007)	
		PIANTADOSI et al., "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity," J. Med. Chem., Vol. 34, No. 4, pages 1408 - 1414 (1991)	
		PIERRA et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrug of the Potent Anti-HGV Agent 2'-C-Methylcytidine," J. Med. Chem., Vol. 49, No. 22, pages 6614 - 6620 (2006)	
		POGAM et al., "No Evidence of R7128 Drug Resistance After Up to 4 Weeks Treatment of GT1, 2 and 3 Hepatitis C Virus Infected Individuals", 44th Annual Meeting of European Association for the Study of the Liver {EASL), Copenhagen, Denmark {April 22 - 26, 2009)	
		RAY et al., "Intracellular Metabolism of the Nucleotide Prodrugs GS-9131, a Potent Anti-Human Immunodeficiency Virus Agent," Antimicrobial Agents and Chemotherapy, Vol. 52, No. 2, pages 648 - 654 (2008)	
		REMY et al., "Studies on Flourinated Pyrimidines. XIV. The Synthesis of Derivatives of 5-Fluoro-2'-deoxyuridine 5'- Phosphate and Related Compounds," J. Org. Chem., Vol. 27, No. 7, pages 2491 - 2500 (1962)	
		Response filed October 25, 2010 at the EPO for European patent application No. EP08732818.3	
		Response to non-final Office Action dated October 1, 2009 for U.S. Application No. 12/142,554	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 27 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		RICE, C. M., "Flaviviridae: The Viruses and Their Replication," Fields Virology, 3rd Edition, Vol. 1, pages 931 - 959 (1996)	
		SABOULARD et al., "Characterization of the Activation Pathway of Phosphoramidate Triester Prodrugs of Stavudine and Zidovudine," Mol. Pharmacol., Vol. 56, pages 693 - 704 (1999)	
		SCHULTZ, C., "Prodrugs of Biologically Active Phosphate Esters" Bioorg. and Med. Chem., Vol. 11, pages 885 - 898 (2003)	
		SHIH et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem., Acad. Sin., Vol. 41, pages 9 -16, (March 1994)	
		SICCARDI et al., "Stereoselective and Concentration-Dependent Polarized Epithelial Permeability of a Series of Phosphoramidate Triester Prodrugs of d4T: An in Vitro Study in Caco-2 and Madin-Darby Canine Kidney Cell Monolayers," J. Pharmacol. and Exp. Ther., Vol. 307, No. 3, pages 1112 - 1119 (2003)	
		SICCARDI et al., "Stereospecific chemical and enzymatic stability of phosphoramidate triester prodrugs of d4T in vitro," European Journal of Pharmaceutical Sciences, Vol. 22, pages 25 - 31 (2004)	
		SIDDIQUI et al., "Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for in Vitro Activity and QSAR," J. Med. Chem., Vol. 42, No. 20, pages 4122 - 4128 (1999)	
		SIDDIQUI et al., "Enhancing the Aqueous Solubility of d4T-based Phosphoramidate Prodrugs," Bioorg. and Med. Chem. Lett., Vol. 10, pages 381 - 384 (2000)	
		SIDDIQUI et al., "The Presence of Substituents on the Aryl Moiety of the Aryl Phosphoramidate Derivatives of d4T Enhances Anti-HIV Efficacy in Cell Culture: A Structure-Activity Relationship," J. Med. Chem. (1999) 42:393-399.	
		SMIRRNOV et al., "A Fluorescent Study of Tryptophan Derivatives of Oligonucleotides and Their Helical Complexes with Polyuridylic," FEBS Letters, Vol. 51. No. 1, pages 211 - 214 (1975)	
		SOFIA et al., "beta-D-2'-Deoxy-2'-C-methyluridine Phosphoramidates: Potent and Selective Inhibitors of HGV RNA Replication", Poster #P-259, 14th International Symposium on Hepatitis C Virus and Related Viruses, Glasgow, Scotland, UK (September 9 to 13, 2007)	
		SOFIA et al., "beta-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine Phosphoramidates: Potent and Selective Inhibitors of HGV RNA Replication", 2nd International Workshop on HGV, Poster #7 (October 31, 2007)	
		SOFIA, M.J., "beta-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine Phosphoramidates: Potent and Selective Inhibitors of HGV RNA Replication", 2nd International Workshop on HCV--Resistance and New Compounds (October 31, 2007)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 28 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		SOFIA, M.J., "R7128, A Potent and Selective Nucleoside Inhibitor of HGV NS5B Polymerase: An Overview of Clinical Efficacy and Progress Toward Second Generation Inhibitors", HGV Drug Discovery 2008, Chicago, IL {April 28, 2008)	
		SONG et al., "Pharmacokinetics of Amino Acid Phosphoramidate Monoesters of Zidovudine in Rats," Antimicrobial Agents and Chemotherapy, Vol. 46, No. 5, pages 1357 - 1363 (2002)	
		STARRETT, Jr. et al., "Synthesis, Oral Bioavailability Determination, and In Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., Vol. 37, No. 12, pages 1857 - 1864 (1994)	
		STELLA, V. J., "Prodrugs as Therapeutics," Expert opinion on therapeutic patents, Vol. 14, No. 3, pages 277 - 280 (March 2004)	
		STUYVER et al., "Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites," J. Viral., Vol. 77, No. 19, pages 10689 - 10694 (2003)	
		STUYVER et al., "Inhibition of hepatitis C replicon RNA synthesis by B-D-2'-deoxy-2'-fluoro-2'-C-methlcytidine: a specific inhibitor of hepatitis C virus replication," Antiviral Chemistry & Chemotherapy, Vol. 17, No. 2, pages 79 - 87 (2006)	
		STUYVER et al., "Inhibition of the Subgenomic Hepatitis C Virus Replicon in Huh-7 Cells by 2'-Deoxy-2'-Fluorocytidine," Antimicrobial Agents and Chemotherapy, Vol. 48, No. 2, pages 651 - 654 (2004)	
		STUYVER et al., "Ribonucleoside Analogue that Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture," Antimicrobial Agents and Chemotherapy, Vol. 47, No. 1, pages 244 - 254 (2003)	
		TAN et al., "Hepatitis C Therapeutics: current Status and Emerging Strategies," Nature Reviews, Vol. 1, pages 867 - 881 (2002)	
		TOMEI et al., "NS3 Is a Serine Protease Required for Processing of Hepatitis C Virus Polyprotein," J. Viral., Vol. 67, No. 7, pages 4017 - 4026 {1993)	
		U.S Application No. 10/828,753, Final Office Action Rejection, mailed 02/26/2008	
		U.S Application No. 11/353,597, Non-Final Office Action Rejection, mailed 10/02/2007	
		U.S Application No. 11/353,597, Non-Final Office Action Rejection, mailed 07/17/2008	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 29 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		U.S Application No. 11/635,898, Pending claims filed on 12/24/2009	
		U.S Application No. 12/142,554, Non-Final Office Action Rejection, mailed 10/01/2009	
		U.S. Application No. 10/828,753, Non-Final Office Action Rejection, mailed 03/30/2007	
		U.S. Application No. 11/225,425, Final Office Action Rejection, mailed 02/18/2010	
		U.S. Application No. 11/225,425, Non-Final Office Action Rejection, mailed 11/13/2008	
		U.S. Application No. 11/225,425, Non-Final Office Action Rejection, mailed 07/07/2009	
		U.S. Application No. 11/353,597, Final Office Action Rejection, mailed 12/02/2008	
		U.S. Application No. 11/635,898, Non-Final Office Action Rejection, mailed 07/28/2009	
		U.S. Application No. 11/854,218, Non-Final Office Action Rejection, mailed 10/01/2009	
		U.S. Application No. 12/142,536, Non-Final Office Action Rejection, mailed 10/02/2009	
		U.S. Application No. 12/240,342, Non-Final Office Action Rejection, mailed 10/01/2009	
		U.S. Application No. 12/553,483, Non-Final Office Action Rejection, mailed 12/17/2009	
		U.S. Application No. 13/099,671, claims filed September 4, 2012	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 30 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		U.S. Patent Application No. 13/956, 195, as filed July 31, 2013	
		U.S. Patent Application No. 14/013,237, as filed Aug. 29, 2013	
		U.S. Patent Application No. 14/013,237, as filed Aug. 29, 2013	
		U.S. Patent Application No. 13/925,078, as filed Jun. 24, 2013	
		U.S. Provisional Patent Application No. 60/392,350, filed on June 28, 2002	
		U.S. Provisional Patent Application No. 60/392,351, filed on June 28, 2002	
		UCHIAAMA et al., "O-Selective Phosphorylation of Nucleosides without N-Protection," J. Org. Chem. (1993) 58:373-379	
		UCKUN et al., "In Vivo Pharmacokinetics and Toxicity Profile of the Anti-HIV Agent Stampidine in Dogs and Feline Immunodeficiency Virus-infected Cats," Arzneim.-Forsch./Drug Res., Vol. 56, No. 2a, pages 176 - 192 (2006)	
		VALETTE et al., "Decomposition Pathways and in Vitro HIV Inhibitory Effects of IsoddA Pronucleotides: Toward aRational Approach for Intracellular Delivery of Nucleoside 5'-Monophosphates," J. Med. Chem., Vol. 39, No. 10, pages 1981 - 1990 (1996)	
		VENKATACHALAM et al., "Rational Drug Design of Multifunctional Phosphoramidate Substituted Nucleoside Analogs," Current Pharmaceutical Design, Vol. 10, No. 15, pages 1713 - 1726 (2004)	
		VENKATACHALAM et al., "Synthesis and metabolism of naphthyl substituted phosphoramidate derivatives of stavudine," Bioorg. and Med. Chem., Vol. 14, pages 5161 - 5177 (2006)	
		WAGNER et al., "Antiviral Nucleoside Drug Delivery via Amino Acid Phosphoramidates," Nucleosides, Nucleotides and Nucleic Acids, Vol. 18, No. 4 & 5, pages 913 - 919 (1999)	
		WALKER et al., "Promising candidates for the treatment of chronic hepatitis C," Expert Opin. Investig. Drugs, Vol. 12, No. 8, pages 1269 - 1280 (2003)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 31 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		WARRENER et al., "Pestivirus NS3 (p80) Protein Possesses RNA Helicase Activity," J. Viral., Vol. 69, No. 3, pages 1720 - 1726 (1995)	
		WISKERCHEN et al., "Pestivirus Gene Expression: Protein p80 of Bovine Viral Diarrhea Virus Is a Proteinase Involved in Polyprotein Processing, Virology, Vol. 184, pages 341 - 350 (1991)	
		WOLFF, "Burger's Medicinal Chemistry and Drug Discovery," Fifth Edition, Vol. 1, pages 975 - 977 (1995)	
		WOZNIAK et al., "The stereospecific synthesis of P-chiral biophosphates and their analogues by the Stec reaction," Chem. Soc. Rev. (2003) 32:158-169	
		~~Written Opinion of the International Searching Authority issued in International Application No. PCT/US2004/012472 (7 pages~~)	
		~~Written Opinion of the International Searching Authority issued in the International Application No. PCT/US2008/058183 (12 pages~~)	
		~~Written Opinion of the International Searching Authority issued in International Application No. PCT/US2004/012472 (7 pages)~~	
		~~Written Opinion of the International Searching Authority issued in the International Application No. PCT/US2008/058183 (12 pages~~)	
		WU et al., "Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug," J. Med. Chem., Vol. 50, No. 15, pages 3743 - 3746 (2007)	
		WU et al., "Targeting NS5B RNA-Dependent RNA Polymerase For Anti-HCV Chemotherapy," Current Drug Targets - Infectious Disorders, Vol. 3, No. 3, pages 207 - 219 (2003)	
		XIAO-LING et al., "Study on the Chirality of Sulfur in Ethyl (2S, 3R,4R)-4,5-0-Isopropylidene-2,3-sulfinyl-2,3,4,5-tetrahydroxy-pentanoate", Acta Chimica Sinica, Vol. 55, pages 600 - 604 (1997)	
		XIAO-LING et al., "The Synthesis of (2S,3R)-Sphingosine from D-Mannitol", Acta Chimica Sinica, Vol. 54, pages 826 - 832 (1996)	
		XU et al., "Bovine Viral Diarrhea Virus NS3 Serine Proteinase: Polyprotein Cleavage Sites, Cofactor Requirements, and Molecular Model of an Enzyme Essential for Pestivirus Replication," J. Viral., Vol. 71, No. 7, pages 5312 - 5322 (1997)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 32 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		YUAN et al., "Expression, Purification, and Partial Characterization of HCV RNA Polymerase," Biochemical and Biophysical Research Communications, Vol. 232, No. 1, pages 231 - 235 (1997)	
		YUODKA et al., "Oligonucleotides and Polynucleotides. XXVI. Synthesis of Esters of Nucleotidyl- and Oligonucleotidyl- (5' -N)-(Amino Acid)S and -Peptides," Soviet Journal of Bioorganic Chemistry, Vol. 2, No. 11 pages 1089 - 1094(1976) Translated from Russian	
		ZHONG et al., "Identification and characterization of an RNA-Dependent RNA Polymerase Activity within the Nonstructural Protein 5B Region of Bovine Viral Diarrhea Virus," J. Viral., Vol. 72, No. 11, pages 9365 - 9369 (1998)	
		ZON, G., "4 Cyclophosphoamide Analogues," Progress in Medicinal Chemistry, vol. 19, pp. 205-246 (1982)	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	04/16/2014	Jinfa Du	37JD-199059-US6	1596

117796 7590 11/03/2014

Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

EXAMINER	
LEWIS, PATRICK T	

ART UNIT	PAPER NUMBER
1672	

NOTIFICATION DATE	DELIVERY MODE
11/03/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

svipdocketing@sheppardmullin.com
ltanner@sheppardmullin.com
CCarter@sheppardmullin.com

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Application No. : 14254737
Applicant : Du
Filing Date : 04/16/2014
Date Mailed : 11/03/2014

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Notice of Allowance Mailed

This application has been accorded an Allowance Date and is being prepared for issuance. The application, however, is incomplete for the reasons below.

Applicant is given two (2) months from the mail date of this Notice within which to respond. This time period for reply is extendable under 37 CFR 1.136(a) for only TWO additional MONTHS.

The informalities requiring correction are indicated in the attachment(s). If the informality pertains to the abstract, specification (including claims) or drawings, the informality must be corrected with an amendment in compliance with 37 CFR 1.121 (or, if the application is a reissue application, 37 CFR 1.173). Such an amendment may be filed after payment of the issue fee if limited to correction of informalities noted herein. See Waiver of 37 CFR 1.312 for Documents Required by the Office of Patent Publication, 1280 Off. Gaz. Patent Office 918 (March 23, 2004). In addition, if the informality is not corrected until after payment of the issue fee, for purposes of 35 U.S.C. 154(b)(1)(iv), "all outstanding requirements" will be considered to have been satisfied when the informality has been corrected. A failure to respond within the above-identified time period will result in the application being ABANDONED.

See attachment(s).

A copy of this notice MUST be returned with the reply. Please address response to "Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450".

/Kam Sin/
Publication Branch
Office of Data Management
(571) 272-4200

Application No. 14254737

IDENTIFICATION OF APPLICATION DEFICIENCIES

[X] Applicant must provide legible text for the following item(s).

- [X] Specification filed 06/13/2014, page(s) 927, 929, 932-933, 952 and 960-963; chemistry structures are illegible.
- [ ] Claims filed , claim(s) .
- [ ] Oath/declaration filed .
- [ ] Other: .

[ ] Applicant must provide missing information on the following page(s) of the specification by amending the specification to add the missing text. No new matter may be added.

[ ] The specification refers to one or more applications by attorney docket number and does not show the U.S. application number(s). Applicant must supply the U.S. application number in place of each attorney docket number.

[ ] Applicant must provide an Abstract of the Disclosure.

[ ] Applicant has submitted a DECLARATION (37 CFR 1.63) FOR A UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) (e.g., form PTO/SB/01A). The Application Data Sheet, however, is not present with the filed application. Applicant must submit an Application Data Sheet or file a new oath or declaration (e.g., PTO/SB/01) executed by the inventors and containing the information required in 37 CFR 1.63.

[ ] Applicant must provide an executed declaration.

[ ] Applicant must provide the missing page(s) of the oath/declaration or Application Data Sheet filed

[ ] Applicant must provide a declaration signed by inventor(s) .

[ ] The oath/declaration filed shows non-initialed and/or non-dated alterations. Applicant must file a new oath/declaration in compliance with 37 CFR 1.67(a).

[ ] Applicant(s) in the latest-filed oath/declaration or Application Data Sheet (ADS) did not show the inventor's residence at all, or did not show both a city and state in the U.S. inventor's residence, or did not show both a city and country in the non-U.S. inventor's residence. Applicant must supply an oath/declaration or Application Data Sheet (ADS) that shows each U.S. inventor's city and state of residence and each non-U.S. inventor's city and country of residence.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

117796 7590 09/25/2014
Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	04/16/2014	Jinfa Du	37JD-199059-US6	1596

TITLE OF INVENTION: NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$960	$0	$0	$960	12/26/2014

EXAMINER	ART UNIT	CLASS-SUBCLASS
LEWIS, PATRICK T	1672	514-051000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Sheppard Mullin Richter
2 & Hampton LLP
3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE: Gilead Pharmasset LLC

(B) RESIDENCE: (CITY and STATE OR COUNTRY): Foster City, California

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:
☒ Issue Fee
☐ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): **(Please first reapply any previously paid issue fee shown above)**
☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number 50-6219 (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)
☐ Applicant certifying micro entity status. See 37 CFR 1.29
NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
☐ Applicant asserting small entity status. See 37 CFR 1.27
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
☐ Applicant changing to regular undiscounted fee status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature /Neeta C. Thakur/ (Reg. No. 59,123) Date November 13, 2014
Typed or printed name for Lorna L. Tanner Registration No. 50,782

PTOL-85 Part B (10-13) Approved for use through 10/31/2013. OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Gilead Exhibit 2026
PGR2023-00046 - Page 001971

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Jinfa Du, et al.
Title:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
Appl. No.	14/254,737
Filing Date	04/16/2014
Examiner:	LEWIS, PATRICK T
Art Unit:	1672
Confirmation No.:	1596

COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

This Communication is being submitted regarding the Notice of Non-compliant Information Disclosure Statement (IDS) issued by the USPTO on October 29, 2014. The Notice alleged that the IDS filed on October 22, 2014 is not compliant because it lacks a statement as specified in 37 C.F.R 1.97(e).

Applicant notes that the Notice is inapplicable or moot because 1) the references submitted in the IDS were disclosed on October 23, 2013 in the parent U.S. Application No. 14/057,675 and a listing of the references was resubmitted in this case merely because the Applicant desired the information to be printed on the patent and 2) the IDS was considered and acknowledged by the Examiner on October 28, 2014.

Gilead Exhibit 2026
PGR2023-00046 - Page 001972

Respectfully submitted,

Date November 13, 2014

By /Neeta C. Thakur/

Sheppard, Mullin, Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301
Telephone: (650) 815-2600
Customer No. 117796

Neeta C. Thakur, Ph.D.
Attorney for Applicant
Registration No. 59,123

Gilead Exhibit 2026
PGR2023-00046 - Page 001973

Electronic Patent Application Fee Transmittal

Application Number:	14254737
Filing Date:	16-Apr-2014
Title of Invention:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
First Named Inventor/Applicant Name:	Jinfa Du
Filer:	Neeta C. Thakur/Aubrett Baker
Attorney Docket Number:	37JD-199059-US6

Filed as Large Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Utility Appl Issue Fee	1501	1	960	960
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
		Total in USD ($)		**960**

Electronic Acknowledgement Receipt

EFS ID:	20688910
Application Number:	14254737
International Application Number:	
Confirmation Number:	1596
Title of Invention:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
First Named Inventor/Applicant Name:	Jinfa Du
Customer Number:	117796
Filer:	Neeta C. Thakur/Aubrett Baker
Filer Authorized By:	Neeta C. Thakur
Attorney Docket Number:	37JD-199059-US6
Receipt Date:	13-NOV-2014
Filing Date:	16-APR-2014
Time Stamp:	18:08:59
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$960
RAM confirmation Number	4826
Deposit Account	506219
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		199056-US6_RNTFCAP.pdf	215925 85d4d99bbe08ea600cbdc8997e32306f585c896c	yes	13

Multipart Description/PDF files in .zip description

Document Description	Start	End
Applicant Response to Pre-Exam Formalities Notice	1	1
Specification	2	12
Applicant Arguments/Remarks Made in an Amendment	13	13

Warnings:					
Information:					
2	Issue Fee Payment (PTO-85B)	199059-US6_IssueFeeTransmittal.pdf	161342 6519329f0428a2b9f80bea4437679f1e46088688	no	1
Warnings:					
Information:					
3	Miscellaneous Incoming Letter	199056_US6_Communication.pdf	79605 b90afea6dcd708a65b4faa1f4441f47e263aea2a	no	2
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	30305 b0517f5a168b39c5374d4d318074596cddfe129b	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	487177		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Jinfa DU, et al.
Title:	NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
Appl. No.:	14/254,737
Filing Date:	04/16/2014
Art Unit	1672
Confirmation Number:	1596

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

In response to the Notice to File Corrected Application Papers mailed November 3, 2014, in the above-identified patent application, Applicants submit an amendment to the specification in compliance with 37 CFR 1.121 to complete the filing of the subject patent application. The Notice provided two-months to respond. Accordingly, this response is timely filed before the due date of January 3, 2015.


Amendment to the specification begins on page 2 of the document.

Remarks begin on page 13 of the document.

Please amend the application as follows:


Amendment to the Specification

Please delete the chemistry structures on page 927, line 19




4 5

and replace with the following chemistry structures




4 5

Please delete the chemistry structures on page 929, line 4



4 5


and replace with the following chemistry structures




4 5

Please delete the chemistry scheme on page 932, line 10 under the heading "General Procedure for Preparation of phosphorodichloridates"


Gilead Exhibit 2026
PGR2023-00046 - Page 001980




and replace with the following chemistry scheme




Please delete the chemistry scheme on page 933, line 1



and replace with the following chemistry scheme




Please delete the chemistry scheme on page 933, line 10 under the heading "General Procedures for nucleoside phosphororamidate derivatives"




4 5 I

and replace with the following chemistry structures




4 5 I


Please delete the chemistry scheme on page 952, line 1
















and replace with the following chemistry scheme








Please delete the table starting on page 959, line 20 ending on page 963, line 1 and also delete the footnote under the table on page 963, line 2

~~Ex #~~	~~Compound~~	~~Log10 Reduction at 50μM~~	~~EC90 (μM)~~
~~5~~		~~1.21~~	~~3.0~~







~~Ex #~~	~~Compound~~	~~Log10 Reduction at 50μM~~	~~EC90 (μM)~~
~~6~~		~~-0.45~~	~~ND~~
~~7~~		~~0.31~~	~~ND~~
~~8~~		~~-1.48~~	~~2.11~~
~~10~~		~~-1.25~~	~~19.15~~
~~11~~		~~-0.55~~	~~ND~~
~~12~~		~~0.31~~	~~ND~~
~~15~~		~~ND~~	~~0.86~~






~~Ex #~~	~~Compound~~	~~Log10 Reduction at 50μM~~	~~EC90 (μM)~~
~~25~~		~~-2.22~~	~~0.39~~
~~27~~		~~-2.25~~	~~0.66~~
~~28~~		~~-2.16~~	~~0.75~~
~~36~~		~~-1.64~~	~~21.9~~
~~39~~		~~-1.78~~	~~0.47~~
~~49~~		~~-2.69~~	~~0.126~~





~~Ex #~~	~~Compound~~	~~Log10 Reduction at 50μM~~	~~EC90 (μM)~~
~~53~~		~~-1.33~~	~~<0.3~~
~~54~~		~~-1.55~~	~~0.57~~
~~55~~		~~-2.38~~	~~<0.3~~
~~69~~		~~-2.25~~	~~< 0.3~~
~~70~~		~~-2.25~~	~~<0.3~~





~~[‡](4-BrPh): 4-bromo-phenyl.~~

and replace with the following table with the footnote

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
5		-1.21	3.0
6		-0.45	ND
7		0.31	ND
8		-1.48	2.11
10		-1.25	19.15
11		-0.55	ND

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
12		0.31	ND
15		ND	0.86
25		-2.22	0.39
27		-2.25	0.66
28		-2.16	0.75

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
36		-1.64	21.9
39		-1.78	0.47
49		-2.69	0.126
53		-1.33	<0.3

Ex #	Compound	Log10 Reduction at 50μM	EC90 (μM)
54		-1.55	0.57
55		-2.38	<0.3
69		-2.25	< 0.3
70		-2.25	<0.3

[1](4-BrPh): 4-bromo-phenyl

REMARKS

The Notice states that in the specification filed on 6/13/2014, the chemistry structures on pages 927, 929, 932-933, 952 and 960-963 are illegible. Applicants have redrawn the chemistry structures of compounds on pages 927, 929, 932-933, 952 and in the table on pages 960-963 such that the chemistry structures are now legible.

Applicants note that the 312 amendment filed on 10/22/2014 referred to the page numbers 676-678 of the specification filed on 4/16/2014. Further, the Notice to File Corrected Application Papers mailed November 3, 2014 asked to correct chemistry structures on pages 960-963 of the specification filed on 6/13/2014 which correspond to pages 676-678 of the specification filed on 4/16/2014. As such, Applicants believe that the 312 amendment filed on 10/22/2014 was not considered, even though "Response to 312 Communication" posted on PAIR on 10/30/2014 states that it was considered and entered. Please clarify.

Applicants submit that no new matter has been added and respectfully request the entry thereof.

Although Applicant believes that no fee is required, the Commissioner is hereby authorized to charge any additional fees which may be due to Deposit Account No. 50-6219.

Respectfully submitted,

Date: November 13, 2014

By: /Neeta C. Thakur/

Sheppard, Mullin, Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301
Telephone: (650) 815-2600
Customer No.: 117796

Neeta C. Thakur, Ph.D.
Attorney for Applicant
Registration No. 59,123

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	04/16/2014	Jinfa Du	37JD-199059-US6	1596

117796 7590 11/20/2014

Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

EXAMINER	
LEWIS, PATRICK T	

ART UNIT	PAPER NUMBER
1672	

NOTIFICATION DATE	DELIVERY MODE
11/20/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

svipdocketing@sheppardmullin.com
ltanner@sheppardmullin.com
CCarter@sheppardmullin.com

Response to Rule 312 Communication	Application No. 14/254,737	Applicant(s)
	Examiner	Art Unit

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☒ The amendment filed on *13 November 2014* under 37 CFR 1.312 has been considered, and has been:

a) ☒ entered.

b) ☐ entered as directed to matters of form not affecting the scope of the invention.

c) ☐ disapproved because the amendment was filed after the payment of the issue fee.
Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☐ entered in part. See explanation below.

N.Y. Horne

PUBLISHING DIVISION

Gilead Exhibit 2026
PGR2023-00046 - Page 001993

PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 22, 2014

(use as many sheets as necessary)

Sheet 3 of 32

Complete if Known	
Application Number	14/254,737
Filing Date	4/16/2014
First Named Inventor	Jinfa Du
Art Unit	1621
Examiner Name	Lewis, Patrick T.
Attorney Docket Number	37JD-199059-US6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		6156501	2000-12-05	MCGALL ET AL.	
		6180134	2001-01-30	ZALIPSKY ET AL.	
		6232300	2001-05-15	SCHINAZI ET AL.	
		6239159	2001-05-29	BROWN ET AL.	
		6348587	2002-02-19	SCHINAZI ET AL.	
		6372883	2002-04-16	ATTWOOD ET AL.	
		6391859	2002-05-21	SCHINAZI ET AL.	
		6410531	2002-06-25	LLINAS-BRUNET ET AL.	
		6420380	2002-07-16	LLINAS-BRUNET ET AL.	
		6455513	2002-09-24	MCGUIGAN ET AL.	
		6455690	2002-09-24	TAM ET AL.	
		6475985	2002-11-05	WAGNER ET AL.	
		6479463	2002-11-12	WANG ET AL.	
		6495677	2002-12-17	RAMASAMY ET AL.	
		6509320	2003-01-21	WANG ET AL.	
Change(s) applied to document, /J.H./ 1/9/2015		6534523	2003-03-18	~~LLINAS-BRUNET ET AL.~~	Llinas-Brunet et al
		6552183	2003-04-22	RAMASAMY ET AL.	
		6555677	2003-04-29	PETRILLO ET AL.	
		6573248	2003-06-03	RAMASAMY ET AL.	
		6642206	2003-11-04	RAMASAMY ET AL.	
		6660721	2003-12-09	DEVOS ET AL.	
		6677314	2004-01-13	KLECKER ET AL.	
		6677315	2004-01-13	KLECKER ET AL.	
		6680303	2004-01-20	SCHINAZI ET AL.	
		6682715	2004-01-27	KLECKER ET AL.	
		6683045	2004-01-27	KLECKER ET AL.	
		6703374	2004-03-09	KLECKER ET AL.	
		6753309	2004-06-22	KLECKER ET AL.	
		6777395	2004-08-17	BHAT ET AL.	
		6784166	2004-08-31	DEVOS ET AL.	
		6787305	2004-09-07	LI ET AL.	
		6787526	2004-09-07	BRYANT ET AL.	
		6815542	2004-11-09	HONG ET AL.	

Examiner Signature	/Patrick Lewis/ (10/28/2014)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP . if possible. and . The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by . This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.L./ (10/28/2014)

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/254,737	02/17/2015	8957046	37JD-199059-US6	1596

117796 7590 01/27/2015

Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
379 Lytton Avenue
Palo Alto, CA 94301

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Jinfa Du, Redwood City, CA;
Gilead Pharmasset LLC, Foster City, CA, Assignee (with 37 CFR 1.172 Interest);
Dhanapalan Nagarathnam, Bethany, CT;
Michael Joseph Sofia, Doylestown, PA;
Peiyuan Wang, Foster City, CA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

PTO/AIA/123 (08-12)
Approved for use through 11/30/2014. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CHANGE OF CORRESPONDENCE ADDRESS
Patent

Address to:
Mail Stop Post Issue
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Patent Number	8,957,046
Issue Date	02-17-2015
Application Number	14/254,737
Filing Date	04-16-2014
First Named Inventor	Jinfa DU
Attorney Docket Number	37JD-199059-US6

Please change the Correspondence Address for the above-identified patent to:

☑ The address associated with Customer Number: 124963

OR

☐ **Firm *or* Individual Name**

Address

City	**State**	**ZIP**

Country

Telephone	**Email**

This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124).

This form will not affect any "fee address" provided for the above-identified patent. To change a "fee address" use the "Fee Address Indication Form" (PTO/SB/47).

I am the:

☐ Patentee.

☐ If the Patentee was not the applicant for patent (37 CFR 1.42), then a Statement under 37 CFR 3.73(c) (Form PTO/AIA/96 or equivalent) is enclosed or was filed on _____. See 37 CFR 3.71.

☑ Attorney or agent of record. Registration Number 50782.

☑ Patent practitioner acting in a representative capacity whose correspondence address is the correspondence address of record. Notice has been given to the patentee or owner. Registration Number 50782.

Signature /Lorna L. Tanner/

Typed or Printed Name Lorna L. Tanner

Date 03-31-2015 Telephone 650-815-2600

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop Post Issue, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.